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The Sonic hedgehog signalling pathway is of key importance during embryonic 
development as well as adult disease. While much is known regarding the main 
intracellular signalling components involved, precise details of the regulation of the 
pathway remain undiscovered. In this thesis, I aim to further our understanding of the 
regulation of the Shh signalling pathway by investigating aspects of the molecular 
mechanism.  
We have previously shown that Tulp3 acts as a negative regulator of the Shh pathway. 
More recently, we have found that Tulp3 interacts with Rgnef and Trim71. In this 
thesis, I test the hypothesis that Rgnef and Trim71 act as regulators of the Shh 
pathway. My investigations centre on assessing pathway activity in relation to changes 
in Rgnef and Trim71 expression, using a cell biology assay. I show that reducing Rgnef 
expression leads to a reduction in Shh pathway activity, while increasing Rgnef 
expression stimulates pathway activity. I show also that increasing Rgnef expression 
significantly reduces the proportion of cells with a primary cilium, an organelle 
fundamental to Shh signalling. Within the embryo, I show that Rgnef is expressed in 
the developing neural tube. Shh pathway suppression was also induced by Trim71 
siRNA, but through validation tests I show this to be a false positive result and 
investigate the possible causes. 
In addition, I have used mass spectrometry to identify putative novel sites of Gli2 post 
translational modification. Gli2 is one of three transcription factors conserved in 
vertebrate Shh signalling, and which are the ultimate target effectors of pathway 
activity. Gli2 is predominantly involved in pathway activation however precise 
regulation of Gli2 activity remains poorly understood. By using mass spectrometry, I 
aimed to reveal novel sites of protein modification that would help to understand the 
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1-01 Neural tube defects 
In the UK birth defects account for over 12,000 live births per year with nervous 
system disorders amongst the most common (EUROCAT, prevelance data tables 2008-
2012 (2014)). Neural tube defects (NTD) are one of the most prevalent forms of 
developmental embryo abnormality second only to congenital heart defects (Detrait et 
al., 2005). The main forms are anencephaly, which results in fetal and infant mortality 
and spina bifida, where almost all individuals affected have lower body paralysis and 
significant physical disability (Oakley, 1998, Detrait et al., 2005). Almost half a century 
has passed since links were first made regarding low folic acid and NTDs through 
clinical observations that lead to preliminary epidemiological research (Hibbard et al., 
1965, Leck, 1974). The first definitive case for identifying folic acid deficiency as a 
factor for the prevalence of NTD came from the Medical Research Council (MRC) 
Vitamin Study (MRC, 1991). The main finding from this and subsequent intervention 
studies was to show that periconceptual use of folic acid supplements can lower the 
risk of NTD by 40% to 80% (Eichholzer et al., 2006). Since 1992 the consensus among 
national and worldwide health organisations was to promote awareness and 
recommend folic acid supplementation for women (Eichholzer et al., 2006). In 1998 
the World Health Organisation reported that approximately 400,000 infants were born 
worldwide with NTD, mostly in China, Mexico and Central America (Oakley, 1998). In 
the same year mandatory folic acid fortification of bread and flour was introduced in 
the USA, a measure soon adopted in South America, Canada, Australia and other 
countries, although not with Europe (Eichholzer et al., 2006). Decreases in prevalence 
of NTD did occur, although progress was slow and results were not as high as predicted 
from the MRC vitamin study (Eichholzer et al., 2006). Despite such progress NTD still 
persists, even when the difficulty in implementing public health preventative measures 
are taken into account (Oakley, 2009, Copp et al., 2013). What has therefore become 
clear is that forms of NTD are folic acid resistant, a condition that has since been well 
established in mouse models of the disorder (Copp et al., 2003b).  
The study of developing mouse embryos has proven to be an effective experimental 
method when identifying genes involved in neural tube development. Investigating the 
abnormal development of NTD mouse models provides a basis for comparison that can 




(Copp et al., 2003b, Detrait et al., 2005). How genetic inheritance determines NTD is 
best summarised as genetic or multi-genetic susceptibilities to the extent and timing of 
environmental factors (Detrait et al., 2005). Identifying such genes in mutant mouse 
models enables a basis to test for environmental factor susceptibilities. For example, in 
folic acid resistant NTD mouse mutant Grhl3, a lack of inositol was identified as a 
potential contributing factor to prevalence of NTD (Greene and Copp, 1997). A factor 
that is currently being investigated in the UK by randomised clinical trial (Copp et al., 
2013). 
Observing the morphological changes after gene disruption by N-ethyl-N-nitrosourea 
(ENU) has become an extensively practiced form of forward mutagenesis screening 
(Cordes, 2005). Alkylating agent ENU is a highly potent mutagen that acts by 
transferring an ethyl group to nucleotides. ENU is toxic but correctly administered can 
produce low numbers of random mutations. Any observed defective phenotypes, 
including NTD, can then be sourced back to the dysfunction of specific genes (Cordes, 
2005). Gene defects discovered in this way cannot be assumed to simply occur in 
human populations as inherited traits but provide a basis for human population 
screens of the same disorders (Detrait et al., 2005, Boyles et al., 2005). Such studies 
have identified risk factors based on genes of the folic acid metabolic pathway and to 
some extent on Wnt and Hedgehog signalling (Boyles et al., 2005). For example, 
elevated homocysteine observed in mothers of children with NTD metabolism could 
relate to three genes within the folic acid pathway; cystathion-β-synthase (CBS), 
methionine synthase (MS) and 5,10 –methylenetetrahydrofolate reductase(MTHFR) 
(Boyles et al., 2005, van der Put et al., 1995). These genes may therefore, individually 
or collectively, infer a susceptibility to environmental factors that contribute to NTD.  
In order to eradicate NTD, the challenge for the research community is to provide a 
complete model of gene involvement in neural tube development. Hence, a model to 
help collectively identify the genes involved as risk factors in human populations. 
1-02 Morphological aspects of mammalian neurulation 
Neurulation is the process of neural tube formation from a plane of columnar 
epithelial tissue in the dorsal region of developing embryos called the neural plate. 




Primary neurulation is responsible for the large majority of neural tube formation 
using a mechanism that folds the neural plate into a tube. Secondary neurulation only 
occurs at the very caudal end of the embryo using a mechanism that involves internally 
hollowing out a lumen to form a tube.  
Primary neurulation starts with the formation of the neural folds. The edges of the 
neural plate elevate on either side of the dorsal midline (Figure 1-01 A-B). The neural 
folds converge and fuse along the midline to form the neural tube. The adjacent 
ectoderm joins to cover the neural tube by forming a layer of surface ectoderm (Figure 
1-01 C). The precise morphology of the bending neural folds varies along the anterior-
posterior axis of the embryo (Figure 1-01 D). Along most of the axis, a median hinge 
point (MHP) forms at the mid-line of the neural plate, and bending at this hinge point 
creates the emergence of the neural folds. In the upper spine, the MHP is the only 
bending region of the neural plate. At mid- and lower-spine levels, each neural fold 
forms a further bend called the dorsal lateral hinge point (DLHP) which helps to turn 
the neural fold ends towards each other for eventual fusion. At low spinal levels, 
DLHPs form in the absence of an MHP. These three forms of neural tube closure are 
referred to as the three modes of spinal closure (Shum and Copp, 1996). 
Neural tube closure does not occur uniformly along the entire embryo but instead 
initiates at specific points where it then continues concurrently until completion 
(Figure 1-01 E). In mice neural tube closure is initiated at three points along the neural 
plate; closure 1 is at the base of the hindbrain and closes in both directions towards 
future brain and spinal regions. Bidirectional closure is also initiated at closure 2 at 
around the forebrain/midbrain boundary, although there is variation in precise 
position of closure 2, between different mouse strains (Copp et al., 2003b). Closure 3 
occurs at the rostral end of the forebrain from where it can only proceed caudally. 
Closure between these points gives temporarily open regions of neural tube, between 
them; these are referred to as the neuropores. In the mouse brain, there are clear 
anterior and hindbrain neuropores. Final closure of the neural tube is seen in the 
posterior region, with closure of the posterior neuropore. In humans, it appears that 
there are only two sites of initiation of closure. It seems that the position of closure 2 is 




neurulation takes place over 2 days of development, from embryonic day (E) 8.5 to 
E10.5. The initiation of neural tube closure 1 occurs at around the 5-6 somite stage, 
with closure 2 and 3 occurring at about the 12-somite stages. Completion of cranial 
closure, with closure of the anterior and hindbrain neuropores, is seen by about the 
17-somite stage. Final completion of primary neurulation, with closure of the PNP, is 
observed usually by the 30-somite stage. Figure 1-01 is a summary of mammalian 
neurulation as outlined so far. 
Formation of the lowest portion of the spinal cord does not require neural folding and 
is instead formed by a process of secondary neurulation. Here mesenchymal cells in 
the dorsal part of the tail bud around the posterior neuropore, condense into an 
epithelial rod that is effectively “hollowed out” to form a lumen continuous with the 
neural tube (Greene and Copp, 2009). 
Prior to and during neurulation the neural epithelium simultaneously extends and this 
is due in part to growth of the caudal region and cell elongation. However most of the 
required lengthening and narrowing is achieved by coordinated intercalation of cells 
that move laterally towards the midline in a process, referred to as convergent 
extension (Keller, 2002). Furthermore, without convergent extension bilateral neural 














Figure 1-01 Mammalian neurulation 
(A-C) A summary of induction, bending and fusion required for NT closure. (A) The 
neural plate, a flat sheet of epithelial cells overlying the notochord (blue), an 
organising centre of the embryo. (B) Signalling from the notochord induces bending in 
the midline, elevating the neural folds and bringing them into proximity. (C) The neural 
folds fuse in the dorsal midline closing the tube and the adjacent ectoderm joins to 
cover the NT by forming a layer of surface ectoderm. The neural crest cells also 
migrate away from the site of closure. (D) Three modes of spinal closure along the 
rostrocaudal axis. Mode one in the upper spine, medial hinge point (MHP, purple) is 
the only bending region of the neural plate. Strong Shh signalling from the notochord 
induces the MHP while repressing formation of the dorsolateral hinge points (DLHP). 
Mode two closure occurs more caudally, where decreased Shh signalling from the 
notochord releases repression of DLHP formation (orange) but maintains the MHP. In 
mode three closure the MHP is lost due to decreased Shh signalling, and the DLHPs are 
induced. (E) Closure initiates at specific points along the rostrocaudal axis of the 
embryo. At E8.5 in mouse closure 1 (C1) occurs bidirectionally at the base of the 
hindbrain. Closure 2 (C2) initiates at the midbrain/hindbrain boundary and also 
progresses bidirectionally. Closure 3 (C3) starts at the rostral-most extent of the NT 
where fusion can only proceed caudally. The open NT between C3 and C2 is the 
anterior neuropore (ANP), between C2 and C1 is the hindbrain neuropore (HNP) and 





1-2-01 Molecular regulation of neurulation 
Highly regulated molecular processes are involved in the complex morphological tissue 
remodelling required to shape and bend the neural plate for neural tube formation 
and closure. (Colas and Schoenwolf, 2001). Detailing the function of the many genes 
involved in this highly complex spatiotemporal regulation is required to clinically 
address the causes of neural tube defects. Central to the process is formation of the 
hinge points, required at variable modes along the nueroaxis to assist neural tube 
closure. The process is initiated by forming the MHP. The MHP is induced by signals 
from the underlying notochord as midline bending is absent as a result of suppressed 
notochordal development (Smith and Schoenwolf, 1989, Davidson et al., 1999, Ybot-
Gonzalez et al., 2002). Whereas complete removal of the surface ectoderm prevents 
formation of the DLHPs. (Jacobson and Moury, 1995, Moury and Schoenwolf, 1995, 
Ybot-Gonzalez et al., 2002). Removal of any remaining adjacent regions of the paraxial 
mesoderm has no effect on either MHP or DLHP formation (Ybot-Gonzalez et al., 
2002). These findings help establish the ventral notochord and dorsal surface 
ectoderm as regions providing the framework of molecular signals for MHP and DLHP 
formation. The regulation of DLHP formation in particular depends on the relationship 
between antagonistic signals from both these poles. Although DLHP is induced by the 
surface ectoderm, the notochord release of Shh suppresses DLHP formation (Ybot-
Gonzalez et al., 2002). Morphogen Shh is secreted from the notochord to form a 
diminishing ventral to dorsal concentration gradient along each emerging neural fold 
(Jessell, 2000). DLHP is therefore only permitted to occur at the threshold point along 
each neural fold that is far enough away from the notochord source of Shh inhibition 
(Ybot-Gonzalez et al., 2002). Bone morphogenic proteins (Bmp) represent a key group 
of developmental signals emanating from the surface ectoderm. Regulation of DLHP 
formation pivots upon a negative feedback loop formed by Bmp2 inducing the 
expression of its own antagonist, Noggin. The molecular mechanism establishing the 
three modes of neural tube closure involve a cascade of negative regulation that 
centres on the relationships between Shh, Bmp2 and Noggin. In mode1 neurulation 
DLHP’s are not formed due to unimpeded negative regulation by Bmp2 resulting from 
suppression of its antagonist Noggin by high Shh expression (Ybot-Gonzalez et al., 




reduced releasing Noggin suppression on Bmp2, but in a concentration dependant 
manner from the ends of neural fold. An opposing concentration gradient of Bmp2 
emanates from the surface ectoderm, continuing to suppress DLHP formation. The 
molecular mechanism that regulates DLHP formation is based on the threshold level of 
antagonist Noggin that is sufficient enough to neutralise Bmp2 suppression on DLHP 
formation (Ybot-Gonzalez et al., 2007). 
At a molecular level convergent extension depends on the planar cell polarity pathway 
(PCP), first discovered by disruption of PCP pathway effector dishevelled in frog 
resulting in shortened embryos and neural folds that could not fuse due to a broad 
neural plate (Wallingford and Harland, 2001, Wallingford and Harland, 2002). In mice, 
findings were repeated as lack of convergent extension resulted in neural tube defects 
from a range of independent gene disruptions either part of or related to the PCP 
pathway (Greene and Copp, 2009). The genes, well reviewed by Greene and Copp et al 
(2009) were vangl2, dishevelled, Celsr1, Scrb1, Ptk7 as well as combined knock out of 
frizzled-3 and frizzled-6. 
1-03 Dorsoventral patterning of the neural tube 
In vertebrates, the cells of the central nervous system originate from the neural tube. 
Dorsoventral (DV) patterning is the process by which differentiating neuroblasts are 
anatomically segregated and organised along a dorsal ventral axis (Jessell, 2000). DV 
patterning depends on the timing and extent of external signals, a model that centres 
on four main signalling pathways; BMP, retinoic acid (RA), fibroblast growth factor 
(FGF) and Shh (Jessell, 2000, Wilson and Maden, 2005). The neural tube therefore 
becomes an environment of opposing morphogen concentration gradients, providing a 
range of developmental cues that induce all neural cell types (Wilson and Maden, 
2005).  
A broad level of spatiotemporal regulation involves directing progenitor cells to either 
proliferate or differentiate. FGF signalling cues emanate from the mesoderm to 
promote proliferation, predominantly a requirement of neuroepithelial cells in the 
immature NT (Bertrand et al., 2000, Diez del Corral et al., 2002, Diez del Corral et al., 




instead an environment for neuroepithelium differentiation (Diez del Corral et al., 
2003, Novitch et al., 2003).  
The advancement of differentiation cues that give rise to DV patterning depend on the 
antagonistic relationship of BMP and Shh signalling within the NT. Specialisation of the 
cells in the dorsal region of the NT result from the high exposure to BMPs produced by 
the roof plate and the surface ectoderm. Yet exposure to a gradient of Shh is 
specifically the determining factor for ventral neural tube patterning (Marti et al., 
1995, Chiang et al., 1996, Ericson et al., 1996, Briscoe et al., 2000, Wijgerde et al., 
2002). Shh expression originates first from the notochord and the high concentration 
and long exposure time experienced by cells in the most ventral region of the neural 
plate, adjacent to the notochord, induces these cells to become the floorplate (Placzek 
et al., 1990, Echelard et al., 1993, Roelink et al., 1995). The cells of the floorplate then 
themselves start to express Shh. The Shh gene exhibits a highly localised region of 
expression, limited only to cells of the notochord and floorplate. The key molecular 
basis of ventral patterning is that the Shh protein diffuses dorsally, creating a ventral-
to-dorsal gradient of Shh protein, within the neural tube; cells at different positions 
within the neural tube are then exposed to different concentrations of Shh protein and 
also receive Shh for differing lengths of time. Evidence in support of the model for NT 
DV patterning came first from experimental studies with neural plate explants, 
cultured for differing lengths of time and at different concentrations of Shh (Yamada et 
al., 1993, Marti et al., 1995, Roelink et al., 1995, Ericson et al., 1997, Briscoe et al., 
2000). Those exposed to the highest concentration of the Shh signal, for the longest 
time, are induced to form the most ventral type of neuronal subtype, the V3 ventral 
neurons. Adjacent to these, cells receive a slightly lower and shorter exposure to Shh, 
and are induced to form motor neurons. At progressively more dorsal positions, the 
gradually decreasing Shh exposure induces the precursors to form the other ventral 
neuronal subtypes, the V2, V1 and V0 ventral interneurons.  Striking evidence for the 
central role of Shh comes from the observation that ventral neural cell types are lost 
when Shh signal is omitted (Chiang et al., 1996). The relation between Shh gradient, 
transcription factor expression and the neuronal subtypes formed is summarised in 




In each neuronal precursor, Shh pathway transduction acts to regulate the balance of 
Gli protein transcription factors in activator and repressor form to reflect the 
graduated Shh signal. In response, the extent of Shh pathway activation determines 
the fate of cells by relative activation of specific progenitor proteins (Briscoe and 
Ericson, 2001, Guillemot, 2007). These are called the class II transcription factors, and 
include NK2 homeobox 2 (Nkx2.2), oligodendrocyte transcription factor 2 (Olig2), and 
others. Another set of transcription factors are repressed at high levels of Shh 
signalling, with differing thresholds of responsiveness. These Class I transcription 
factors include Pax6, Pax7 and Irx3. The Class II and Class I transcription factors then 
act to co-repress, in particular pairs of factors. For instance, Nkx2.2 and Pax6 co-
repress, while Olig2 and Irx3 co-repress. The co-repression results in a clearly defined 
boundary of gene expression, between each pair of transcription factors. The position 
of the boundary differs between different pairs. The result is that at different positions 
along the dorso-ventral axis, the cells express different combinations of Class I and 
Class II transcription factors. The specific combination of transcription factors then 
determines the neuronal subtype that is induced at each position along the DV axis. 
For instance, V3 interneurons differentiate from neuronal precursors expressing 













































Figure 1-02 Shh expression by notochord and floor plate controls ventral 
pattern 
Cross-section through stage-18 chick spinal cord showing the expression in the 
notochord (N) and floor plate (FP) of (A) Shh RNA and (B) Shh protein. (C) Diagram of 
the neural tube showing the effect of high ventral to low dorsal Shh concentration 
gradient (blue dots) on the specification of ventral neuronal fates. Five classes of 
neurons are generated in response to graded Shh signalling; four different classes of 
ventral interneurons V0–V3, Motor neurons MN and floor plate FP. To the right is 
shown the profile of neuronal generation in intermediate neural plate explants grown 
in different concentrations of the recombinant amino-terminal fragment of Shh, 
termed Shh-N. The more dorsal the position of neuronal subtype generation in vivo, 
the lower the concentration of Shh required to induce the same neuronal 
subpopulation in vitro. 




1-04 The Shh Signalling pathway 
The Shh pathway has been primarily identified for its crucial role in early development. 
Abnormal pathway signalling has been attributed to a wide range of birth defects, 
including holoprosencephaly, spina bifida, polydactyly, craniofacial and skeletal 
malformations (McMahon et al., 2003). Correct regulation of pathway activity is 
important across the entire life of an organism, noted by the oncogenic effects of 
increased pathway activity in adults (Pasca di Magliano and Hebrok, 2003). 
1-4-01 In Drosophila 
Essentially, the components of the Hedgehog (Hh) signalling pathway are well 
conserved across invertebrates and vertebrates (Huangfu and Anderson, 2006). 
Pathway effectors were first discovered through observing abnormal larva segmental 
development after gene disruption in Drosophila. It led to the early identification of 
morphogen hedgehog (Hh) and Patched (Ptc), discovered later to be the membrane 
receptor for Hh (Nusslein-Volhard and Wieschaus, 1980, Ingham et al., 1991). Hh 
effectors further identified downstream of Ptc were Smoothened (Smo), Fused (Fu), 
suppressor of Fused (Su(fu)), Costal2 (Cos2) and Cupitus Interuptus (Ci) (Nusslein-
Volhard and Wieschaus, 1980, Preat, 1992, Forbes et al., 1993, Motzny and Holmgren, 
1995, Alcedo et al., 1996, van den Heuvel and Ingham, 1996).  
Ci is the single culminating transcription factor for the invertebrate Hh pathway and is 
bi-functionally responsible for either target gene activation or suppression (Methot 
and Basler, 1999). During pathway inactivity, when the Hh ligand is absent, Ci remains 
in the cytoplasm bound to Cos2 and Fu (Robbins et al., 1997). Formation of this 
complex initiates phosphorylation of Ci by protein kinase A (PKA), glycogen synthase 
kinase 3 (GSK3) and casein kinase 1 (CK1) (Chen et al., 1998, Chen et al., 1999, Price 
and Kalderon, 1999, Jia et al., 2002, Price and Kalderon, 2002, Jia et al., 2005). This 
sequential phosphorylation triggers targeting for proteolytic cleavage (Price and 
Kalderon, 1999, Jia et al., 2002, Price and Kalderon, 2002, Zhang et al., 2005). Ci is 
processed to a 75 kDa repressor form (CiR) and translocates to the nucleus for pathway 
suppression by inhibitive target gene promoter binding; CiR acts as a transcriptional 
repressor (Aza-Blanc et al., 1997, Jiang and Struhl, 1998). During pathway activation, 




Smo (Hooper and Scott, 1989, Marigo et al., 1996, Stone et al., 1996, Alcedo et al., 
1996, van den Heuvel and Ingham, 1996). Smo interacts with Cos2 to inhibit its 
association with Ci and this arrests processing of Ci to CiR. Full length Ci can now 
function as a transcriptional activator by translocation to the nucleus for target gene 
activation (Methot and Basler, 1999). 
1-4-02 In mammals 
Many elements of the Hh pathway first elucidated in Drosophila are essentially the 
same as the mammalian Shh signalling cascade. A key difference is that certain 
proteins in the invertebrate pathway are represented by a family of proteins in 
vertebrates. This includes vertebrate homologues of the Hh ligand, represented by a 
functionally divergent family of ligands, including Sonic hedgehog (Shh). Other 
members of the family in mammals are Desert hedgehog (Dhh) specialised for a role in 
male gonad development and Indian hedgehog (Ihh) for skeletal development (Bitgood 
et al., 1996, St-Jacques et al., 1999). Shh is the ligand that functionally relates to 
embryonic development, neural tube pattern formation and inducing proliferation in 
numerous tissues including the central nervous system (McMahon et al., 2003). 
The homologue to Ci in mammals has also diverged to a family of proteins, named 
Glioma-associated oncogene homologs 1 to 3 (Gli1, Gli2 and Gli3) (Matise and Joyner, 
1999, Sasaki et al., 1999). Although each Gli protein is specialised, they are functionally 
coordinated to a point that can be summarised in two states; Gli activator and Gli 
suppressor proteins, akin to the bi-functional activation states of Ci in Drosophila 
(Huangfu and Anderson, 2006). Simplistically, it is fair to functionally assign Gli3 as 
repressor and Gli2 as activator although full length Gli3 can act a weak activator and 
Gli2 also has as a weak repressor form (Bai et al., 2004, Pan et al., 2006). The 
conversion of full length 190 kDa Gli3 to repressor form involves proteolytic cleavage 
to form an 83 kDa Gli3 repressor that can directly block transcription promoter sites 
(Huangfu and Anderson, 2005). As mentioned, full length 185 kDa Gli2 is subject to the 
same processing mechanism to produce 78 kDa Gli2 but in comparison to Gli3, 
proteolysis is 6 times less efficient (Pan et al., 2006). Gli1 is a potent activator that only 




activation as Gli1 is a Gli2 target gene and as such is not involved in onset of pathway 
activation (Bai et al., 2004). 
As with Ci repressor processing in Drosophila, both Gli2 and Gli3 homologues are 
found to be subject to same sequential phosphorylation of PKA, GSK and CK1 (Wang et 
al., 2000, Pan et al., 2006, Pan et al., 2009). A significant difference however is that the 
vertebrate pathway requires the cellular mechanisms of primary cilium signalling, an 
organelle absent from invertebrate cells (Oh and Katsanis, 2012, Pal and 
Mukhopadhyay, 2014). Instead, ciliary regulation of Gli2 and Gli3 during pathway 
inactivation involves Shh membrane receptor Patched1 (Ptch1) localisation to the 
primary cilia and in conjunction with β-arrestin, prevents membrane receptor 
Smoothened (Smo) from entering the cilium (Rohatgi et al., 2007, Kovacs et al., 2008). 
As Shh binds and internalises Ptch1, it releases its inhibition allowing Smo 
translocation to the primary cilium (Rohatgi et al., 2007, Kovacs et al., 2008, Rohatgi et 
al., 2009). Accumulation of Smo on the ciliary membrane arrests Gli3 processing to 
repressor form as the pathway mechanism changes towards promoting Gli activator 
proteins, a process that is less well understood (Haycraft et al., 2005, Tran et al., 2008). 
Recent discovery of negative regulator Gpr161 has helped further understand the 
mechanism of ciliary cAMP activation of PKA phosphorylation and its pivotal role in 
regulating Gli repressor processing (Mukhopadhyay et al., 2013). During pathway 
activation, the reduction of cAMP levels in the primary cilia resulting from loss of 
Gpr161 is proposed to reduce PKA activity required to process Gli repression 
(Mukhopadhyay et al., 2013). Reduction of Gli3 repressor removes target gene 
inhibition of Gli2 increasing the incidence of successful Gli2 translocation to the 
nucleus for target gene activation.  
Suppressor of Fused (Sufu) is a key regulator of Gli transcription factor activation 
states. During pathway inactivation Sufu can bind and sequester all Gli proteins in the 
cytoplasm, including Gli1, restricting Gli translocation to the nucleus (Ding et al., 1999, 
Dunaeva et al., 2003, Jia et al., 2009). Sufu-Gli complexes also promote active 
repression by recruiting GSK3β to help promote proteolytic cleavage of full length Gli3 
to Gli3R (Kise et al., 2009). Dissociation of Sufu-Gli complexes during pathway 




2005, Huangfu and Anderson, 2005). The mechanism involves reduced primary cilia 
induction of PKA activity that in turn reduces stability of Sufu-Gli binding complexes 
(Humke et al., 2010, Tukachinsky et al., 2010, Chen et al., 2011a).  
Also evident but less understood is the molecular mechanism of positive regulation in 
Shh signalling pathway. Serine/threoine kinase phosphorylation by Unc-51-like kinase 
3 (ULK3) as is reported to increase nuclear localisation of Gli1 and Gli2, resulting in 
pathway activation (Maloverjan et al., 2010b). ULK3 is also regulated by Sufu in a Sufu-
Ulk3 complex that blocks it from phosphorylating Gli2 for pathway activation 
(Maloverjan et al., 2010a). 
Increasingly, certain  mechanisms involved in the formation or function of primary cilia 
are also identified as Shh pathway effectors and regulators (Oh and Katsanis, 2012). 
Hence the focus of the next section has taken a ciliary centric view of the structure and 
function of primary cilia in the context of cell signalling. In particular, the requirement 
for bidirectional protein transportation to and from the primary cilia has identified 
intraflagellar transport (IFT) proteins as a class of pathway effectors in Shh pathway 
signalling. Main pathway related effectors can be divided into two functional groups; 
the IFT complex B proteins IFT57, IFT172, IFT88, IFT52 and the kinesin, Kif7, are 
involved in anterograde transport towards the ciliary tip and the IFT complex A 
proteins Dync2h1 (a dynein), IFT122 and Thm1 enable retrograde transport of proteins 
back to the ciliary pore (Huangfu et al., 2003, Haycraft et al., 2005, Huangfu and 
Anderson, 2005, Liu et al., 2005, Cortellino et al., 2009, Tran et al., 2008, Cheung et al., 
2009, Liem et al., 2009, Qin et al., 2011, Mukhopadhyay et al., 2010). Interestingly, the 
discovery that Kif7 is the mammalian homologue of Cos2 suggests that these effectors 
are still integrated within the conserved elements of the pathway and not necessarily 
an appendage to it (Cheung et al., 2009, Liem et al., 2009).  
In summary of the vertebrate Shh signalling pathway as detailed here, figure 1-03 







Figure 1-03 Sonic hedgehog signalling 
(A-B) A simplified representation of the Shh signalling pathway.  (A) In the absence of 
Shh ligand Ptch1 inhibits Smo, preventing its ciliary accumulation. Sufu binds and 
sequesters Gli2 preventing translocation to the nucleus. Sufu also binds positive 
regulator Ulk3 to prevent Gli2 phosphorylation. Gpr161 is transported to the cilium in 
complex with Tulp3 and IFTA proteins. Cilium levels of cAMP are increased by Gs alpha 
protein coupled receptor activation of the cAMP-dependant pathway. PKA 
phosphorylates Gli3 which primes Gli3 for further phosphorylation by CK1 as well as 
from GSK3 recruited from Sufu. Gli3 is then targeted for proteolytic cleavage to the 
repressor form which translocates to the nucleus to repress gene expression.  
(B) In the presence of Shh, Pthc1 inhibition of Smo is relieved. Smo is internalised and 
translocated to the cilium in a Kif dependent manner. Gli2 and Gli3 localise to the 
cilium and dissociate from Sufu and Gli3 processing to Gli3 repressor is arrested. 
Instead suppression of Gli2 is relieved and activation is enhanced by Ulk3 





1-05 Primary cilium 
Primary cilia are microtubule-based sensory organelles that project singly from the cell 
surface of most vertebrate cells. All cilia originate from a modified form of the 
centriole, called the basal body, that is a barrel-shaped structure composed of nine 
triplet microtubule blades (Ringo, 1967). The centriole becomes the basal body when a 
complex structure of proteins form around the mother centriole as it migrates and 
integrates itself into the cell cortex (Marshall, 2008). Their inner barrel arrangement of 
nine microtubule doublets provides a structural template for tubulin polymerisation 
(Marshall, 2008). During early formation, a primary cilia vesicle attaches to projections 
on mother centriole and expands as tubulin polymerisation projects within forming a 
microtubule “shaft” (Molla-Herman et al., 2010). The surrounding “sheath” formed by 
the vesicle is the precursor to the ciliary membrane as it fuses with the plasma 
membrane prior to extracellular projection (Molla-Herman et al., 2010). 
A feature of primary cilia is that they do not have a central microtubule doublet, a 
structure referred to as 9 + 0 cilia (Satir and Christensen, 2007). The 9 + 2 structure, in 
connection with axonemal dyneins, evolved as a functional requirement for motile cilia 
(Satir and Christensen, 2007). Figure 1-04 A and B provide a schematic cross sectional 
comparison of 9 + 2 motile cilia and 9 + 0 primary cilia. The role of microtubules in 
primary cilia is to provide structural support and tracks for intraflagellar transport (IFT) 
enabling bidirectional transport of large protein complexes (IFT particles) along outer 
doublets of the central microtubule structure (Rosenbaum and Witman, 2002). IFT-B 
complex cargo transport to the ciliary tip, referred to as anterograde transport, is 
achieved by kinesin-2 motor proteins whereas retrograde IFT-A complex cargo 
transport away from the ciliary tip requires cytoplasmic dynein 2 proteins (Kozminski 
et al., 1993, Kozminski et al., 1995, Pazour et al., 1999, Porter et al., 1999). The 
transport process also requires carriage of the dynein or kinesin motor proteins when 
inactive (figure 1-04 C). 
Primary cilia are compartmentalised organelles that strictly regulate their environment 
and protein composition (Garcia-Gonzalo and Reiter, 2012). Devoid of ribosomes, Cilia 
depend on the cell body for synthesis and delivery of all proteins (Johnson and 




vesicles that fuse with membrane at the base of the cilium to exocytose proteins into 
the transition zone. The transition zone is a diffusion barrier made up of tightly 
associated proteins and an opening at the base called the ciliary pore (Pazour and 
Bloodgood, 2008, Garcia-Gonzalo and Reiter, 2012). Entry to the cilium is therefore 
regulated within the transition zone and its ciliary pore complex of proteins. Unless 
actively transported, the ciliary pore restricts access, comparable to the nuclear pore 
where proteins larger than 30 kD are reported to be restricted access (Cook et al., 
2007, Garcia-Gonzalo and Reiter, 2012). The influence of the transition zone extends 
across to the contiguous cell membrane where it can also regulate membrane proteins 
able to transverse across to the ciliary membrane. Hence passage of ciliary proteins 
across the transition zone depends on their specific association of with the IFT 
machinery (Qin et al., 2004). Only protein complexes containing specific ciliary protein 
motifs can continue through to the ciliary compartment via anterograde transport 
(Pazour and Bloodgood, 2008, Garcia-Gonzalo and Reiter, 2012). Retrograde transport 
back from the ciliary tip involves remodelling IFT protein complex and activating 
cytoplasmic dynein 2 proteins (Qin et al., 2004). IFT is a central process during 
ciliogenesis as it delivers axonomal precursors for assembly (Pedersen and 
Rosenbaum, 2008). It is a mechanism that continues even after cilia are formed to 
maintain constant turnover of the axoneme at the ciliary tip (Pedersen and 
Rosenbaum, 2008). 
Evidence of protein trafficking for purposes other than axoneme formation is rapidly 
accumulating, particularly in relation to cell signalling (Pazour and Bloodgood, 2008, 
Oh and Katsanis, 2012). Regulating the interchange of select proteins within the cilia is 
key to understanding the mechanism of primary cilia signalling (Garcia-Gonzalo and 
Reiter, 2012). This is exemplified in the previous section by the regulated passage of 
receptors Ptch1, Smo and Gpr161 in Shh signal transduction (section 1-04). 
The mature axoneme is a complex of many distinct tubulin isoforms, rather than a 
homogenous polymerisation of soluble tubulin (Redeker et al., 2005). Interestingly, 
most of the post translational modifications (PTM) seen in tubulin are not found in 
organisms that lack cilia and therefore thought to be cilia specific (Alfa and Hyams, 




categorised as acetylation (addition of an acetyl group), detyronisation (removal of C-
terminal tyrosine to expose a glutamate), glutamylation and glycation (covalent 
bonding to a sugar molecule) (Westermann and Weber, 2003, Verhey and Gaertig, 
2007, Marshall, 2008, Gaertig and Wloga, 2008, Wloga and Gaertig, 2010). Although 
the functions of tubulin PTMs are mostly related to structure and assembly, α-tubulin 
acetylation has been shown to directly regulate the transport of kinesin-1 cargo (Reed 
et al., 2006, Dompierre et al., 2007). Hence axoneme PTMs can regulate ciliary 













Figure 1-04 Cilia structure and intraflagellar transport 
(A and B) Cross section diagrams of the forms of cilia in vertebrate cells.  (A) The motile 
cilium is formed of nine outer microtubule doublets arranged around a central pair in a 
9+2 configuration.  Dynein arms project from the microtubules, and radial spokes 
extend towards the central pair to facilitate motion.  (B) Primary cilia have a 9+0 
configuration, with similar arrangement of the outer microtubule doublets but loss of 
the central pair.  (C) Movement along the cilium is achieved by Intraflagellar transport 
(IFT).  Anterograde transport of cargo is mediated by kinesin complexes linked to IFT-B 
complex particles.  Retrograde transport is mediated by dynein motors and the IFT-A 
complex proteins binding to the cargo. Components of the IFT machinery and IFT cargo 
accumulate near the basal body in preparation for loading but are prevented from 






1-5-01 Primary cilia in Shh signalling 
The increased focus on primary cilia in the last 12 years is largely due to the 
identification of disorders resulting from dysfunctional cilia, termed ciliopathies (Goetz 
and Anderson, 2010). Primary cilia are now established in connection with a range of 
signal transduction pathways including canonical and non-canonical Wnt, fibroblast 
growth factor (FGF) and platelet-derived growth factor (PDGF) pathways (Gorbatyuk et 
al., 2007, Gerdes et al., 2009, Berbari et al., 2009, Oh and Katsanis, 2012). New 
pathways are expected to yet be identified given the increasing emphasis on primary 
cilia research in recent years (Oh and Katsanis, 2012). The organelle is therefore 
becoming understood to be a signalling nexus for enabling pathway to pathway 
interconnections or crosstalk and regulation. (Oh and Katsanis, 2012). 
The Shh signal pathway was first to be identified in connection with primary cilia. Loss 
of cilia was observed along with NT closure and patterning defects in mutants for 
genes polaris and wim (the homologues of Chlamydomonas IFT88, IFT172) as well as 
kinesin transport protein kif3a (Huangfu et al., 2003). Hence loss of cilia, due to 
disruption of the IFT machinery, resulted in phenotypes consistent with lack of Shh 
pathway activation. Reduced Shh pathway activity was identified in the NT by absence 
of Shh-dependant ventral cell types, as compared with Shh mutants and with Gli2 and 
Gli3 double mutants, in particular (Huangfu et al., 2003). Disruption of cilia or IFT 
machinery also resulted in reduced Shh pathway activation in mutants for Dync2h1, 
IFT52, IFT57, Ofd1 and Ftm/Rgrip1 (May et al., 2005, Liu et al., 2005, Houde et al., 
2006, Ferrante et al., 2006). Important also were examples of cilia disruption causing 
pathway activation as seen in Arl13b and Thm1 mutants (Caspary et al., 2007, Tran et 
al., 2008). Together the evidence recognizes primary cilia regulation of Shh signal 
pathway as involved with both suppression and activation, ultimately based on its 
influence on the nuclear ratio of Gli transcription suppressor versus activator. 
1-06 Tulp3 - negative regulator of the Shh signalling pathway  
ENU mutagenesis derived “hitchhiker” is a mouse mutant with neural tube defects, as 
identified in our laboratory by observing embryonic phenotypes of anencephaly and 
spina bifida (Patterson et al., 2009). Where closure had occurred, histological sections 




(Patterson et al., 2009). Abnormalities not related to the neural tube include preaxial 
polydactyly and forked rib formation (Patterson et al., 2009). Immuno-detection of cell 
differentiation markers Foxa2, Nkx2.2, Nkx6.1 and Oligo2 were revealed to have 
expanded dorsally from their normal domain of expression in the neural tube 
(Patterson et al., 2009). This revealed a disruption of dorso-ventral patterning in the 
spinal cord, with an expansion of the ventral marker domains, indicating ventralization 
of the neural tube.  
The gene disruption responsible for the hitchhiker mutant was identified as a single 
point mutation in Tubby-like-protein 3 (Tulp3), the result of TA transversion at the 
splice acceptor site of intron 3 causing skipping of exon 2 (Patterson et al., 2009). This 
single base change results in deletion of 52 bp of the coding sequence, which leads to a 
frameshift and premature truncation of the protein. Almost complete absence of the 
Tulp3 protein was confirmed by Western blotting. Nevertheless, it seems that this 
altered splice site can function as an acceptor site with low efficiency. The Western 
blot analysis revealed some expression of the Tulp3 protein, at around 4% of the wild-
type expression level (Patterson et al., 2009). 
Previously identified Tulp3 mouse mutant Tulp3tm1Jng generates a truncated form of 
Tulp3 that lacks the C-terminal Tubby domain. Homozygous Tulp3tm1Jng mutant mice 
have similar phenotype to hitchhiker and exhibit exencephaly and spina bifida, with 
abnormalities in neural tube development apparent from E9.5 (Ikeda et al., 2001). The 
phenotype of the Tulp3tm1Jng is a little more severe than hitchhiker, consistent with the 
complete absence of Tulp3 protein function in the knockout, but retention of a small 
amount of protein expression in hitchhiker (Patterson et al., 2009). Intercrosses 
between Tulp3 knockout mice and hitchhiker mice produce embryos with the same 
phenotypes of exencephaly and spina bifida, consist with these mutations being allelic 
(Patterson et al., 2009). 
The multiple phenotypes observed in mice with Tulp3 disruption, including preaxial 
polydactyly, expansion of ventral markers and neural tube defects, were consistent 
with defects found in mice with Rab23, FKBP8 or Tectonic disruption (Eggenschwiler et 
al., 2001, Bulgakov et al., 2004, Reiter and Skarnes, 2006). Hence, in comparison to 




regulators in Shh pathway signalling (Cameron et al., 2009, Norman et al., 2009, 
Patterson et al., 2009). 
Further epistasis was used to establish and place Tulp3 within the Shh signalling 
pathway. Starting with Shh, compared to hhkr-/- mutants some distinct phenotypes of 
Shhtm1Amc mutants are that they are reduced in size, exhibit cyclopia, 
holoprosencephaly and an expansion of dorsal markers in the NT (Chiang et al., 1996). 
Doubly homozygous Shhtm1Amc /hhkr-/- mutant embryos exhibit phenotypes that more 
resemble that of the hhkr and as such provide evidence that Shh is dependent on 
downstream effector Tulp3 (Patterson et al., 2009). Similarly, hhkr-/- phenotypes were 
expressed in doubly homozygous mutants hhkr-/- /smo smotm1Amc mutants as opposed 
to the distinct Smotm1Amc mouse genotypes, including cyclopia and holoprosencephaly 
(Zhang et al., 2001, Patterson et al., 2009). Similar comparisons with Tulp3tm1jng 
mutants again placed Shh and Smo upstream of Tulp3 (Norman et al., 2009). In 
addition IFT transport protein Kif3a and transcription factor Gli2 were identified as 
downstream of Tulp3 by demonstrating Gli2tm1Alj/Tulp3tm1jng and Kif3atm1Gsn/ Tulp3tm1jng 
double mutants had phenotypes resembling single mutants of Gli2tm1Alj and Kif3atm1Gsn 
respectively (Mo et al., 1997, Marszalek et al., 1999, Norman et al., 2009). 
1-07 Interacting protein partners of Tulp3 
In vertebrates, the tubby family of proteins comprises of 5 members; the founding TUB 
protein and 4 tubby-like proteins 1-4 (TULP 1-4) (Mukhopadhyay and Jackson, 2011). 
All share a signature carboxy-terminal tubby domain predicted to membrane interact 
with phosphatidylinositol 4,5-biphospahte (PIP2) (Santagata et al., 2001, Boggon et al., 
1999). The wide diversity of these proteins is mostly characterised by features in their 
amino-termini (Mukhopadhyay and Jackson, 2011).  
In order to understand the role of proteins, it is useful to identify interacting protein 
partners. At the time of beginning the work for this thesis, no Tulp3 protein partners 
had been identified. More recently, Tulp3 interacting protein partners have been 
identified by another group. This was specifically a conserved helical domain in the 
amino-terminal of TULP3 that interacts with the core IFT-A proteins IFT122, IFT140 and 
WDR19 forming a TULP3/IFT-A complex (Mukhopadhyay et al., 2010). Formation of the 




(GPCR) proteins and is a role independent to canonical IFT-A retrograde primary cilia 
protein transportation (Mukhopadhyay et al., 2010, Qin et al., 2011). More recently, G-
coupled receptor Gpr161 was identified as a negative regulator of the Shh signal 
pathway through TULP3/IFTA mediated localisation to the primary cilia 
(Mukhopadhyay et al., 2013). Therefore Tulp3 mediates ciliary dependant regulation of 
the Shh signalling pathway IFT-A transport proteins.  
In order to identify potential binding partners, before the IFT-A interactions were 
known, previous study in our laboratory was undertaken using a yeast-2-hybrid 
approach. The yeast 2-hybrid screens were performed by a company, Hybrigenics. The 
screens involved using full length Tulp3 as a bait protein to screen a library generated 
from an E10.5/12.5 mouse brain cDNA library. The procedure was outsourced to 
Hybrigenics, as they are specialists in protein interaction studies. Upon receiving our 
full length Tulp3 cDNA clone, Hybrigenics sub cloned the cDNA to create two N-
terminal tagged Tulp3 bait proteins. One bait protein contained the Gal4 transcription 
factor DNA binding domain, while the second bait protein was tagged with the LexA 
DNA binding domain The two bait proteins were then screened for potential 
interacting proteins from a cDNA library generated from E10.5 and E12.5 embryonic 
mouse brain. These library clones were tagged with the corresponding activation 
domain of either Gal4 or LexA, converting them to prey protein clones. The protein to 
protein interaction of Tulp3 “bait” with binding partner “prey” would pair the Gal4 or 
LexA DNA binding and activation domains together, creating a functional 
transcriptional activator that would then permit colony survival.  
All constructs were co-transfected into yeast cells, resulting in identification of 49 
clones, sequenced to identify 16 proteins that potentially interact with Tulp3. After 
eliminating three common false positives, 11 sequenced proteins remained and of 
these only 5 produced 2 or more colonies from the screen. These were “Family with 
sequence similarity 193 member A” (Fam193a), Tripartite motif protein 71 (Trim71), 
Nucleoporin 155 (Nup155) Cyclin B1 (Ccnb1) and Rho-guanine nucleotide exchange 
factor (Rgnef). In particular, Trim71, Nup155 and Fam193a were identified from both 
the screens, indicating that the interaction is tag-independent. In our laboratories, 




from reciprocal co-immunoprecipitation experiments using tagged constructs in 
HEK293T cells (Anju Paudyal, Vikki Patterson, unpublished data). 
It is notable that no IFT-A complex proteins were identified in this screen, which is 
perhaps surprising, given the recently published data from Mukhopadhyay et al. 
However, the IFTA interactions were found to occur with the N-terminal region of 
Tulp3. The bait proteins were created so that the tag was fused at the N-terminal end 
of Tulp3, in order to optimise the chance of obtaining proteins that interact with the 
conserved Tubby domain. The orientation of the tagged construct would likely make 
the N-terminal less accessible to interacting proteins. Indeed, proteins that interacted 
with the N-terminal region might then have prevented the DNA binding domain from 
binding to DNA, thus preventing positive identification in this assay. This may explain 
the reason for not detecting IFT complex proteins in the yeast 2-hybrid screen. 
Moreover, proteins can often function in multi-protein complexes. Thus, publication of 
the Tulp3-IFT-A interaction does not render our results meaningless but, rather, adds a 
greater importance to investigating their relevance. The aim is to therefore try and 
identify the function of Trim71 and Rgnef binding partners in relation to Shh signalling 
pathway and in conjunction with negative regulator Tulp3. 
1-7-01 Potential Tulp3 binding partner, Rgnef 
Previously named p190RhoGEF, Rgnef is a 190 kDa guanine nucleotide exchange factor 
(GEF) protein, containing PH –DH domains for membrane localisation (Gebbink et al., 
1997). In their capacity to activate GTPases, the GEF proteins act as switches or 
activators in signal transduction by metabolising the energy transference of GDP to 
GTP (Machesky and Hall, 1996). Rgnef binds the depleted GDP bound form of RhoA to 
then facilitate its transfer to an activated GTP form (van Horck et al., 2001). Another 
key feature of Rgnef is that it can bind Focal Adhesion Kinase (FAK) , one of the integrin 
dependent factors involved in the maturation process of extracellular matrix (ECM) 
adhesion sites (Zhai et al., 2003). Focal adhesions (FA) comprise of a large complex of 
proteins that can provide mechanical anchorage to the ECM as well as a nexus for 
adhesion-mediated signalling (Zamir and Geiger, 2001). Cell motility requires FA 
structures to be dynamically regulated to the point that either under- or over- 




al., 2009, Miller et al., 2012, Miller et al., 2013). Rgnef is responsible for providing a 
layer of FA regulation in its capacity to bind FAK and activate RhoA whilst holding the 
FAK complex in proximity of the cell membrane by its DH-PH domain attachment 
(Miller et al., 2013). 
Interestingly, Rgnef has been shown to also bind scaffolding protein JIP-1, to then 
promote JNK activation (Meyer et al., 1999).It is a role completely unrelated to its 
capacity as GEF protein and provides an example of the functional diversity of Rgnef in 
connection with other binding partners for involvement in another signal transduction 
mechanism.  
Another quite diverse role to consider is that Rgnef is involved in regulating light 
neurofilament neural expression by its ability to destabilise light neurofilament mRNA 
transcripts (Canete-Soler et al., 2001). Neurofilaments comprise of ordered bundles of 
three different types of filaments, each categorised by their molecular weight, hence 
light (NFL), medium (NFM) and heavy (NFH) (Yuan et al., 2012). Abundant in neural cell 
axons, they form an intricate network of fibres that are essential for radial growth 
during development and future maintenance of axon calibre (Zhu et al., 1997, Elder et 
al., 1998, Yum et al., 2009). Current focus on neurofilament modulation is mainly 
driven by the observed cellular phenotype of abundant unregulated neurofilaments in 
a range of neurological diseases. In In mice and other model organisms, NF knockout 
studies has largely shown normal development and a lack of any overt developmental 
phenotypes (Yuan et al., 2012). This Rgnef function is at least another example of its 
functional diversity. Although worth bearing in mind is that microtubule axoneme 
structure and function in neural cells is a potential model for understanding primary 
cilia. Like the axon, the primary cilium is compartmentalised and comprises of a central 
microtubule element. Protein regulation in the axon is also highly regulated either by 
selective protein targeting and removal of selective retention and exclusion (Garcia-
Gonzalo and Reiter, 2012). By comparison, it offers further insight to Rgnef function 
and raises the question of whether Rgnef has a role in primary cilia. 
In relation to Shh signalling pathway, RhoA has been shown to trigger Smo-induced 
Gαi-coupled protein receptor signalling cascade (Kasai et al., 2004). Coupled with the 




Furthermore in our laboratory, preliminary expression studies in mutant mice embryos 
have also implicated Rgnef, in that Shh mutants lack Rgnef expression and yet in Ptch 
mutants Rgnef expression was found to be increased. The aim of finding further 
connection is now also coupled with identifying the possible role of Rgnef in Shh signal 
transduction. 
In Rgnef knockout mice, numbers of Rgnef -/- mice born were lower and smaller in size 
compared to Rgnef+/- (Miller et al., 2012). At Embryonic stage E13.5 development was 
reported to be normal and neural tube closure defects were not observed. Embryos 
earlier than E13.5 were not examined in this study or the reason for the lower number 
of mice born. The evidence is therefore against the involvement of Rgnef in NT closure, 
although embryonic development defects may have been overlooked particularly in 
relation to DV patterning. 
1-7-02 Potential Tulp3 binding partner, Tripartite motif protein 71 
Tripartite motif 71 (Trim71), also known as mlin41, is the mouse homologue of lin-41, 
first discovered in Caenorhabditis elegans. The loss of Lin-41 in C.elegans results in 
premature cell cycle exit and differentiation resulting in adult phenotypes during larval 
stages of development. Lin-41 is a heterochronic gene that is regulated by Let-7, a 21 
nucleotide sequence of miRNA that destabilises Lin41 by binding to sites along the 3’ 
UTR of the Lin-41 transcript (Reinhart et al., 2000, Slack et al., 2000, Vella et al., 2004). 
The Let-7 miRNA pathway regulation of Lin-41 is a mechanism found conserved in 
more complex organisms such as zebra fish, chicken, mouse and human and although 
precise function is unknown, it is reasonably hypothesised to regulate cell proliferation 
or differentiation timing cues (Pasquinelli et al., 2000, Kloosterman et al., 2004, 
Lancman et al., 2005, Schulman et al., 2005, Kanamoto et al., 2006). Preliminary 
evidence of a Shh signalling pathway connection was identified by inducing cLin-41 
(Trim71 chick homologue) with Shh-coated bead implant in chick embryo and an 
observed inverse relationship with Gli3 expression during chick limb development 
(Lancman et al., 2005). In mice, Trim71 mutants exhibit exencephaly, an anterior 
neural tube closure defect although the precise mechanism is not known (Maller 
Schulman et al., 2008). Trim71 is of particular interest, as it is a heterochronic gene and 




The Trim71 protein is characterised as an E3 ubiquitin ligase as part a large TRIM/RBCC 
domain family, identified by its tripartite motif, a RING type zinc finger domain 
consisting of two B Box zinc fingers and coiled-coil domain (Slack et al., 2000, Meroni 
and Diez-Roux, 2005). Trim71 negatively regulates miRNA processing protein 
Argonaute 2 (Ago2) in vitro, by ubiquitination of Ago2, targeting for proteosome 
mediated degradation (Rybak et al., 2009). Ago2 is the only Argonaute protein (Ago1-
4) required for embryonic development as discovered by NTD in Ago2-deficient mice, 
particularly in the cranial region, as observed in Trim71-deficient mice (Liu et al., 2004, 
Maller Schulman et al., 2008). However the protein interaction between Trim71 and 
Ago2 is disputed, particularly as neural progenitor cells from wild-type mice had similar 
Ago2 levels and ubiquitylation patterns in vivo (Chen et al., 2012). Trim71 is 
alternatively proposed to maintain proliferation of neural progenitor cells as a 
temporal regulator of the FGF pathway (Chen et al., 2012). The reasons why these 
studies differ is unclear and may simply reflect the inherent aberration of Lin41 
overexpression in different cell lines (Ecsedi and Grosshans, 2013). Nevertheless, 
despite questions regarding the mechanism, evidence for the involvement of Trim71 in 
neural tube development is accumulating. Particularly in our laboratory, Trim71 was 
identified as a Tulp3-interacting protein and Tulp3 is negative regulator of the Shh 
Signal pathway. 
1-08 Project summary 
In this thesis I test the hypothesis that Rgnef and Trim71 act as regulators of the Shh 
signalling pathway. The hypothesis is based on their interaction with Tulp3, identified 
by previous studies in our laboratory using yeast-2-hybrid screen and CO-IP 
investigation. Tulp3 is an established negative regulator of Shh signalling pathway 
involved in a mechanism that involves primary cilia, an organelle fundamental to Shh 
signalling. My investigations centre on using Shh Light-II cell based assay to monitor 
states of Shh pathway activation in relation to changes in Rgnef and Trim71 
expression. Using siRNA, I show in vitro that reducing Rgnef expression significantly 
reduces the extent of induced Shh pathway activation. To investigate the contrasting 
effect of increasing Rgnef expression, I use an established HA tagged Rgnef expression 
construct (pcDNA3-HA-p190RhoGEF) as well as sub-clone a mammalian expression 




shown to stimulate pathway activity, hence opposite to the effect induced previously 
by siRNA Rgnef suppression. Investigation as to the possible causes of Rgnef regulation 
of Shh signal transduction was taken at a cellular level by investigating the effects on 
the primary cilia organelle. Through fluorescent immunocytochemistry, I demonstrate 
that increasing Rgnef expression significantly reduces the proportion of cells with a 
primary cilium. At an organismal level I also show that within the mouse embryo Rgnef 
is expressed in ventral floorplate of the developing neural tube. 
Shh pathway suppression was also induced by Trim71 siRNA, but through validation 
tests I discover Trim71 is not expressed in the NIH 3T3 cell line, used to construct the 
Shh-LIGHT2 cell based assay. In discovering my results to be a false positive, I 
endeavour to investigate possible causes and identify the result to be from a single 
siRNA amongst the total mix used for the experiments. 
My thesis also investigates established effectors of Shh signalling pathway by focusing 
on the vertebrate pathway transcription factor Gli2, by using mass spectrometry to 
identify putative novel sites of Gli2 post translational modification. Gli2 is one of three 
transcription factors conserved in vertebrate Shh signalling and is predominantly 
involved in pathway activation. By using mass spectrometry, I aimed to reveal sites of 
protein modification that would help to understand the role of Gli2. The challenge was 
to devise methods to adequately identify Gli2 by SDS PAGE electrophoresis and best 
practice techniques to ensure adequate protein extraction and preparation for MS. I 
also compared the use of two Mass spectrometers, The MALDI-ToF and AmaZon ETD 
ion Trap mass spectrometer. Using the Amazon ETD I was able to sequence specific 
regions of Gli2 protein. I was also able to identify established sites of Gli2 
phosphorylation as well as discover potentially novel sites. 
In summary my thesis aims are broadly to help build towards a more comprehensive 
model of the Shh signalling pathway. I aimed to further confirm and investigate 
potential new effectors of the Shh signalling Pathway, Rgnef and Trim71 and to further 
understand one its key effectors, Gli2. The model of Shh signal transduction and its 

















2-01 Mouse Embryo protocols 
2-1-01 Riboprobe synthesis 
The Rgnf expression plasmid, pBS Rgnef, was linearised (37°C, 2 hr) with XbaI 
restriction enzyme and appropriate buffer (Fermentas fast digest). Sample digests 
were then analysed using gel electrophoresis to check for digest completion. 
Linearised DNA plasmids were precipitated (0.15 M sodium acetate, 66% ethanol, -
20°C, 1 hr), centrifuged (13,000rpm, 4°C, 10 min) and washed with 70% ethanol. 
Resulting pellets were then air dried and re-suspended in RNase-free water. 
Dioxigenein-labelled (DIG-labelled) riboprobe was synthesised by incorporating 
digoxygenin-labelled dUTP during targeted transcription from the linearised plasmid 
(37°C, 2 hr). Each 20 μl reaction mix consisted of 1 x transcription buffer (Roche), 1 x 
digoxygenin labelling mix (Roche), 1 μg linearised plasmid, 20 units of RNase inhibitor 
(Invitrogen) and 10 units of T3 RNA polymerase (Roche). Transcription efficiency was 
tested by analysing a 1 μl aliquot on a 1% agarose electrophoresis gel. Successful DIG-
labelled riboprobe transcription would reveal an RNA band to be approximately 10 
times as intense as the plasmid band. The probe was then precipitated using 100 μl TE, 
10 μl 4M LiCl and 300 μl ethanol and incubated at -20°C for 2 hr. Finally probe was 
pelleted (13000 x g, 20 min at 4°C), then washed with 70% ethanol to remove salt and 
immediately re-suspended in RNase-free TE buffer. The dioxigenein-labelled riboprobe 
(DIG-labelled) could then be identified using anti-digoxygenin antibody conjugated to 
alkaline phosphatase. Visualisation requires incubation with substrates nitro-blue 
tetrazolium chloride (NBT) and 5-bromo-4-chloro-3’-indolyphosphate 
phosphotoluidine (BCIP). 
2-1-02 Wholemount in situ hybridisation 
Wild type E10.5 mouse embryos were obtained from previously processed stock, 
stored in 70% ethanol at RT. Embryos were fixed overnight with 4% paraformaldehyde 
in PBS. Following day, embryos were dehydrated through a methanol series and then 
rehydrated to PBT (0.1% Tween-20 in PBS) and then bleached (6% H2O2 in PBT, 1 hr). 
After short treatment with proteinase K (10 µg ml-1, 10 min, RT) followed by glycine (2 
mg ml-1), embryos were washed and refixed for 20 min (0.2% glutaraldehyde in 4% 




solution (50% formamide, 4x saline sodium citrate buffer (SSC; 0.6 M sodium chloride 
(NaCl), 0.06 M sodium citrate in ddH2O, pH4.5), 50 µg ml-1 yeast tRNA, 1% SDS, 50 µg 
ml-1 heparin) before adding 0.1 µg ml-1 digoxygenin-labelled riboprobe in 
prehybridisation solution for overnight incubation (70°C). 
Following day, embryos were washed twice (70°C, 30 min) in solution 1 (50% 
formamide, 5x SSC (pH4.5), 1% SDS) and twice (70°C, 30 min) in solution 2 (50% 
formamide, 2x SSC (pH 4.5), 1% SDS). Prior to blocking, embryos were washed in Tris 
buffered saline with Tween 20 (TBST: 0.14 M NaCl, 3 mM potassium chloride, 25 mM 
Tris-HCl (pH7.5), 1% Tween-20, 0.05% Levamisole) and then blocked by incubation in 
10% sheep serum/TBST (4 hr, RT). 
Anti-digoxygenin alkaline phosphatase antibody (anti-DIG-AP (Roche) 1:500) was 
incubated (4°C, 4 hr) in pre-absorbing solution (embryo powder, 1% sheep serum in 
TBST) before centrifugation (3000 rpm, 10 min). Supernatant was made up to volume 
with 1% sheep serum/TBST and applied to embryos (4°C, overnight). 
Embryos were washed with 6-8 changes of TBST (over 24 hr), equilibrated in NTMT 
(0.1M NaCl, 0.1M Tris-HCl (pH9.5), 0.05M magnesium chloride, 0.1% Tween-20, 0.05% 
Levamisole) incubated with nitro-blue tetrazolium chloride (NBT) and 5-bromo-4-
chloro-3’-indolyphosphate phosphotoluidine (BCIP) salt (20 µl ml-1 TBST) and washed 
in PBT. 
Photographs were taken using a Leica MZ16 microscope, and then embryos were 
embedded for Vibratome sectioning. 
2-1-03 Vibratome sectioning            
Embryos were fixed (20 min, 4% PFA/PBS) then washed in PBS. Embryos were coated 
in vibratome embedding mixture (0.56% gelatine 300 bloom, 22.5% sucrose, 33.75% 
albumin/ PBS). Glutaraldehyde (10 μl of 25% stock/100 μl) was added to embedding 
mixture in a mould, mixed quickly and embryos were immediately positioned in the 
desired orientation. Blocks were allowed to set (30 min, RT) then removed from the 




Embryos were sectioned using a Vibratometm series 1000 sectioning system. Blocks 
were trimmed into a trapezoidal shape and glued to the mounting plate, which was 
secured to the vibratome. Sections of 30 μm were collected on slides. Sections were 
mounted (50% glycerol/PBS), and photographed with a Zeiss AxioPhot 2 microscope. 
2-02 Cell culture 
2-2-01 Cell lines 
The mouse fibroblast (Shh-LIGHT2) cell line was provided by James Briscoe MRC, 
London (Taipale et al., 2000). The Human Embryonic Kidney (HEK293T) and NIH 3T3 
cell lines were provided by George Dickson RHUL, London. Inner Medullary Collecting 
Duct cell line (IMCD3) was provided by D. Norris, MRC Harwell. 
Sterile plastic ware and media were used, and equipment was washed (70% ethanol) 
and solutions warmed (37°C) prior to use. Shh-LIGHT2, NIH 3T3 and HEK293T Cells 
were grown in Dulbeccos’s Modified Eagle’s Medium (Sigma D6546) with 2 mM L-
Glutamine (Sigma G7513) added, 10% Foetal Bovine Serum (Gibco 10500-064) and 1% 
Antibiotic-Antimycotic (Gibco 15140-122). Selective antibiotics for Shh Light cells were 
added to a concentration of 0.4 mg ml-1 for Geneticin (Gibco 10131-019) and 0.15 mg 
ml-1 for Zeocin (Invitrogen 46-0509). IMCD3 cells were grown in DMEM: Nutrient 
mixture F-12 plus GlutaMAX™ (Gibco 31331-028), 10% Foetal Bovine Serum (Gibco 
10500-064) and 1% Penicillin-Streptomycin (Gibco 15140-122). 
2-2-02 Waking, plating and growth culture 
Frozen cell aliquots (1 ml) were rapid-thawed (37°C, gentle shaking) and gradually over 
2 min 5 ml culture media was added. To remove trypsin, Cell suspension was 
centrifuged (1000 g 10 min) and supernatant removed. Cell pellet was then re-
suspended in 10 ml culture media, transferred to T75 cell culture flasks and placed in 
an incubator (37°C, 5% CO2). At between 85-95% cell confluence a portion of cells were 
sub cultured to new flasks to continue cell line growth. 
2-2-03 Subculturing 
Culture media was aspirated and cells washed twice with PBS (without calcium or 
magnesium (Gibco)). Trypsin (TryPLE™ Select Gibco 12563-029) was added (1 ml for 75 




detachment. Once cells were detached, 5 ml medium was added to inhibit trypsin and 
entire cell suspension was then transferred to a 15 ml falcon tube. To remove trypsin 
the cell suspension was centrifuged (1000 g, 10 min) so that the supernatant could be 
separated from the resulting cell pellet. The pellet was suspended in culture medium 
(10 ml) and apportioned to new culture flasks depending on requirement and 
incubated (37°C, 5% CO2). At 85-95% confluence cells were again sub cultured. 
2-2-04 Counting cells 
Spent media was aspirated; cells were washed twice, and trypsinised and pellets 
collected as described (section 2-2-03). 16 μl of cell suspension was applied to a 
haemocytometer and cells were counted in 3 individual 10-4ml sections. An average 
was taken of the three counts and multiplied by x104 to give an estimation of cells/ml.  
2-2-05 Freezing cells 
To store, cells were trypsinised as described (section 2-2-03), centrifuged (1000 g, 10 
min) pellets were resuspended in Recovery™ cell culture freezing medium (Gibco 
12648-010) at 1 ml/million cells concentration. One ml cell suspensions were aliquoted 
into 1.5 ml cryotubes (Nunc) and stored at -70°C overnight in a CoolCell® (BioCision) to 
ensure a controlled -1°C per minute temperature drop before long term storage in a 
liquid nitrogen dewer. 
2-03 Mammalian cell transfection 
2-3-01 siRNA reverse transfecting cells with Dharmafect 
Assay samples were prepared in sterile 96 well plates (corning). All siRNA and 
transfection reagent Dharmafect was supplied by Dharmacon (Thermo Fisher 
Scientific). In each well was added 18 μl Optimem serum-free, antibiotic-free medium 
(Gibco), 2 μl Dharmafect and 100 nM siRNA (Table 2-01 for siRNA smartpools). The 
siRNA and Dharmafect were then incubated for 20 min, to optimise transfection 
complex formation. A 2x105 cells ml-1 suspension of Shh-LIGHT2 cells were prepared 
and 80 µl was added to each well containing pre-prepared 20 μl transfection complex. 
The total 100 μl Optimem preparation therefore consisted of 1.6x104 cells/well and 
complexed 20 nM siRNA concentration. Shh-LIGHT2 cells were incubated overnight 




Table 2-01 - siRNA sequences* 
ON-TARGETplus SMARTpool - Mouse Rgnef (L-040493-01-0005) 
Name Catalogue reference sequence 
Rgnef siRNA(1) J-040493-09 GUGAUGAAGUCUACGCUAA 
Rgnef siRNA(2) J-040493-10 CAUCAAACUCUUCCGGAAA 
Rgnef siRNA(3) J-040493-11 ACAUUGACCCUGACCGUUA 
Rgnef siRNA(4) J-040493-12 GCGAAUACGAGAAGAACCA 
ON-TARGETplus SMARTpool - Mouse LOC636931 (L-161015-00-0005) 
Name Catalogue reference sequence 
Trim71 siRNA(1) J-161015-01 GAUCAUAGUGGCCGACAAA 
Trim71 siRNA(2) J-161015-02 CAUCAUAGUGGCUGACCGA 
Trim71 siRNA(3) J-161015-03 CAAGAAGAUGACCGCCAUUA 
Trim71 siRNA(4) J-161015-04 GGGCAAGAUCCUCGUUUCA 
ON-TARGETplus Non-targeting pool  
Name Catalogue reference sequence 
Non-Targeting pool D-001810-10-05 Unknown 
*All siRNA was supplied by Dharmacon (Thermo Fisher Scientific) 
2-3-02 Lipofectamine 2000 DNA transfection 
Cells were grown to 80-95% confluence and transfected with Lipofectamine 2000 
(Invitrogen) according to optimised manufacturer’s instructions.  Lipofectamine (6 
μl/μg DNA) was diluted in required amount of Optimem serum-free, antibiotic-free 
medium, incubated (5 min, RT), added to the DNA (0.2-0.4 μg μl-1) in serum-free, 
antibiotic-free medium) and incubated (30 min, RT). Cell medium was replaced and 
DNA/Lipofectamine mix was introduced. Cells were incubated (4 hr-overnight, 37°C, 
5% CO2), media was replaced with serum-positive, antibiotic-free medium and 
incubated (37°C, 5% CO2, overnight). 
2-04 Gene expression protocols 
2-4-01 RNA extraction 
Total RNA was extracted from whole 3T3 cell pellets with the GenElute™ Mammalian 




instructions. Samples were lysed (with a series of needles) in lysis buffer (500 μl) 
containing guanidine thiocyanate (a protein denaturant which releases RNA) and 2-
mercaptoethanol (which inactivates RNase). Lysate was then filtered through a column 
to remove cell debris and shear DNA. Ethanol was added to the filtrate before 
application to a high capacity silica column which binds total RNA. Contaminants were 
washed away and the RNA eluted in RNase-free water. Concentrations were 
determined using a NanoDrop ND-1000 spectrophotometer (Thermoscientific) to read 
absorbance at 260 nm. 
2-4-02 cDNA Synthesis 
A 14 μl genomic DNA elimination reaction was prepared for each sample on ice, adding 
0.3 μg total RNA in 12 μl RNase-free water with 2 μl gDNA wipeout buffer. The reaction 
mix was incubated for 2 min (42°C) then immediately placed on ice. A 6 μl master mix 
was added to each reaction containing 4 μl Quantiscript RT buffer, 1 μl Quantiscript 
Reverse Transcriptase and 1 μl RT primer mix (a mix of random and oligo dT primers). 
The final 20 μl reverse transcriptase reaction was incubated for 15 min (42°C) followed 
by 3 min at 95°C to inactivate the reverse transcriptase. Preparations were used 
immediately or stored at -20°C for long term use. 
2-4-03 Polymerase chain reaction 
PCRs were performed as a 25 μl reaction consisting of 0.5 μM of each primer and 25 ng 
DNA or cDNA in 1x PCR Master Mix (BIOTAQ DNA polymerase, 1.5 mM MgCl2, 200 µM 
of each dNTP, 1 x NH4 buffer). Reactions were performed with a Chromo4 thermo 
cycler (MJResearch) and the appropriate primer combinations. 
The program comprised initial denaturation (95˚C, 5 min) followed by up to 38 cycles 
of denaturation (95°C, 15 sec), annealing (60˚C, 30 sec) and extension (72˚C, 15 sec), 
followed by a final extension (72˚C, 5 min). 
Table 2-02 Site directed primer sequences 
PCR Forward Reverse 
Rgnef GCGCGCGCGATATCATGGAGTTG GCGCGCGCGCTAGCTCAGAGGTAAAGAAT 





2-4-03 Real Time quantitative PCR 
The thermal cycler used for RT qPCR was a Rotor-Gene 6000 (Qiagen). Each individual 
20 μl sample was prepared by Qiagility, a robotic automated sample preparation 
system (Qiagen) pre-loaded with master mixes for SYBR green, Gene specific primer 
and cDNA preparations. Each 20 μl sample preparations consisted of 10 μl 2X SYBR 
green jumpstart Taq (Sigma, S4438), 5 μl gene specific primer mix (1 μM) and 5 μl of 
cDNA preparation (1:5 dilution from cDNA synthesis (section 2-5-02)). The cycling 
program comprised of initial denaturation (94˚C, 2 min) followed by 40 cycles of 
denaturation (95°C, 15 sec), annealing (60˚C, 60 sec) and extension (72˚C, 20 sec), 
during which a read was taken. The melt curve analysis program comprised of 
temperature ramping form 65 ˚C to 95 ˚C by 1 ˚C increments every 5 sec. 
Expression changes were calculated using the 2-ΔΔCT method, a method that depends 
on using the stable expression of selected reference genes for normalisation of initial 
template RNA variations (Livak and Schmittgen, 2001). In order to select sufficient 
controls, the effect of experimental conditions on the expression of 6 reference genes 
was assessed by RT-qPCR. The genes selected were GAPDH, β2-Microglobulin, 
ribosomal protein L13a, ubiquitin C, ATP synthase subunit and β-Actin. Reference gene 
primers were designed and purchased from Primer Design Ltd and were pre-validated 
to ensure they targeted their specific genes. Visual basic application GeNorm, 
incorporated in Biogazelle qbase+ software tool, was used to manage the large 
amount of data and recurring calculations required for assessment of the most stable 
reference gene in any specific experimental condition (Vandesompele et al., 2002). 
Assessment is based on the principle that expression between any two reference 
genes should be the same in all samples. Hence measurable differences between them 
indicate that one or both of these genes are not constitutively expressed 
(Vandesompele et al., 2002). By using 6 different control genes, all possible 
permutations of gene by gene stability ratios can be calculated to provide an overall 
value ratio M. Therefore M has an inverse relationship to stability; a lower value will 
RT-qpcr Forward Reverse 
Rgnef  CAGCCACAGACACTCACAAC GCCACACAATCAGAGGTAAAGA 




indicate the most stable gene expression. The worst-scoring reference gene (highest M 
value) was eliminated to then recalculate M values for all remaining genes and so on. 
By ranking the genes in this way, the optimal number of the most stable reference 
genes are identified also taking into account V; the inherent systematic variation from 
factors like machine, enzymatic and pipette variations. 
2-4-04 Agarose gel electrophoresis 
DNA was analysed by electrophoresis using agarose gels (1-2% agarose in 1 x TAE 
(Tris/Borate/EDTA: 89 mM Tris base, 89 mM Boric acid, 20 mM EDTA) containing 1x 
Sybrsafe (Invitrogen) in TBE buffer. Samples were prepared with loading buffer (25% 
glycerol in TAE with dye) and applied to the gel along with a DNA ladder Generuler 1kb 
plus DNA ladder (Promega) for bands of 0.5-12 kb or 1 kb plus DNA ladder (Invitrogen) 
for bands of 0.1-12 kb) to allow estimation of band size. A voltage of 90 V was applied 
across the gel for 30-45 min, and bands were visualized with a UV transilluminator. 
2-4-05 Sequencing 
PCR fragments and sequencing primers were sent by post to GATC for sequencing 
following the company guidelines for volume, concentration and labelling instructions. 
The results were sent via email and analysed by search and alignment tools Vector NTi 
(Invitrogen) and NCBI blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
2-05 Cloning and Subcloning 
2-5-01 Bacterial transformation 
Prior to use, competent Escherichia coli (E. coli) cells (α-Selecttm competent cells silver 
efficiency, Bioline (Cat# Bio-85026)) were stored at -70°C. When required, each sample 
aliquot (25 μl) was thawed on ice and gently mixed with 50 ng of plasmid before 30 
min incubated on ice. To facilitate plasmid transformation, cells were subjected to 
short heat-shock treatment (42°C, 45 sec) and cooled on ice. Cells were allowed to 
recover by adding 250 μl Luria Bertani (LB) broth (shaking, 37°C, 1 hr). 
Depending on plasmid induced resistance, respective antibiotic was added (50 μg ml-1 
ampicillin or 20 μg ml-1 kanamycin or 25 μg ml-1 zeocin (Invitrogen)) to melted Luria 
Bertani (LB) agar. The mixture was poured into sterile 90 mm plates. Once set, plates 




(37°C). Individual colonies were picked and grown (37°C, 8 hr with shaking) in 3 ml LB 
broth (10% tryptone, 5% yeast extract, 10% NaCl, pH7.0), again with appropriate 
antibiotic (50 μg ml-1 ampicillin or 20 μg ml-1 kanamycin or 25 μg ml-1 zeocin). 
2-5-02 Plasmid purification 
LB broth with appropriate antibiotic (30 ml) was seeded with transformed bacterial 
culture (30 μl) and incubated (37°C, overnight with shaking). Plasmids were purified 
using Plasmid Purification Midi kit (Promega) according to manufacturer’s instructions.  
Cells were pelleted by centrifugation (5000 x g, 15 min) and subjected to a modified 
alkaline lysis procedure and RNase A. Lysed cells were cleared through a filter 
cartridge, and applied to an anion-exchange resin column under low-salt and pH 
conditions. Contaminants are washed away with medium-salt wash and plasmid is 
eluted in high-salt buffer. DNA is precipitated (0.7 volumes isopropanol), pelleted 
(15000 x g, 30 min, 4°C), washed (70% ethanol) and re-suspended in Tris-EDTA (TE) 
buffer (10 mM Tris, 1 mM EDTA). 
Purification was quantified using a NanoDrop ND-1000 spectrophotometer 
(Thermoscientific) to read absorbance at 260 nm. 
2-06 Protein extraction, quantification and analysis 
2-6-01 Protein extraction 
Cells were harvested in 300-1000 µl lysis buffer (50 mM HEPES (pH 7.5), 150 mM NaCl, 
1 mM EDTA, 10% Glycerol, 1% Triton-X 100) containing 3-10 µl 100X HALT protease 
and phosphatase inhibitor (HALT #1861281 Thermo scientific) for 20 min at 4°C. Cell 
debris and nuclei were removed by centrifugation (10,000 x g, 10 min, 4°C) and 
supernatants stored at -20°C or used immediately. 
2-6-02 Protein quantification 
The DC Protein assay kit (Bio-Rad) was used to quantify protein. The protein reacts 
with copper, causing reduction of Folin reagent and development of the blue colour 
such that intensity reflects protein concentration. DC reagent A (an alkaline tartrate 




protein standard (5 μl) in wells of a flat bottom 96 well plate. DC reagent B, Folin 
reagent (200 μl) was added and the mixture incubated (45 min, RT).  
A series of BSA standards (0.25 mg ml-1, 0.5 mg ml-1, 0.75 mg ml-1, 1.0 mg ml-1, 1.25 mg 
ml-1 and 1.5 mg ml-1) were prepared by diluting BSA stock (Sigma) in the buffer used to 
extract the protein. If sample protein concentrations were expected to be high, 1:10 
dilutions were prepared to ensure measurements were taken within the assay’s 
optimal range of between 0.2 and 1.5 mg/ml. The absorbance at 750 nm was 
measured with μ Quant (Bio-tek Instruments). 
Quantification of each sample and standard was performed in duplicate, and 
absorbance values for the BSA standards were used to generate a standard curve to 
which sample absorbance values could be compared. 
2-6-03 SDS-PAGE 
Protein samples (1-16 μg) were added to SDS-PAGE buffer (1 x orange loading buffer 
(Licor) and, 1 x reducing agent (Invitrogen). Samples were then heated to denature 
proteins (70°C, 10 min) and chilled on ice until loaded. Pre-made NuPAGE 3-8% or 7% 
Tris Acetate gels (Life Tech EA03752) were used depending on molecular weight 
resolution requirements. Once removed from sealed packaging, gel preparation 
involved rinsing in water, removing comb and taking care to wash lanes with 1 x 
NuPAGE® Tris-Acetate SDS Running Buffer. Gels were secured in the XCell SureLock® 
Mini-Cell electrophoresis chamber (Life Tech), creating inner and outer chambers. 
Inner chamber was filled using 200 ml 1 x NuPAGE® Tris-Acetate SDS Running Buffer 
with 500 µl NuPAGE® antioxidant. Outer chamber was filed with 600 ml 1 x NuPAGE® 
Tris-Acetate SDS Running Buffer. Protein samples were loaded (1-16 µg) together with 
marker ladder, using either HiMark Prestained Protein Standard (Invitrogen) for 3-8% 
TA gels or Novex Sharp Pre-stained Standard (Invitrogen) for 7% TA gels. Gels were 
then electrophoresed for 70 min at 150 V. 
2-6-04 Western blotting 
Electrophoresed gels were removed from cassettes by carefully trimming edges. Prior 
to blotting, the electrophoresis gel, membranes, filter paper and sponges were soaked 




before assembly of the blotting system. When using ECL detection nitrocellulose 
membranes were used (Hybond-ECL, GE Healthcare) and when using fluorescent 
antibody detection PVDF-FL membranes (Millipore) were substituted to reduce 
background signal. PVDF-FL membranes (Millipore) were first activated by soaking in 
methanol for 15 sec.  
During blot assembly care was taken to ensure that the membrane was on the 
positively charged side of the tank relative to the gel. The tank was then filled with 
transfer buffer and transfer was performed at 100 V for 1 hr. An ice pack and magnetic 
stirrer were also included in the tank to prevent against over-heating and enable 
uniform heat distribution. 
2-6-05 Immunodetection 
After proteins of interest were transferred, the nitrocellulose membranes were 
blocked (1hr at RT with shaking) using 2% ECL Advance blocking reagent (GE 
Healthcare) in TBST (0.14 M NaCl, 20 mM Tris-HCl pH 7.6, 0.1% Tween 20). In the case 
of PVDF membranes, the blocking solution used was Odyssey blocking solution (Licor) 
to reduce background fluorescence. Blocking solution was then removed and replaced 
with primary antibody diluted in respective block for overnight incubation (4°C with 
gentle rocking). Following day, antibody solution was removed and membrane washed 
in TBST (2 rinses, 1x 15 min then 3 x 5 min at RT) to remove excess antibody. The 
appropriate HRP-conjugated or fluorescent secondary antibody was diluted in block 
and incubated with the nitrocellulose or PVDF membrane respectively (1 hr, RT with 
gentle rocking). The membrane was then washed with TBST (2 rinses, 1 x 15 min then 3 
x 5 min at RT). 
The Enhanced Chemiluminescence (ECL) Advance Western Blotting Detection Kit (GE 
Healthcare) was used for detection. Solution A (containing hydrogen peroxidase) and 
Solution B (containing luminol) were equilibrated to RT then mixed in a 1:1 ratio in a 
volume of TBST equal to the combined volume, then applied to the nitrocellulose and 
incubated in the dark (5 min, RT). The HRP-conjugated secondary antibody catalyses 
the oxidation of luminol, producing luminescence. Blots were drained and mounted 
between acetate sheets in a light-proof cassette. Blots were exposed to X-ray film (GE 




The Odyssey fluorescent reader (Licor) was used for fluorescent secondary antibody 
detection. The damp membrane was loaded onto the glass plate and loaded into the 
Odyssey for two channel near-infrared fluorescence detection, at 800 nm and 700 nm. 
Detailed below is a summary table of primary and secondary antibodies used for 
immunoblotting (IB), immunocytohistochemistry (IHC) and protein pulldowns. This 





Table 2-03 Antibody 
Primary Antibody IB IHC Species Source 
Acetylated α-tubulin - 1:100,000 mouse Sigma 
Fatty Acid Synthase 1:5000 - mouse Santa Cruz 
Gli2 1:2000 - rabbit B Wang 
Gli2 (AB26056) 1:1000 - rabbit Abcam 
Gli2 (AB7195) 1:1000 - rabbit Abcam 
HA (Clone 16B12) 1:1000 1:1000 rabbit Sigma 
Rho A B and C 1:2000 - rabbit Thermo Sci 
β-tubulin 1:5000 - rabbit Santa Cruz 
mLin41 1:1000  rabbit G. Wulczyn 
Secondary Antibody IB IHC Species Source 
IRDye 680RD anti-mouse 1:15000 - Goat Li-Cor 
IRDye 680RD anti-rabbit 1:15000 - Goat Li-Cor 
IRDye 800CW anti-mouse 1:15000 - Goat Li-Cor 
IRDye 800CW anti-rabbit 1:15000 - Goat Li-Cor 
Anti-mouse Alexa Fluor 594  1:250  Invitrogen 
Anti-mouse Alexa Fluor 488  1:250  Invitrogen 
Anti-rabbit Alexa Fluor 488  1:250  Invitrogen 
Anti-rabbit Alexa Fluor 594  1:250  Invitrogen 
Anti-mouse HRP 1:1000   DAKO 
Anti-rabbit HRP 1:1000   DAKO 





2-07 Shh-LIGHT2 cell based assay 
Media is removed from 96-well plates containing cell sample preparations to be 
assayed and replaced with 100 µl serum free medium (Dulbeccos’s Modified Eagle’s 
Medium (Sigma; D6546) with 2 mM L-Glutamine added (Invitrogen), 1% Antibiotic-
Antimycotic, 0.5% 1M HEPES buffer). Shh pathway stimulation was achieved by 
Smoothened-agonist purmorphamine. Cells were incubated for 24 hr and cells 
requiring pathway stimulation were given 25 µl of 25 µM Purmorphamine 
(Calbiochem, 540223) in 1.25% DMSO in serum free media, making a final 
concentration of 5 µM Purmorphamine, 0.25% DMSO in each well. Cells to remain 
unstimulated were given 25 µl of 1.25% DMSO in serum free media. After 24 hr the 
medium was removed and replaced with 70 µl DMEM as well as adding 70 µl DMEM to 
an additional column of wells. All wells were assayed using the Dual-Glo® luciferase 
assay system (Promega E2920) as per manufacturer’s instructions. Plate readings were 
measured on the Glomax – 96 microplate luminometer (Promega). Initial readings 
were made by adding firefly luciferase substrate (beetle luciferin) to generate 
luminescence relative to Gli transcription activity. Initial luminescence is quashed by 
the second reagent and instead replaced by luminescence from renilla luciferase 
substrate (coelenterazine). The background luminescence was assessed from DMEM 
media only assay and subtracted from all readings. Calculation of a firefly 
luminescence/Renilla luminescence ratio provides a normalised Gli Response factor 
relative to cell number. 
2-08 Immunocytohistochemistry 
Microscope slide preparation was achieved by first seeding adherent cells on 
coverslips that were in turn inserted in 6 well plates. Cells were then left overnight to 
adhere and grow on coverslips in antibiotic free culture media (37°C, 5% CO2). Cell 
transfection and control procedures were then carried out on the following day as 
described previously (section 2-03). Each sample transfection medium was then 
replaced with serum-free medium and cells incubated for 48 hr to promote 
ciliogenesis (37°C, 5% CO2). After removing medium and rinsing once with PBS, cells 
were fixed using 4% formaldehyde, 2% Triton-X in PBS (10 min, RT). Non-specific 
binding was blocked (2% BSA in PBS, 1 hr, RT) followed by primary antibody in block 




suspended in block for 1 hr incubation (gentle rocking, RT). After removing secondary 
antibody and washing cells three times with PBS, coverslips were mounted face down 
onto slides with Vectashield (Vector Laboratories) and fixed at edges with nail varnish. 
2-09 Active Rho pull-down and detection 
For each sample and control preparation, NIH 3T3 cells were cultured in T75 flasks and 
transfected according to requirement (Section 2-02; Section 2-03). Active Rho Pull-
Down and Detection Kit (Thermo Scientific 16116) was used to identify Rho activity, as 
per manufacturer’s instructions. After completion of sample transfection and control 
preparations, cells were cultured for 48 hours. Protein extraction was achieved by first 
removing all media from the flasks by aspiration and PBS wash. Then by adding 1 ml of 
Lysis buffer (25 mM Tris HCl, pH7.2, 150 mM NaCl, 5 mM MgCl2, 1% NP-40 and 5% 
glycerol) containing 10 µl 100X HALT protease and phosphatase inhibitor (HALT 
#1861281 Thermo scientific) for lysate preparation (20 min at 4°C). Cell debris was 
pelleted (16,000 x g at 4°C for 15 min) and the supernatant was measured for total 
protein (section 2-6-02). Lysate required for each sample was then taken, ensuring 
there was 500 µg of total protein per preparation (recommended range between 500 – 
1000 µg). Positive and negative controls were prepared by first adding 10 µl 0.5 M 
EDTA pH8 to 1 ml un-transfected lysate. The positive control was prepared by adding 5 
µl 10 mM GTPγS to 500 µl lysate preparation and 5 µl 10 mM GDP to remaining 500 µl 
lysate for the negative control. These control samples were then agitated and 
incubated (30°C, 15 min) before stopping the reaction with 32 µl 1 M MgCl2. 
The Rho pull-down spin cups were prepared with 100 µl glutathione agarose (50% 
resin slurry), 400 µg of GST-Rhotekin-RDB. For each sample 700 µl (500 µg total 
protein) was added to a spin cup, as well as the for the 500 µl negative and 500 µl 
positive controls. Sample reaction mixture were incubated at 4°C for 1 hr with gentle 
rocking. The spin cup samples were then washed three times by centrifugation (6000 x 
g, 20 sec) with lysis buffer. Sample proteins were eluted with 50 µl SDS-PAGE loading 
buffer and prepared for SDS-PAGE and immunoblotting (section 2-6-03 to 2-6-05). The 
primary antibody used was rabbit anti-Rho (RhoA, RhoB and RhoC) at a concentration 




2-10 Mass Spectrometric protein preparation and analysis 
2-11-01 Cell culture protein production 
HEK293-T cells were grown in vented T75 cell culture flask (Corning) using DMEM 
supplemented with 10% fetal bovine serum and 1% Penicillin/Streptomycin. Cells were 
seeded, grown overnight and then transfected with a plasmid encoding the HA-tagged 
gene of interest using Lipofectamine 2000. After 48 hr, cells were harvested in lysis 
buffer (50mM HEPES (pH 7.5), 150 mM NaCl, 1 mM EDTA, 10% Glycerol, 1% Triton-X 
100) containing 1 x HALT protease and phosphatase inhibitor cocktail (Thermo 
Scientific) for 20 min at 4°C. Cell debris and nuclei were removed by centrifugation at 
10,000 x g (10 min, 4°C). 
2-10-02 Enrichment of Gli proteins using a biotinylated DNA oligonucleotide 
Both the Gli binding site sequence and the mutated binding site control sequence 
oligonucleotides (oligo) were resuspended in water to a final concentration 5 µg µl-1. 
The sense sequence oligo, with biotin at the 5’ end, was annealed to the reverse 
sequence oligo by incubating for 2 min at 90°C followed by 10 min at 65°C and 10 min 
at 37°C. The mix consisted of 5 µl sense oligo, 5 µl antisense oligo and 5 µl 10 x 
annealing buffer (100 mM Tris-HCl (pH 8.0), 10 mM EDTA, 500 mM NaCl). Final volume 
of 50 µl was prepared by adding 35 µl water. 
The sequences used for Gli binding and mutated Gli binding site was as follows (Pan et 
al., 2006): 
Gli binding sequence  
GAC GCG TGG ACC ACC CAA GAC GAA ATT CAC A 
CTG CGC ACC TGG TGG GTT CTG CTT TAA GTG T  
 
Mutated sequence (changes underlined)  
GAC GCG TGG ATT ACA TAA GAC GAA ATT CAC A 
 CTG CGC ACC TAA TGT ATT CTG CTT TAA GTG T 
Streptavidin conjugated magnetic beads (New England BioLabs) were prepared by 
washing  A 100 µl of beads 4 times with TNE buffer (10 mM Tris (pH8), 100mM NaCl, 1 
mM EDTA). Beads were then resuspended in 200 µl TNE and equally divided for 




oligos (2 ug) were added to 100 µl beads, then rotated 30 min at RT. Beads were then 
washed with TNE buffer and resuspended in 100 µl TNE buffer. 
Confluent cells from T75 cell culture flask (corning) were lysed in 300 µl lysis buffer 
(50mM HEPES (pH 7.5), 150 mM NaCl, 1 mM EDTA, 10% Glycerol, 1% Triton-X 100) 
containing 1X HALT protease and phosphatase inhibitor cocktail (Thermo Scientific) for 
10 min at RT, then incubated with 20 µl of earlier prepared beads whilst being rotated 
for 1-2 hr at 4°C. The magnetic beads were pulled down and washed with lysis buffer 
four times (using 500 µl or more for each wash). Proteins were then eluted with 20 µl 
Elution buffer (50mM HEPES (pH 7.5), 1M NaCl, 1 mM EDTA, 10% Glycerol, 1% Triton-X 
100) at RT for 15 min. 
2-10-03 In-gel trypsin digestion 
Gels were loaded and electrophoresed as detailed previously (section 2-6-03). 
Electrophoresed gels were removed from the plastic cassettes and trimmed to remove 
the stacking gel and wells. Proteins were silver stained using Sigma ProteoSilverTM 
silver stain kit, as per manufacturer’s instructions. Required protein regions or bands 
were excised from the gel with a sharp scalpel and fragmented to 15 mm3 cubes, then 
destained in a 1:1 mixture of 30 mM K3Fe(CN)6 and 100 mM Na2S2O3 until completely 
clear. Gel fragments were equilibrated in 50 mM ammonium bicarbonate before 
drying in acetonitrile in three 15 min washes. Once dry gradual (5 µl volume) additions 
of 12.5 ng µl-1 Trypsin (Promega Cat:V5111) in 50 mM ammonium bicarbonate buffer 
was made to allow absorption into the gel until the gel pieces were rehydrated to their 
original size. After 30 min on ice to allow the enzyme to saturate gel pieces, 25 µl 50 
mM ammonium bicarbonate buffer was added and preparations were incubated for 36 
hr at 37°C.  
The supernatant from the in-gel digest was removed by pipette from the gel pieces 
into a 1.5 ml protein LoBind tube (Eppendorf 022431081). To the gel pieces was added 
25 µl of 50% acetonitrile solution with 5% formic acid for 15 min sonification. The 
supernatant was removed and added to the previous supernatant collection and the 
procedure then repeated twice more. The peptides were concentrated down to 1-2 µl 
using a speed-vac then enriched and purified using a C18 Zip tips© (Merck Millipore).  




resin tips, used for concentrating and desalting procedures for peptides up to 40 kDa. 
Peptides were then eluted with 80% acetonitrile solution with 5% formic acid for 
MALDI-ToF mass spectrometry. 
2-10-04 Anti-HA magnetic bead Immunoprecipitation 
The method required magnetic beads covalently coupled to high-affinity mouse IgG1 
monoclonal antibody (Pierce clone 2-2.2.14). For each sample preparation, 25 µl (0.25 
µg) anti-HA magnetic beads (Pierce 88836) were mixed with 125 µl of 0.05% TBS-T in 
1.5 ml protein LoBind tubes (Eppendorf 022431081). The supernatant was removed 
using a magnetic stand to hold the beads and the beads were washed twice more with 
1 ml 0.05% TBS-T. Sample containing the HA-tagged protein was added to the pre-
washed magnetic beads and incubated at room temperature with gentle rocking. 
Remaining lysate supernatant containing unbound protein was collected for analysis 
and beads were washed twice more with 0.05% TBS-T, followed with a final ultra-pure 
water wash. Protein elution was achieved by adding 100 µl 50mM NaOH to the beads 
at room temperature for 5 min with mixing. The eluent was magnetically separated 
from the beads and stored at -20°C if not used immediately. 
2-10-05 In-solution trypsin digest 
Protein was precipitated from the sample eluents by adding five volumes of ice cold 
acetone and incubating overnight at -20°C. To pellet precipitated proteins, samples 
were centrifuged (13,000 x g for 30 min at 4°C), then supernatant discarded and 
pellets allowed to partially dry for 10 min. Samples were then re-suspended for a 15 
min incubation at 50°C in 20 µl of 45 mM dithiothreitol (DTT) in 50 mM ammonium 
bicarbonate buffer (ABC) in LC-MS Chromasolv water (Sigma 39253). Samples were 
then incubated for 15 min at room temperature in the dark after adding 20 µl of 100 
mM solution of iodoacetamide (IAA) dissolved in 50 mM ABC in LC-MS Chromasolv 
water (Sigma 39253). To destroy any excess IAA a further 20 µl of 45 mM DTT in 50 
mM ABC in water was added followed by 20 µl 12 ng µl-1 in 50 mM ABC water to make 
a final concentration of 3 ng µl-1 trypsin in 80 µl 50 mM ABC water. Samples were 
incubated overnight at 37°C where proteins were reduced to trypsin digested 
fragments. Sample peptide enrichment and purification was achieved by C18 column 




2-10-06 Mass spectrometric analysis – AmaZon ETD 
LC-MS/MS analysis was performed on an Ultimate™ 3000 RSLCnano HPLC system 
(Thermo Scientific Dionex) coupled to an Amazon ion trap mass spectrometer (Bruker) 
by a nano spray ion source (Bruker). Tryptic peptide mixtures were automatically 
injected (3 μl) and loaded at a flow rate of 4 μl min-1  in loading solvent (2% acetonitrile 
and 0.1% formic acid in HPLC-grade water) onto a nano trap column (75 μm i.d. × 2 cm, 
packed with Acclaim PepMap100 C18, 3 μm, 100 Å; Dionex). Peptides were eluted and 
separated on the analytical column (75 μm i.d. × 25 cm, Acclaim PepMap RSLC C18, 
2μm, 100 Å; Dionex) by a multi-step gradient. Starting conditions consisted of 96% 
solvent A (0.1% formic acid in HPLC grade water), 4% solvent B (0.1% formic acid in 
acetonitrile) at a flow rate of 250 nl min-1. Peptides were eluted from the column by 
graduated introduction of solvent B to 25% at 70 min, the rate was increased up to 
60% at 90 min and to 90% at 90.5 min. The column was washed with solvent B (90%) 
for 10 min before equilibration in the starting conditions for a further 20 min. The 
complete runtime was 120 min. 
The eluted peptides were analyzed using an AmaZon ion trap ETD mass spectrometer. 
From the mass spectrometry (MS) survey scan with a mass range of 300–1,500, the 5 
most intense multiply charged ions were selected for fragment analysis in the ion trap 
if they exceeded an intensity of at least 2500 counts. Every ion selected for 
fragmentation was excluded for 20 sec by dynamic exclusion. Fragmentation was 
actioned consecutively by both collision-induced dissociation (CID) and electron 
transfer dissociation (ETD). The normalised collision energy for CID was optimised 
automatically by Smartfrag (Bruker). 
For qualitative results the raw data were analyzed using Mascot (Matrix Science; 
version 2.4.0). Tandem mass spectra were extracted, charge state deconvoluted and 
deisotoped by DataAnalysis (ESI Compass, version 4.0) and BioTools. All MS/MS 
spectra were searched against the SwissProt database using Mascot. The search was 
restricted to Mammalia (Mammals), 2014_01 to 03 database, assuming the digestion 
enzyme trypsin, a fragment ion mass tolerance of 0.5 Da and a parent ion tolerance of 
0.5 Da. Carbamidomethyl of cysteine was specified as a fixed modification and 




phosphorylation events Serine, Threonine and Tyrosine was specified in Mascot as 
variable modifications. Protein identifications were only accepted if they contained at 
least 2 identified peptides and the ion score values (-10log(P)) above a 95.0% 
probability threshold value (p<0.05) that the observed match was not a random event. 
2-10-07 Mass spectrometric analysis – MALDI ToF 
All analyses were prepared on a MALDI-ToF instrument in positive reflectron mode 
(Bruker) and peptide mass fingerprints were searched using the MASCOT search 
engine (Perkins et al., 1999). Calibration was achieved using peptide calibration 
standard (Bruker 206195) in 0.1% formic acid water (CHROMASOLV, Sigma 39253). 
Peptide standards covered a mass range between 1000 Da – 3200 Da and were; 
angiotensin II, angiotensin I, Substance P, Bombesin, ACTH clip 1-17, ACTH clip 18 – 39 
and Somatostatin 28. During analysis, calibration was conducted before first analysis 
and every hour thereafter. Samples were prepared by premixing 1:1 with a saturated 
solution of HCCA matrix. HCCA matrix was prepared by sonification of 3 mg α-cyano-4-
hydroxycinnamic acid (HCCA, (Bruker 201344)) in 300 μl high grade acetone 
(CHROMASOLV® plus, Sigma 650501) before adding 600 μl molecular grade ethanol 
(Sigma E7023). A 0.5 µl of each sample was spotted to MTP AnchorChip 600/385 target 
plate (Bruker), mixed with 0.5 µl HCCA matrix suspension. Once all samples were 
prepared they were left to dry, forming crystallised complexes. Monoisotopic peptide 
masses in the mass range  800-3500 Da were collected and used in the database 
search. The search parameters allowed for an error of 0.5 Da, carbamidomethyl 
modification of cysteine residues, oxidation of methionine and assumed trypsin 














Chapter 3: Investigation of the role of 





Rgnef is a 190 kDa guanine nucleotide exchange factor (GEF) that binds and activates 
RhoA by facilitating energy transfer exchange of bound GDP to GTP. Rgnef has largely 
been associated with cytoskeleton remodelling, specifically in the regulation of a large 
complex of proteins called focal adhesions that provide mechanical anchorage to the 
ECM. Focal adhesions are also a hub for integrin and adhesion-mediated signalling. In 
this chapter I test the hypothesis that Rgnef acts as regulator of the Shh signalling 
pathway. The hypothesis is based on being identified as a Tulp3 binding partner by 
previous yeast-2-hybrid screen and CO-IP investigations in our laboratory. Tulp3 is an 
established negative regulator of Shh signalling pathway involved in a mechanism that 
involves primary cilia, an organelle fundamental to Shh signalling.  
My investigations centre on using a Shh-LIGHT2 cell based assay to monitor states of 
Shh pathway activation in relation to changes in Rgnef expression. Using siRNA 
transgenic suppression, I show in vitro that reducing Rgnef expression significantly 
reduces the extent of induced Shh pathway activation. To investigate the contrasting 
effect of increasing Rgnef expression, I use an established HA tagged Rgnef expression 
construct (pcDNA3-HA-p190RhoGEF) and sub-clone a mammalian expression vector 
pCAGGS Rgnef, for untagged expression. Increasing Rgnef expression is then shown to 
stimulate pathway activity, consistent with the pathway suppression results induced 
by Rgnef suppression. Investigation as to the possible causes of Rgnef regulation of 
Shh signal transduction was taken at a cellular level by investigating the effects on the 
primary cilia organelle. Through fluorescent immunocytochemistry, I demonstrate that 
increasing Rgnef expression significantly reduces the proportion of cells with a primary 
cilium. At an organismal level I also show that within the mouse embryo Rgnef is 
expressed ventrally in the floorplate of the developing neural tube. 
3-01 In developing embryos Rgnef is expressed in the neural tube. 
The aim was to examine the expression of Rgnef in the developing mouse embryos. 
Whole mount in situ hybridisation (WMISH) can effectively provide snapshots of 
localised gene expression during different periods of embryonic development. This 
required the sub-cloning of Rgnef cDNA into a suitable plasmid vector to allow RNA 
probe synthesis. The full length Rgnef cDNA was obtained from Dr Moolenaar in 




information available on the multiple cloning site was found to be incomplete after 
preliminary restriction enzyme mapping. The aim was to therefore remove the whole 
Rgnef sequence from pcDNA3-HA-p190RhoGEF and insert it into pBluescript (KS). The 
vector pBluescript is a well-established high yield plasmid containing RNA polymerase 
promoter sites for probe synthesis. 
3-1-01 pBS Rgnef: Subcloning Rgnef from pRgnefHA (pcDNA3) into pBluescript (KS) 
The first step was to remove the Rgnef cDNA insert from pcDNA3-HA-p190RhoGEf; an 
Rgnef expression construct that adds a 5’ HA tag epitope (Gebbink et al., 1997). A 
working schematic of pcDNA3-HA-p190RhoGEF was devised by a combination of 
published pcDNA3 sequence and Rgnef sequence MMU73195 (Figure 3-01 A). Multiple 
cloning site information was found to be incomplete after preliminary restriction 
enzyme mapping. Rgnef insertion site regions were sequenced to detail the multiple 
cloning sites flanking the inserted 6.2 kb Rgnef sequence. This was then used to 
accurately combine sequences for pcDNA3 and 6.2 kb Rgnef (MMU73195). This 
revealed that there were no restriction sites that could remove the 6.2 kb Rgnef coding 
sequence from the pcDNA3 vector in a single fragment.  
It was however possible to remove Rgnef in two fragments using SacII and EcoRI 
restriction enzymes (Figure 3-01 A). Restriction enzyme SacII digest of pcDNA3-HA-
p190RhoGEF produced a 3 kb product consisting approximately of the first half of the 
Rgnef sequence, named 5’-Rgnef fragment. This fragment contained an XbaI 
restriction site situated 12 bp upstream from the Rgnef sequence start codon. XbaI 
enzyme digest provided a 5’ cleavage restriction site that is not repeated along Rgnef’s 
entire sequence. The second half of Rgnef was removed by an EcoRI digest, producing 
a 2.4 kb product, referred to as the 3’-Rgnef fragment. The overlap of 113 bp with the 
5’-Rgnef fragment was removed with SacII digest. An entire Rgnef sequence would 
require both fragments to be ligated. 
The 2.4 kb SacII-EcoRI 3’-Rgnef fragment was first ligated into pBluescript, prepared by 
double digest with SacII and EcoRI. This plasmid was subsequently linearised with SacII 
and the SacII-SacII 5’Rgnef fragment inserted, to complete the entire Rgnef sequence. 
As both ends of the 5’ fragment have SacII overhangs, this fragment can insert in either 




the SacII-SacII insert cloned in the correct orientation. Correct orientation of the 5’-
Rgnef fragment would be identified by the presence of 5.9 kb and 2.4 kb fragments 
following EcoRI digestion, as opposed to 5.2 kb and 3 kb fragments. Once identified, 
respective colonies were further cultured for high yield followed by maxi-prep plasmid 
purification of pBS Rgnef (figure 3-01 B). It was then possible to synthesise antisense 
RNA probes from the 3’ end of the full length cDNA sequence of Rgnef (Figure 3-01 C). 
3-1-02 Rgnef ventral neural tube expression in developing embryos 
Whole mount in situ hybridisation (WMISH) on six E10.5 embryos using Rgnef 
antisense RNA probes revealed defined Rgnef expression all along the neural tube 
(Figure 3-02 B). WMISH on E10.5 embryos using Shh antisense RNA probes were also 
prepared and demonstrated a comparable, although more intense, expression pattern 
along the neural tube (Figure 3-02 A). Transverse sections of neural tube revealed 
Rgnef expression was localised to the ventral region of the neural tube, in the floor 
plate (Figure 3-02 D). This was similar to the floor plate expression domain observed 
for Shh although, unlike Shh, Rgnef was not expressed in the notochord (Figure 3-02 C 
and D). This expression pattern was not observed in Rgnef sense controls. The results 
are consistent with Rgnef expression potentially playing a role in neural tube 































































Figure 3-01 Working schematic of pcDNA3-HA-p190RhoGEF and Rgnef 
Riboprobe synthesis 
(A) A working schematic of pcDNA3-HA-p190RhoGEf; an Rgnef expression construct 
that adds a 5’ HA tag epitope (Gebbink et al., 1997). Multiple cloning site information 
was found to be incomplete after preliminary restriction enzyme mapping. Rgnef 
insertion site regions were sequenced to detail the multiple cloning sites flanking the 
inserted 6.2 Kb Rgnef sequence. This was then used to accurately combine sequences 
for pcDNA3 and 6.2 Kb Rgnef (MMU73195). It was then possible to discover a means 
of removing Rgnef in full by restriction digest removal of two fragments, 5’-Rgnef and 
3’-Rgnef using SacII and EcoRI restriction enzymes. (B) A schematic of p blusescript II 
(K+) Rgnef (pBS Rgnef), the final plasmid construct that was used to synthesise Rgnef 
riboprobe used in this study. (C) Validation of riboprobe synthesis results by loading 5 
µl sample of synthesised product onto 1% agarose gel. Results show a 2.2 Kb Rgnef 
riboprobe synthesised from pBS Rgnef. Antisense riboprobe is synthesised from the 3’ 




















































Figure 3-02 In developing embryos Rgnef is expressed in the neural tube 
Representative example of wholemount in situ hybridisation on E10.5 wild-type 
embryos with antisense probe for (A) Shh and (B) Rgnef expression.(A-B) Rgnef 
antisense probe reveals expression all along the neural tube that is comparable to 
neural tube expression of Shh neural tube expression. (C) Mid region neural tube 
transverse sections reveals intense Shh expression in floorplate and notochord (D) 
Rgnef expression is also detected in the floorplate but not in the notochord. (E) 
Negative control preparation using Rgnef sense probe on E10.5 wild-type embryo 
reveals a distinct lack of neural tube expression demonstrated in (B) when using Rgnef 
antisense probe.    












3-02 Efficacy of Shh-LIGHT2 cell assay in monitoring Shh pathway activation 
The hypothesis that Rgnef is involved in regulating the activity of the Shh signalling 
pathway was tested functionally using the Shh-LIGHT2 cell assay. The aim was to test 
whether changes in pathway activation were detectable following forced changes in 
Rgnef expression level. Shh-LIGHT2 cells provide a cell based assay that can monitor 
states of Shh pathway activation. Initially a mouse fibroblast NIH 3T3 cell line, these 
cells were adapted by stably transfecting with two reporter constructs (Taipale et al., 
2000). Quantitative assay of Gli activity is achieved using a firefly-luciferase reporter 
gene with 8 copies of the Gli-binding site promoter (Sasaki et al., 1997). Shh signalling 
pathway Gli activator transcription factors will attach to the Gli binding sites and drive 
firefly-luciferase expression to providing a detectable readout of activity in the 
presence of a luminescent substrate. The second reporter enables cell number 
normalisation between experimental replicates as it encodes a stable Renilla luciferase 
enzyme and different luminescent substrate (Taipale et al., 2000). Tests were carried 
out in order to ensure that in our hands, the Shh-LIGHT2 cells provided a viable test for 
Shh pathway activation. Shh pathway stimulation was achieved by Smoothened-
agonist purmorphamine. Shh pathway stimulation was tested by purmorphamine in a 
dose response manner with readings taken at 0.05, 0.5, 5 and 50 μM purmorphamine 
concentrations (Figure 3-03 A). Readings conform to a dose response curve with 
maximum activation at 5 μM and 0.6 μM EC50. At the highest dose of purmorphamine, 
luciferase activation starts to drop. Cell toxicity is not observed as there are no changes 
in relative cell number indicated by the renilla reporter. The assay window is the 
measure of minimum and maximum levels, calculated here as the difference between 
unstimulated and purmorphamine-stimulated signalling states. The maximum level of 
activation was calculated as the normalised Gli luciferase response at 5 μM 
purmorphamine, ensuring luminescence reading from a blank (DMEM culture media) 
was subtracted. Taking the background level of response as the baseline, 5 µM 
purmorphamine activation led to an approximately 10-fold increase in response 
(Figure 3-03 B). The assay window was also tested across a range of cell confluence 
levels. The results show that above 50% cell confluence it is possible to clearly discern 






















































































































Figure 3-03 Shh-LIGHT2 cell reporter assay detects Shh pathway 
activation 
(A) Dose response Purmorphamine activation of Shh-LIGHT2 reporter assay. At 95% 
confluence, cells were serum starved for 24 hours before Shh pathway was stimulated 
at 0.05, 0.5, 5 and 50 μM purmorphamine concentrations (n=4). The resulting dose 
response curve shows maximum activation at 5 μM and the EC50 at 0.6 μM 
purmorphamine (B) The difference between purmorphamine stimulated and 
unstimulated cells. A concentration of 5 µM purmorphamine used to activate the cells 
led to an approximately 10 fold increase in luciferase activity and is a measure of the 
potential assay window (p<0.001, n=12). (C) The effects of reducing cell number on 
normalised Gli activity. Cells were seeded in 96-well plates using the range of initial cell 
numbers indicated. Following overnight incubation the percentage cell confluence was 
approximately determined before being left 24 hours in low serum conditions. Cells 
were incubated for a further 24 hours in the presence (red) or absence (blue) of 5 µM 
purmorphamine. The resulting combined Gli-luciferase normalised activation level is 






3-03 Rgnef siRNA transfection validation  
Shh pathway activation in Shh-LIGHT2 cells can provide a means to monitor any 
changes in relation to variation in Rgnef expression. To achieve Rgnef gene 
suppression cells were transfected with a 20 nM pool of 4 Rgnef siRNA 
oligonucleotides. Once bound to their targets, creation of  dsRNA evokes RNA-induced 
silencing complex (RISC) proteins  that effectively remove them before they can direct 
protein synthesis (Filipowicz, 2005). 
Identification of endogenous Rgnef expression in Shh-LIGHT2 cells was first achieved 
by standard PCR (Figure 3-04). Following on from this, the effect of targeted siRNA 
knockdown on Rgnef expression was monitored by quantitative RT-PCR (RT-qPCR), 
using SYBR green assays.  Experiments compared cells transfected with Rgnef-targeted 
siRNA against cells transfected with non-target siRNA. Expression changes were 
calculated using the 2-ΔΔCT method and accurate normalisation was achieved by using 
GeNorm to ensure stable reference genes were selected (section 2-4-03) (Livak and 
Schmittgen, 2001, Vandesompele et al., 2002). The overall results show the average of 
all geNorm values M was less than 0.2, an indication of very high reference target 
stability. Specifically, the optimal number of reference targets in this experimental 
situation is 2 (geNorm V <0.15). ATP synthase subunit and β-Actin were identified as 
the two most stable reference genes for optimal normalisation (Figure 3-05 A). When 
using ATP synthase subunit and β-Actin as calibrators, Rgnef siRNA transfection was 
found to reduce Rgnef gene expression by 50% (Figure 3-05 B).  
In summary, Rgnef siRNA transfection has been shown to reduce endogenous Rgnef 
expression. Also highlighted is the importance of identifying stable reference genes 














Figure 3-04 PCR detection of endogenous rgnef expression in Shh-LIGHT2 
cells 
(A) Primers designed from Rgnef sequence accession number NM_12026.2 are 
predicted to produce a PCR product of 585 bp. These primers successfully detected 
Rgnef from E10.5 mouse embryo cDNA. Detection of Rgnef in Shh-LIGHT2 cells is 
shown by bands in lane 2 and 4. The faintness of the bands suggests a low amount of 
template cDNA synthesis or initial RNA extraction. Lanes 1-2 and 3-4 differ by the 
presence or absence of serum in the culture media;  lanes 3-4 are from cells cultured in 
serum free media whereas lane 1-2 are from cells cultured in standard 5% serum 
media. These two types of culture media are required during each Shh LII experimental 
assay. Lane 2 and 4 cDNA synthesis controls are RT reactions without the reverse 
transcriptase enzyme. The bands here are considerably fainter than Rgnef primer 
detection in lane 1 and 3. Genomic DNA is not detected as primers were designed to 
be intron spanning and RNA samples were treated with DNAse to remove any 
contaminating genomic DNA prior to cDNA synthesis. In conclusion, the contrast in 
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Figure 3-05 RT-qPCR validation of Rgnef siRNA knockdown in Shh-LIGHT2 
cells 
(A) RT-qPCR using 6 reference genes; GAPDH, β2-Microglobulin (B2M), ribosomal 
protein L13a (RPL13A) ubiquitin C (UBC), ATP synthase subunit (ATP5B) and β-
Actin(ACTB). The stability of the reference genes could be assessed ,under these 
specific experimental conditions, based on relative expression with each other 
(Vandesompele et al., 2002). (B) The two most stable reference genes were ATP5B and 






3-04 Lipid based transfection reagents reduce the Shh-LIGHT2 cell based 
assay window 
Investigating loss of targeted gene function in the Shh-LIGHT2 cell based assay was 
achieved through transfection of siRNA oligonucleotides. To assist the passage across 
cell membranes siRNA is complexed with lipid-based transfection reagent Dharmafect® 
(Dharmacon Ltd). However tests revealed that Dharmafect® treated cells had 
suppressed activation when stimulated with 5 µM purmorphamine (p<0.001, n=12) 
(Figure 3-06 A). Furthermore the baseline level of activation detected in unstimulated 
cells was also reduced when cells were treated with Dharmafect (p=0.013, n=12), thus 
demonstrating an effect produced by Dharmafect alone and not in combination with 
stimulating agent purmorphamine (Figure 3-06 A). Although the assay window is 
reduced, Dharmafect treated cells are still able to show significant differences 
between activation states (p=0.001, n=12) (Figure 3-06 A). 
Although the integrity of the assay window from Dharmafect treatment is still 
sufficient to measure changes in Shh pathway activation, this in itself cannot be taken 
to imply that the cell and molecular mechanisms of the Shh signalling pathway are now 
entirely representative of a normal state. One organelle in particular, the primary 
cilium, is hypothesised here to be particular susceptible to lipid-based transfection 
reagents. In allowing passage through cell membranes, lipid based transfection 
reagents are disruptive to cell membranes and the proteins they contain. Hence 
Dharmafect may directly disrupt the primary cilia or the process of ciliogenesis, putting 
into question the efficacy of these cells in representing the Shh pathway. The effect of 
Dharmafect on primary cilia was examined by immunocytochemistry comparison of 
Dharmafect treated and untreated NIH 3T3 cells. Cells were stained with mouse anti-
acetylated tubulin primary antibody, as tubulin acetylation is a post translational 
modification found predominately in primary cilia and visualised in red with secondary 
antibody anti-mouse Alexa Fluor 594. Preparations were mounted with Vectashield™ 
mounting media (Vector Labs) plus nuclear stain DAPI and viewed with 60X oil 
immersion objective. Images taken at random clearly displayed contrasting nuclei in 
blue and and cilia in red (Figure 3-06 B). Comparisons of the proportion of cells 
exhibiting cilia were found to not be significantly different between treated and 




Dharmafect does not lower primary cilia numbers. Given the importance of primary 
cilia in Shh signal transduction, a lack of primary cilia in Shh-LIGHT2 cells would make 
this assay an obsolete reporter of Shh pathway activity. Hence the results provide a 
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Figure 3-06 Dharmafect suppresses Shh pathway cell assay response 
without affecting number of cells expressing cilia. 
(A) NIH 3T3 cells grown in 96 well plate wells were incubated in transfection reagent 
before 24 hour serum starvation. Transfection reagent Dharmafect suppresses both 
the background level of Gli reporter activation (p<0.001, n=12) and the level of 5 µm 
purmorphamine stimulated activation (p=0.013, n=12). Despite the effect of 
Dharmafect, the Shh-LIGHT2 assay window can still distinguish between activation 
states (p=0.001, n=12). (B) An example image of well contrasted cell nucleus in blue 
and primary cilia in red. Cells were probed with mouse anti-acetylated tubulin primary 
antibody and stained in red with Alexafluor anti-mouse 585 fluorescent secondary 
antibody. Preparations were mounted with Vectorshield plus DAPI (blue). (C) Results 
summarising image counts of cilia and nucleus in repeated images of stained cells. The 
ratio of cilia to nucleus in 190 Dharmafect treated cells is not significantly different 






3-05 Investigating the role of Rgnef in Shh pathway regulation  
The assay results of Shh-LIGHT2 cells transfected with 20 nM Rgnef-targetted siRNA 
were compared with Non-target siRNA transfected cells to ensure the changes were 
based only on the effect of specific Rgnef targeting sequences. Shh Pathway activation 
was induced by 5 µM purmorphamine and luminesce measured using the Promega 
dual-Glo Luciferase assay. 
Results show a significant 22% suppression of normalised Gli-luciferase activity 
following Rgnef siRNA knockdown compared to non-target siRNA transfected cells 
(p=0.01, n=52) (Figure 3-07). A further increase of Rgnef siRNA concentration to 100 
nM resulted in 43% suppression. As shown above (Section 3-03) the knockdown of 
Rgnef expression identified by RT-qPCR was 50%, so that at best not even a near 
complete knock down of expression and yet suppression of pathway activation was 








Figure 3-07 Investigating the role of Rgnef in Shh pathway regulation 
Shh-LIGHT2 cells are serum starved to induce ciliogenesis prior to Shh pathway 
activation induced by 5µM purmorphamine. Shh-LIGHT2 cell assay results show that 
pathway stimulation is significantly suppressed in cells transfected with Rgnef siRNA 
compared to cells transfected with non-target siRNA under the same conditions. A 
five-fold increase of Rgnef siRNA treatment to 100 nM further suppresses activation. 












































3-06 Investigation of Rgnef over-expression on Shh signalling pathway 
A further test for the involvement of Rgnef in regulating Shh signalling was achieved by 
observing the effect of Rgnef overexpression on the Shh signalling pathway. The 
overexpression of HA tagged Rgnef was possible by using plasmid construct pcDNA3-
HA-p190RhoGEF (Gebbink et al., 1997). The expressed HA-taggedRgnef protein can 
assist in future protein purification or protein localisation studies. However, as the 
addition of an HA tag may impair normal protein function, a second sub-clone of Rgnef 
in pCAGGS-IRES-nls-GFP plasmid vector was also constructed. Expression vector 
pCAGGS-IRES-nls-GFP (pCAGGS) is a bicistronic mammalian expression vector 
consisting of a gene insertion site upstream of an internal ribosomal entry site (IRES) 
and nuclear localization sequence (nls) (Niwa et al., 1991). Therefore pCAGGS Rgnef 
can independently express untagged Rgnef protein and GFP protein , hence a means of 
validating plasmid transfection without adding (potentially) functionally interfering 
attachments to your protein of interest. Furthermore pCAGGS Rgnef is an ideal 
construct for in ovo electroporation of chick embryo, a powerful system to study in 
vivo effects of increasing Rgnef gene expression on dorsal ventral patterning 
(Voiculescu et al., 2008, Briscoe and Ericson, 2001). 
3-6-01 pCAGGS Rgnef: Subcloning Rgnef from pBS Rgnef into pCAGGS 
Full length Rgnef was extracted from pBS Rgnef (Section 3-01) through XbaI and ClaI 
double digest, then ligated into pCAGGS plasmid multiple cloning sites prepared by 
NheI and ClaI double digest. The overhanging DNA strand created by XbaI digest at the 
5’ end of Rgnef fragment complements the NheI overhang at the 3’ end of pCAGGS. 
The Cla I site on pCAGGS was initially found to be blocked by Dam I methylation, which 
was overcome by preparing the plasmid in Dam I methylation mutated E.coli SCS110 
Competent cells. These cells lack the ability to produce Dam1 methylation, so that the 
block on the ClaI restriction sites was removed. 
The NheI and XbaI enzyme digests produce complementary DNA strand overhangs, but 
once ligated both the NheI and XbaI restriction enzyme sites are lost. After ligation, the 
construct was tested by EcoRV restriction enzyme digestion that produced the 




of the entire Rgnef insert was also conducted, including both insertion sites to confirm 
that pCAGGS Rgnef was achieved without introducing any mutations.  
Testing for GFP expression was also conducted by transfection into NIH 3T3 mouse 
fibroblast cells. Before Rgnef gene insertion, the vector pCAGGS produced detectable 
GFP expression. However, after Rgnef insertion the GFP expression was almost 
undetectable, sometimes just visible. Excision of the majority of the Rgnef insert, by 
EcoRV enzyme digestion and religation again enabled the expression of GFP. This 
verified that there was no mutation within the GFP expression part of the construct. 
Thus the presence of an Rgnef insert diminishes GFP expression from the bi-cistronic 
construct. As it is not possible to monitor pCAGGS Rgnef transfection, the construct 
cannot be used in chick electroporation studies. However pCAGGS Rgnef was still 
viable as an Rgnef expression construct to be used to assess overexpression in Shh-
LIGHT2 assay experiments. 
3-6-02 Rgnef over-expression stimulates the Shh signalling pathway 
Quantitative validation of Rgnef expression increase induced by pCAGGS Rgnef and 
pcDNA3-HA-p190RhoGEF transfection was validated by quantitative RT-PCR using the 
2-ΔΔCT method. Under these experimental conditions, a geNorm stability analysis was 
conducted using 6 reference genes; GAPDH, β2-Microglobulin, ribosomal protein L13a, 
ubiquitin C, ATP synthase subunit and β-Actin. All primers were pre-validated to ensure 
they targeted their specific genes and ubiquitin C, ATP synthase subunit and β-Actin 
were designed to be intron-spanning. The expression changes could now be assessed 
by identifying the most stable reference gene under these specific experimental 
conditions (Claes et al., 2002). Overall the results show very high reference target 
stability (geNorm < 0.2) and amongst them GAPDH was found to be the single most 
stable gene under these experimental conditions (Figure 3-08 A). Using GAPDH for 
reference gene calibration, an increase in Rgnef expression of 356 fold was detected in 
cells transfected with pCAGGS Rgnef and 86 fold with regards to pcDNA3-HA-
p190RhoGEF (Figure 3-08 B). 
Significant Shh pathway activation was detected by the Shh-LIGHT2 cell assay when 
transfected either with pCAGGS Rgnef (p=0.013, n=12) or pcDNA3-HA-p190RhoGEF 




also account for the possibility of pathway suppression, transfected cells were 
monitored after pathway activation induced by 5 µM purmorphamine. Surprisingly, 
significant pathway activation was also detected in relation to pCAGGS Rgnef 
transfection (p=0.035, n=12) in addition to the stimulation induced by potent 
smoothened agonist purmorphamine (Figure 3-09 A). Possible conclusions are that 
pCAGGS Rgnef is counteracting the assay window reduction caused by the transfection 
reagent. Also increased Rgnef in the cells may be affecting pathway suppressors and as 
such increasing the extent of pathway stimulation.  
This increase in pathway activation was not observed in cells transfected with pcDNA3-
HA-p190RhoGEF (Figure 3-09 B). Three possibilities may account for the difference 
between the results for the two Rgnef expression constructs after activation. First the 
increased gene expression detected by RT-qPCR was 86 fold for pcDNA3-HA-
p190RhoGEF, approximately a quarter of the increase induced by pCAGGS Rgnef. 
Secondly, during pcDNA3-HA-p190RhoGEF transfection experiments, the assay 
window was reduced by 30% due to a higher baseline level of activation. An increase in 
the number of experimental samples may therefore provide a statistically significant 
increase in activation, particularly as an increased trend was observed (Figure 3-09 B). 
Finally, although pathway activation was induced under unstimulated assay conditions, 
the addition of an HA tag may have specifically restricted Rgnef’s ability to extend 
pathway activation even after pathway stimulation.  
Although the unexpected increase in activation in cells already stimulated should not 
detract from the main findings of these experiments; Shh pathway activation due to 








































Figure 3-08 RT-qPCR validation of over-expression and from pCAGGS 
Rgnef and pRgnefHA transfection in Shh-LIGHT2 cells 
(A) Results of RT-qPCR G-norm analysis for stability of 6 reference genes; GAPDH, β2-
Microglobulin (B2M), ribosomal protein L13a (RPL13A) ubiquitin C (UBC), ATP synthase 
subunit (ATP5B) and β-Actin (ACTB). Expression changes relate to the Shh-LIGHT2 
assay of Rgnef overexpression experiments (n=2). The stability of the reference genes 
were assessed by comparison with each other under the specific experimental 
conditions (Vandesompele et al., 2002). GAPDH and ACTB were identified as the most 
stable reference genes. (B) Results of RT-qPCR expression change analysis of Shh-
LIGHT2 cells transfected with pCAGGS Rgnef and pRgnefHA. On average, Rgnef 
expression was increased 356 fold (n=4) and 86 fold (n=2) in response to pCAGGS and 
pRgnefHA transfection respectively. Expression change was calculated using the 2ΔΔCt 






















































































* (p=0.041, n=12) 
 
* (p=0.013, n=12) 





Figure 3-09 Rgnef over-expression results in Shh pathway activation 
(A and B) Shh-LIGHT2 cells are transfected with (A) pCAGGS Rgnef and (B) pcDNA3-HA-
p190RhoGEF (pRgnefHA) prior to being serum starved to induce ciliogenesis. A 
comparison is also established between unstimulated cells and cells stimulated with 
5µM purmorphamine. (A) Shh-LIGHT2 assay results show that pathway stimulation is 
significantly increased in cells transfected with pCAGGS Rgnef when pathway 
unstimulated and further increased in cells already stimulated (B) Shh pathway 
stimulation is also observed in pRgnefHA transfected cells. The results identify Rgnef as 




3-07 Rgnef over expression inhibits primary ciliogenesis 
In identifying Rgnef as Shh signalling pathway activator the aim was to investigate 
Rgnef subcellular localisation, particularly in relation to primary cilia. Experiments to 
assess Rgnef localisation were conducted in NIH 3T3 cells as they are the same cell line 
as Shh-LIGHT2 cells before stable transfection of reporters (section 3-02). Ciliogenesis 
was induced in NIH 3T3 cell by culturing in serum free media and transfection was 
performed using the same conditions as used to demonstrate Shh pathway activation 
in Shh-LIGHT2 cells. The cells were then fixed (4% Formaldehyde 0.2% Triton-X PBS) 
and immunostained with anti-acetylated tubulin antibody to identify each cell’s 
primary cilium. The N-terminal HA tagged Rgnef protein synthesised from pcDNA3-HA-
p190RhoGEF construct enabled HA-Rgnef detection by anti-HA antibody. Secondary 
antibodies Alexa Fluor® 594 (red) and 488 (green) were used for fluorescent detection 
of primary cilia and Rgnef respectively. Finally the cells were mounted using 
fluorescent signal guard, Vectashield™ with DAPI nuclear stain to identify each 
individual cell nucleus. 
In untransfected NIH 3T3 cells the nuclei and primary cilia were clearly identified 
however there was a degree of general nonspecific background fluorescence relating 
to the use of the anti-HA rabbit polyclonal antibody (Figure 3-10 A, B and E). The anti-
HA antibody detected basal body proteins at the base of each cilium, even in the cells 
without the HA-tagged protein construct transfected (Figure 3-10 E). Although basal 
body co-localisation evidence would be required to confirm this, the evidence does 
sufficiently show that that this antibody would interfere with any basal body protein 
co-localisation results. 
Transfected NIH 3T3 cells overexpressing Rgnef protein were clearly identified by high 
intensity fluorescence (Figure 3-10 A). This is consistent with the high Rgnef gene 
expression detected by RT-qpcr results (Section 3-06). The most evident finding was 
the lack of primary cilia in cells identified as over-expressing Rgnef (Figure 3-10 A). The 
control un-transfected cells and even surrounding un-transfected cells were clearly 
able to ciliate (Figure 3-10 A). The same prepared slides were examined further using 
confocal microscopy without fluorescent identification of nuclear stain DAPI (Figure 3-




masked by the combination of high intensity Rgnef expression, nuclear staining and 
cell rounding. These high resolution stacked images were able to confirm the absence 





E Untransfected control 











































Figure 3-10 Rgnef overexpression inhibits ciliogenesis 
(A-D) NIH 3T3 cells are transfected with pcDNA3-HA-p190RhoGEF for tagged HA-Rgnef 
expression prior to being serum starved to induce ciliogenesis. (A) Merged overlay of 
cell staining with (B) immunostained for HA tag protein (green), (C) counterstained 
with DAPI (blue) and (D) immunostained for acetylated tubulin (red). (E) Testing the 
specificity of antibodies revealed a degree of unspecific binding of basal body proteins 
by rabbit anti-HA antibody, this did not however deter from detecting Rgnef 
overexpressing cells. (F) The average primary cilia to nucleus ratio of cells 
overexpressing HA-Rgnef was significantly reduced compared to the average cilia to 
nucleus ratio of 739 untransfected cells expressing primary cilia (p<0.001, n=19). (G) 
Maximum projection of Z stacks from confocal microscopy to provide further evidence 
that cells overexpressing Rgnef lack primary cilia. (A-G) Scale bars = 20 μm 
  




3-08 The effect of Rgnef overexpression on Rho activation 
The activation of Shh signalling pathway observed by over-expression of Rgnef and HA-
Rgnef was investigated in relation to RhoA activation. The aim was to determine if 
Rgnef overexpression also resulted in the activation of RhoA to help elucidate the 
mechanism by which the Shh signalling pathway was activated. A preliminary study 
was undertaken using an active Rho pull-down and detection kit (Thermo Scientific 
16116), able to monitor small GTPase activation. The procedure involves column 
binding activated Rho-GTP moieties and then eluting for immunoblotting that detect 
the relative levels of activated RhoA, RhoB and RhoC. To ensure the pull down was 
working effectively, immunoblotting was also conducted using lysate treated with 
GTPϒS (positive control) compared with lysate treated with GDP for negative control 
(Figure 3-11 A). The results show comparable levels of Rho activation detected in all 
three transfected cell sample preparations (Figure 3-11 B). The levels of activation 
were not significantly different in the cells transfected with pCAGGS-Rgnef or HA-
Rgnef, compared to cells transfected with pCAGGS alone, showing that increasing 




































































Figure 3-11 The effect of Rgnef overexpression on Rho activation  
(A) Results of positive and negative controls from Active Rho pull-down and detection 
kit (Pierce Cat 16116). The addition to cell lysate of GTPγS for positive control and GDP 
for negative control enabled pull down and detection enabled validation of Rho 
activation assay window. (B) Representative immunoblot showing levels of activated 
Rho from three transfected NIH 3T3 mouse fibroblast cell samples, cultured in T75 cell 
culture flasks. The three transfection comparisons were pCAGGS, pCAGGS Rgnef and 
pcDNA3-HA-p190RhoGEF (HA-Rgnef). As per manufacturer’s instructions, lysate was 
extracted and tested to identify levels of activated Rho through immunoblot band 
intensity comparison by the Odyssey fluorescent reader (Licor). Two lane volumes, 20 
µl and 10 µl were loaded to allow a choice for optimal band intensity for comparison. 
(C) Results show no significant difference between levels of activated Rho in cells over-






3-9-01 The Shh-LIGHT2 assay as a reporter of Shh signalling pathway activation states 
The Shh-LIGHT2 cell based assay was widely used in this thesis as a means to 
investigate the activation state of the Shh signalling pathway. It is a cell line that has 
been extensively used in many other studies (Taipale et al., 2000). Initial tests were 
made to test the robustness of this assay system, in our hands. For example, it was 
established that at least a 50% cell confluence was required in order to ensure the 
integrity of the assay window. The main limitation with the assay, identified in this 
thesis, was reduction of the assay window due to treatment by the transfection 
reagent Dharmafect. In the presence of Dharmafect, the extent of pathway activation 
was much reduced. However, it was still possible assess different activation states 
using this system despite this activation suppression. Further investigation revealed 
that Dharmafect does not detectably reduce the number of cells producing primary 
cilia. This is important, as the primary cilium is an organelle essential for Shh signal 
transduction and its loss would invalidate the integrity of the assay. An important 
conclusion to these results is the need to thoroughly identify potentially compromising 
factors of the Shh-LIGHT2 assay and conduct appropriate case by case controls. It is 
however still not known why this suppressive effect occurs with Dharmafect 
treatment. Hence future uses of Dharmafect, or indeed any transfection reagent 
should be carefully assessed for effects on pathway activation as well as cell structure 
and morphology. 
A further consideration is the extent at which signalling cross-talk from other pathways 
can cause Shh pathway activation in Shh-LIGHT2 cells. This is well demonstrated by the 
first study of its kind, where Shh pathway activation changes were monitored against 
90% of individually overexpressed human kinases (Varjosalo et al., 2008). In total 380 
kinases significantly affected pathway activation, although clearly the degree of change 
was far less than any of the known effectors of the Shh signalling pathway (Varjosalo et 
al., 2008). It is not clear whether these results represent signalling crosstalk, as 
proposed in the study or effects on other systems due to kinase over expression. The 




using overexpression as a means to define pathway activation states in the Shh-LIGHT2 
assay. 
Therefore the Shh-LIGHT2 assay does provide an effective measure to broadly assess 
Shh signalling pathway activation. It is nevertheless important to consider its 
limitations in the context of the molecular complexity of all signalling pathways.  
Questioning such limitations will better help establish the extent to which cellular and 
molecular mechanisms in Shh-LIGHT2 cells represent an endogenous setting for the 
Shh signalling pathway. 
3-9-02 Rgnef as a positive regulator of the Shh signalling pathway 
The results in this chapter demonstrate a correlation between Rgnef expression levels 
and the extent of Shh signalling pathway activity. Increases or decreases in Rgnef 
expression were shown to activate or suppress pathway activation, respectively, in 
Shh-LIGHT2 cell based assay experiments. Expression analysis in E10.5 mouse embryos 
demonstrated Rgnef expression along the length of the neural tube. In transverse 
sections, Rgnef expression was seen ventrally in the floor plate, comparable to Shh 
expression. A notable difference is that Shh expression is also seen in the notochord 
wheras Rgnef was not. Shh expression originates from the notochord and the high 
ventral concentration induces Shh floorplate expression (Placzek et al., 1990, Echelard 
et al., 1993, Roelink et al., 1995). In Shh-LIGHT2 assay experiments, increased Rgnef 
expression was able to significantly increase Shh pathway activation even when the 
pathway was activated using potent agonist purmorphamine. This observation 
proposes the possibility that the extent or threshold of pathway activation is increased 
by Rgnef. Conversely, reducing Rgnef expression resulted in reduced Shh pathway 
activation, following purmorphamine treatment. From our results, we would predict 
that, in Rgnef mouse mutants, there would be reduced activation of the Shh pathway.  
This would be expected to lead to altered DV patterning in the neural tube. The 
patterning of the neural tube in Rgnef mouse mutants has not been reported. 
However, the Rgnef knockout mice are smaller than their littermates (Miller et al., 
2012) which is intriguing given the role of the Shh pathway in regulating cell 
proliferation (Chiang et al., 1996, Epstein et al., 1996, Goodrich et al., 1997, Rowitch et 




2000b, Wijgerde et al., 2002, Kenney et al., 2003, Cayuso et al., 2006). Otherwise the 
Rgnef mutants are reported as exhibiting normal development at E13.5, and there was 
no investigation as to why litters were reported as smaller than expected (Miller et al., 
2012). It would be interesting to examine the mutants for subtle defects in embryonic 
development, particularly in relation to perhaps minor changes in DV patterning. 
The results in this chapter also demonstrate a lack of primary cilia in cells over-
expressing Rgnef. Primary cilia are involved in regulatory mechanisms that determine 
the balance between Gli activators and Gli repressors of transcription in Shh signal 
transduction. Primary cilia are required for both creation of Gli activator and 
processing of Gli3 to the repressor protein as regulators of pathway activity (Haycraft 
et al., 2005, Tran et al., 2008). The Gli repressor/Gli activator ratio is influenced by the 
rates of anterograde and retrograde intraflagellar transport, and disruption of specific 
IFT proteins can lead to either an overall increase or an overall decrease in Shh 
pathway activity (Huangfu and Anderson, 2005, Goetz and Anderson, 2010).  
For instance, increased Shh signalling is observed in IFT-A mutant mice with cilia that 
are not lost but disrupted, shortened and bulged (Tran et al., 2008, Cortellino et al., 
2009). This is in contrast to IFT complex B mutants which again display compromised 
or even absent cilia that instead leads to reduced Shh pathway activation (Huangfu et 
al., 2003, Tay et al., 2005). In our experiments, we have observed that Rgnef 
overexpression has caused a reduction in cilia in transfected cells, while also causing 
an overall increase in the activity of the Shh pathway. Therefore our results seem to 
show that Rgnef overexpression has shifted the balance of Gli repressor transcription 
factor processing in preference to Gli activator. It would be interesting to ascertain 
whether this occurs as a direct consequence of the transfected cells, or on some 
additional non-autonomous effect that extends beyond the proportion of transfected 
cells. 
In Hek 293 cells, Shh  treatment results in increased activation of RhoA, an effect that 
is suppressed by addition of Smo antagonist cyclopamine (Chen et al., 2002, Kasai et 
al., 2004). In this chapter, I have shown that increased Rgnef expression, while 
sufficient to lead to Shh pathway activation, did not cause a detectable increase in the 




the three Rho proteins, RhoA, RhoB and RhoC, and instead reported on the overall 
levels of activation from all three Rho proteins. It is therefore possible that net 
activation of Rho proteins remains constant in the assay only because relative 
differences between RhoA, B and C are offsetting each other. Alternatively, it is 
possible that Rgnef is affecting Shh pathway activation through another mechanism, 
not involving RhoA. Interestingly, investigations into endothelial cell lines have 
discovered that Shh induced cell activity in these cells is mediated by Rho in a process 
that does not involve Gli transcription factors (Renault et al., 2010). In fibroblast cells,  
Shh induction of RhoA GTPase activity has also been shown to involve a non-canonical 
Gli-independent Shh pathway activity (Polizio et al., 2011). Therefore the evidence 
from the literature suggest that there are two pathways downstream of Shh: a RhoA-
dependent but Gli-independent pathway, in addition to the Rho-independent 
canonical Gli-dependant Shh pathway activation. Of course, the Shh-LIGHT 2 cell based 
assay will only detect Gli-dependent activity. However, the findings reported in my 
thesis support a role of Rgnef in the Rho-independent, Gli-dependent mechanism. This 














Chapter 4: Investigation of Trim71 in 





Heterochronic gene Trim71 is an E3 ubiquitin ligase, negatively regulated by Let7 
miRNA pathway regulation and a system well conserved across many organisms. The 
role of Trim71 was first defined in C.elegans (Reinhart et al., 2000, Slack et al., 2000, 
Vella et al., 2004) and is broadly assumed across all organisms as providing temporal 
cues to prevent premature development of adult phenotypes (Pasquinelli et al., 2000, 
Kloosterman et al., 2004, Lancman et al., 2005, Schulman et al., 2005, Kanamoto et al., 
2006, Chang et al., 2012).  In mice, a lack of Trim71 results in NTD and in chick, inverse 
correlations have also been detected with Gli3 expression, both findings that relate to 
possible involvement in the Shh signalling pathway (Lancman et al., 2005, Maller 
Schulman et al., 2008). In our laboratory Trim71 was identified as a Tulp3-interacting 
protein a negative regulator of the Shh Signal pathway. 
In this chapter I attempt to identify and investigate the possible role of Trim71 in Shh 
signal transduction. My investigations centre on using Shh Light-II cell based assay to 
monitor states of Shh pathway activation in relation to changes in Trim71 expression. 
Using siRNA transgenic suppression, I show in vitro that reducing Trim71 expression 
reduces the extent of induced Shh pathway activation. However through validation 
tests I discover a lack or already very low level of Trim71 expression in the NIH 3T3 cell 
line, used to construct the Shh-LIGHT2 cell based assay. In discovering my results to be 
a false positive, I endeavour to investigate possible causes and identify the result to be 
from a single siRNA amongst the total mix used for the experiments. I also successfully 
express GFP-Trim71 in NIH-3T3 cells and observe cell localisation patterns akin to 
published endogenous Trim71 cell localisation. 
4-01 Suppression of Shh pathway activation by Trim71 siRNA transfection 
The Shh-LIGHT2 cell based assay can provide a means to monitor Shh pathway 
activation (Section 3-03). To evaluate the effect of Trim71 on pathway activity, the aim 
was to knockdown Trim71 gene expression with specific siRNA oligonucleotides. Shh-
LIGHT2 cells were transfected with a 20 nM pool of four different Trim71 siRNA 
sequences aimed at silencing gene expression. The results were compared with 
transfection with a control non-silencing siRNA oligonucleotide to ensure the results 




activation was induced by 5 µM purmorphamine and luminescence measured using 
the Promega Dual-Glo Luciferase assay.  
The results show a significant 22% suppression (p=0.008, n=35) in activation compared 
to non-target siRNA transfected cells (Figure 4-01 A). Qualification of these results was 
therefore made by separately examining the independent effects for each of the four 
siRNA oligonucleotides in the pool. The results revealed an inconsistent pattern of 
effect from the individual siRNA species (Figure 4-01 B). Only siRNA(1) was able to 
show a significant 64% suppression (p=0.04, n=4) of pathway activation compared to 
all other individual siRNAs tested. In further tests siRNA(1) transfected at 20 nM and 
100 nM concentrations suppressed purmorphamine pathway activation by 31% 
(p=0.009, n=12) and 54% (p<0.001, n=12) respectively (Figure 4-01 A). The results show 
that the suppression induced collectively by a pool of 4 siRNAs was able to be repeated 
by using only one of the four siRNA species included in the pool. This result raises the 
possibility that the suppression of pathway activity was induced by an off-target effect 










































































































































Figure 4-01 Suppression of Shh pathway activation by Trim71 siRNA 
transfection 
(A) The results show the effects of Shh pathway activation from 20 nM pool of four 
different Trim71 siRNA sequences transfected to Shh-LIGHT2, aimed at silencing 
Trim71 gene expression. The results were compared with non-target siRNA transfected 
cells. Shh pathway activation was induced by 5 µM purmorphamine and luminesce 
measured using the Promega Dual-Glo Luciferase assay.  Results show a significant 
22% suppression (P=0.008, n=35) in activation compared to non-target siRNA 
transfected cells. In the smartpool the concentration of just siRNA(1) was 5 nM, as 
15nM consisting of the other three siRNA sequences. In further tests siRNA(1) 
transfected at 20 nM and 100 nM concentrations suppressed purmorphamine 
pathway activation by 31% (p=0.009, n=12) and 54% (p<0.001, n=12) respectively . The 
results show that the suppression induced collectively by a pool of 4 siRNA was able to 
be repeated by using only one of the four included in the pool. 
(B) Prliminary result leading to further examination of siRNA(1) figure (A). Result 
compares each of the four siRNA oligonucleotide tested independently by Shh-LIGHT2 
assay as well as collectively in the pool. The results revealed an inconsistent result 
pattern of effect from all the individual siRNA. Only 20 nM siRNA(1) was able to show a 
significant 64% suppression (p=0.04, n=4) of pathway activation compared to all other 





4-02 Trim71 expression in Shh-LIGHT2 cells 
The results from the Shh-LIGHT2 cell experiments indicated that some, but not all, 
Trim71 siRNA species caused a suppression of Shh pathway activity. In order to assess 
the effects of the siRNA transfection on Trim71 expression, PCR assays were developed 
to analyse endogenous Trim71 expression in Shh-LIGHT2 cells. Total RNA was 
extracted from cells cultured in media with and without fetal bovine serum. This was 
to ensure Trim71 expression was assessed across all media conditions required during 
Shh-LIGHT2 cell assay experiments. PCR with primers designed to span an intron did 
not produce an expected 587 bp product from cDNA synthesised from Shh-LIGHT2 
cells cultured in either serum containing or serum free media (Figure 4-02 A). Yet even 
at lower relative amounts of template, these Trim71 primers amplified the expected 
product from E10.5 mouse embryo cDNA (Figure 4-02 A). PCR products were not 
detected from the negative control reactions without reverse transcriptase (Figure 4-
02 A), confirming the amplification is not from contaminating genomic DNA. The 
Trim71 primers did however consistently produce 2 bands in close proximity, 
marginally under and over 200 bp in size (Figure 4-02 A). As the primer sets were 
intron spanning, from exon 1 to exon 4, consideration was made for possible Trim71 
splice variation. Loss of exons 2 and 3 would bring the primer sites closer to deliver a 
285 bp product (Figure 4-02 B). Yet both products detected were clearly smaller than 
285 bp and rejects the hypothesis that a Trim71 exon 1 and 4 splice variant was 
detected. In conclusion, Trim71 expression was unable to be detected in Shh-LIGHT2 
cells. Furthermore, since these experiments were conducted, the lack of Trim71 
expression in NIH 3T3 mouse fibroblasts (Shh-LIGHT2 cells were initially derived from 
NIH 3T3 cell line) has been reported (Chang et al., 2012). Despite the conclusion of the 
authors that there is no Trim71 expression, the qPCR data of Chang et al (2012) appear 
to show a very low level of Trim71 expression rather than a complete absence of 
expression. We note also the apparent positive identification of Trim71 protein from 
NIH 3T3 cells using commercially available antibody ab99487 from Abcam 
(http://www.abcam.com/trim71-antibody-ab99487.html). It therefore remains 














Figure 4-02 Trim71 expression is undetected in NIH 3T3 cells 
(A) Trim71 primer PCR products after electrophoresis through a 2% agarose gel. The 
expected 587 bp product was observed using the positive control E10.5 mouse embryo 
cDNA (lane 5). This was not detected in Shh-LIGHT2 cells (lanes 1 and 3) and instead 
two bands were resolved in close proximity, marginally under and over 200 bp in size. 
There were no bands in negative control reactions without reverse transcriptase 
enzyme (lanes 2 and 4). (B) A schematic representation of Trim71 sequence showing 
positions of all four exons. The position and size of the 587 bp product is shown from 
intron spanning primers. Also shown is a hypothesised 284 bp product expected from 
an Exon 1 and 4 Trim71 splice variant. Overall results shows that the products detected 








4-03 Over-expression of GFP-Trim71 in NIH 3T3 cells 
NIH 3T3, the cell line used to create Shh-LIGHT2 assay, is investigated in respect to 
overexpression of Trim71. The overall aim was to determine the possibility of using 
Shh-LIGHT2 assay to assess the effect of Trim71 overexpression on Shh pathway 
activity. Furthermore, by using RT-qPCR techniques detection of endogenous Trim71 
could be re-attempted and assessed in contrast with Trim71 overexpression by 
plasmid construct transfection. 
Trim71 expression in NIH 3T3 cells was increased, using a GFP-tagged Trim71 
expression construct. Transfection was achieved by reagent Lipofectamine 2000® 
complexed with pEGFP-N1-Trim71; an N-terminal eGFP tagged Trim71 expression 
construct obtained from Professor G. Wulczyn at the Charite Hospital in Berlin. 
Determination of GFP-Trim71 expression after transfection was validated by 
quantitative RT-PCR using 2-ΔΔCT method and calibrated by reference genes GAPDH and 
β2 Microglobulin. Total RNA extracted from cells was quantified to ensure equal 
amounts were added as templates for cDNA synthesis.  
The 2-ΔΔCT method depends on the presence of endogenous Trim71 as it reports 
increases in GFP-Trim71 from the pEGFP-N1-Trim71 transfection relative to the level of 
detectable Trim71 without transfection. On two attempts, increases in expression 
were found to be as much as 4000 and 8000 fold, respectively. These high fold 
calculations represent the difference in the induced GFP-Trim71 expression relative to 
any detected endogenous Trim71 expression. However, given previous findings and 
the inconsistent reports regarding Trim71 expression in these cells, detection of 
endogenous Trim71 requires further investigation. 
The first observation was that when detecting endogenous Trim71 in un-transfected 
cells, Ct values were over 30 cycles. Such late detection increases the probability of 
detecting unspecific binding. Melt curve analysis results in a single peak average of 
87.9 ˚C for cells over-expressing GFP-Trim71. However, the same primer set instead 
detected 2 peaks in NIH 3T3 cells transfected with plasmid alone. Statistical 
comparison of melt curve peaks found that the peak with highest average temperature 
of 87.6 ˚C from endogenous Trim71 expression analysis, was not significantly different 




An analysis using uMelt (Utah University) was conducted, to assess the predicted 
amplicon melt curve expected from the Trim71 primer set used. uMelt predictions are 
based on nucleotide content and pattern, as well as concentration of monovalent 
cations and free Mg++ present in the reaction (Dwight et al., 2011). The 92 bp 
amplicon sequence (60% GC content) expected from Trim 71 primer set predicted a 
single melt curve peak of 88 ˚C (Figure 4-03 B). Concentration of monovalent cations 
and Free Mg++ was 0.69 mM and 26 mM respectively. The results therefore present a 
case of corresponding predicted and actual melt curves, with single primer products, 
consistent with positive Trim 71 detection (Figure 4-03 A and B). The production of the 
second lower temperature amplicon is possible when low endogenous Trim71 levels 
increase the probability of unspecific primer binding, or primer dimers (Figure 4-03 A). 
This is not observed in cells overexpressing GFP-Trim71 due to the abundance of 
template, shown by the early Ct values of between 18 and 20 cycles and the single 
peak melt curve (Figure 4-03 A). 
Fluorescent microscopy of pEGFP-N1-Trim71 transfected NIH 3T3 cells shows distinct 
points of GFP-Trim71 within the cytoplasm (Figure 4-03 E). This is consistent with 
images of endogenous Trim71 localized to cytoplasmic foci, shown to be RNA 
processing structures called p-bodies (Rybak et al., 2009). It therefore qualifies protein 
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Figure 4-03 Over-expression of GFP-Trim71 in NIH 3T3 cells 
(A) Representative melt curve analysis result showing temperature peaks that identify 
PCR products. In cells over expressing Trim71 a single 87.9 ˚C peak is observed 
consistent with a single PCR product. Double temperature peaks were found when 
attempting to detect endogenous Trim71 in untransfected cells and an indication of 
multiple PCR products. In both melt curves examined, the higher temperature 87.6 ˚C 
peak was found to not be significantly different to the single peak detection resulting 
from GFP-Trim71 expression (p=0.2, n=5). (B) Graph derived from uMelt predictive 
software, showing the expected melt curve analysis with single 88 ˚C peak expected 
from the amplicon expected from the Trim71 primer set used.(C - F) Representative 
images of NIH 3T3 cells transfected with pEGFP-N1-Trim71. (C) Shown as single 
channel, live cell brightfield image of NIH 3T3 cells and (D) identified transfected GFP-
Trim71 expression. (E) Merged image of live cell and GFP-Trim71 with (F) Enlarged 
examples to highlight GFP-Trim71 localized to cytoplasmic foci. This is consistent with 
reported localisation to RNA processing structures called p-bodies (Rybak et al., 2009). 





4-4-01 Investigating the false positive results from Trim71 siRNA  
The results determined that Shh signalling Pathway suppression was induced by a 
single Trim71 siRNA(1) and not by the collective pool of four siRNAs used. The results 
conclude the effect to be an off target effect, particularly as a lack of Trim71 
expression in NIH 3T3 cells has since been reported elsewhere. The question therefore 
arises as to what this single siRNA was targeting to have induced pathway suppression 
and potentially identifying a known or novel positive regulator of the Shh signalling 
pathway. Further examination, using nucleotide BLAST searches 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi), revealed a 15 bp sequence homology to 
glycogen synthase kinase 3 beta (GSK3β). 
siRNA(1) GAUCAUAGUGGCCGACAAA 
GSK3β   ATCATAGTGGCCGA 
The results determined that Shh signalling pathway suppression was induced by a 
single Trim71 siRNA(1) and not by the collective pool of four siRNAs used. The results 
conclude the effect to be an off target effect, particularly as a lack of Trim71 
expression in NIH 3T3 cells has since been reported elsewhere (Chang et al., 2012).The 
question therefore arises as to what this single siRNA was targeting to have induced 
pathway suppression and potentially identifying a known or novel positive regulator of 
the Shh signalling pathway. Further examination, using nucleotide BLAST searches 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi), revealed a 15 bp sequence homology to 
glycogen synthase kinase 3 beta (GSK3β). 
siRNA(1) GAUCAUAGUGGCCGACAAA 
GSK3β   ATCATAGTGGCCGA 
However, GSK3β has already been identified as a negative, not positive, regulator of 
Shh signalling pathway. GSK3β is one of the kinases responsible for Gli3 
phosphorylation that leads to the proteolytic processing of Gli3 to form the pathway 
repressor Gli3R (Jia et al., 2002, Kim et al., 2009b). Disruption of GSK3b would 
therefore be expected to reduce the phosphorylation of Gli3, leading subsequently to 




in the Shh-LIGHT2 cell based assay. This robust model therefore opposes the possibility 
that pathway suppression was induced by a knock down of GSK3β by an off-target 
effect of Trim71 siRNA(1). It is however important to state that although this is a 
possibility, it cannot be positively stated  that direct effect of GSK3β knock-down on 
Shh signalling pathway activation has occurred in this assay without further validation. 
At very least RT-qPCR validation would be required to demonstrate that GSK3β 
expression was altered. This finding therefore only proposes a hypothesis to further 
test the role of GSK3β using the Shh-LIGHT2 assay. 
An assessment was made following the overexpression of GFP-Trim71 in NIH 3T3 in 
light of the absence of expression in this cell line. An increase in expression was 
achieved as well as a cell localisation pattern consistent with reported P-body 
localisation (Rybak et al., 2009). In order to further qualify P-body localisation, further 
co-localisation with P-body effectors, would be required, Ago2 for instance (Rybak et 
al., 2009). Future plans for Trim71 expression changes on Shh signalling pathway 
activation could therefore involve using Shh-LIGHT2 assay in respect to Trim71 
overexpression. It is however an unsuitable assay for reducing Trim71 expression, as 




















In previous chapters investigations were based on identifying two novel protein 
regulators of Shh signal transduction. Results in this chapter instead investigate the 
established effector Gli2, one of three transcription factors conserved in vertebrate 
Shh signalling. This study aims to help further understand pathway regulation in 
relation to the PTM of Gli2, the principle initiator of pathway activity. 
Gli2 was characterised by mass spectrometry, attempted by both the MALDI-TOF and 
AmaZon ion Trap mass spectrometers. In characterising Gli2 I aimed to reveal sites of 
protein modification that would help to further understand its role. My results also 
detail the processes involved in identifying Gli2 by SDS PAGE and immunoblotting, as 
well as MS sample preparation techniques. The aim is an assessment of these 
processes in relation to effective and improved MS analysis and characterisation. 
5-01 Endogenous Gli2 detection in NIH 3T3 cell lysate using ECL detection 
immunoblotting 
To identify endogenous Gli2 protein abundance in NIH 3T3 cells, protein extracts were 
resolved from total cell lysate by use of SDS PAGE and detected by immunoblotting 
using anti-Gli2 antibody obtained from Dr Baolin Wang (Cornell University). 
Endogenous Gli2 is a 185 kDa protein that is also processed to a 78 kDa cleaved 
isoform (Pan et al., 2006). Due to its low abundance the shorter cleaved Gli2 isoform 
has been reported to be undetectable without enriching for Gli2 protein before 
immunoblotting (Pan et al., 2006). The enrichment method used was provided by Dr 
Baolin Wang. This was based on magnetic bead separation using biotinylated 
oligonucleotide Gli transcription factor binding sequences to bind and enrich Gli2. 
Control purification reactions were also prepared, using oligonucleotides with mutated 
Gli binding sequences (Pan et al., 2006), to evaluate if Gli2 enrichment was effective. 
Also, proteins that non-specifically bind the complex can be identified from the 
mutated Gli2 binding site oligo enrichments. 
Results, demonstrated in a representative immunoblot, show a band detected in a 
region between 180 and 190 kDa (Figure 5-01 A). Based on the Invitrogen HiMark™ 
protein marker standard curve, this band was calculated to be 187 kDa, therefore close 
to the 185 kDa size expected for full length Gli2 (Figure 5-01 A). Bands in the region of 




however proteins were detected at around 129 kDa, 70 kDa and 61 kDa, as calculated 
by comparison to the protein marker standard curve (Figure 5-01 A). The abundance of 
processed Gli2 has previously been reported to be low relative to full length Gli2 (Pan 
et al., 2006), which may explain why the cleaved isoform is not detected here. 
Moreover, the intensity of the 70 kDa protein relative to the proposed 187 kDa full 
length Gli2 makes this band an unlikely candidate for processed 78 kDa Gli2. However, 
the proteins detected still merit investigation as they did not appear in the control 
enrichments and may possibly be degraded Gli2 protein or indirectly enriched Gli 
binding partners. 
The immunoblots were used as references for gel section extraction from equivalent 
silver stained SDS PAGE gels prepared in parallel (Figure 5-01 A). Sample preparation 
and SDS PAGE of the silver stained gels was executed using the same procedure as gels 
prepared for immunoblotting. Initial observations from silver stained gels revealed 
multiple protein bands without distinctive or conclusive differences between Gli2 
binding sequence oligo and mutated oligo purification lanes (Figure 5-01 A). The silver 
staining demonstrates that during the Gli2 enrichment procedure, a considerable 
amount of protein was retained during the purification wash steps, and the 
enrichment does not generate pure Gli2 protein. The enrichment of Gli2 detected in 
the immunoblots was not observable as a distinct band amongst the protein detected 
in the silver stained gels (Figure 5-01 A).  
Gel regions were excised relating to any bands detected in their paired immunoblots 
and in the precise region of the 185 kDa and 78 kDa protein migration expected for 
Gli2. All gel sections were fragmented, de-stained and incubated for tryptic digestion, 
before being prepared for MALDI-TOF mass spectrometry analysis. However, Gli2 was 
not detected in any of these preparations, concluding that endogenous Gli2 is was not 
abundant enough in these preparations for protein identification and protein 
extraction. Clearly the requirement is to be able to see a stained band in order to 



































Figure 5-01 Endogenous Gli2 detection in following enrichment of NIH 
3T3 cell lysate 
(A) Representative example of silver-stained SDS PAGE gel and blot probed for Gli2, 
following oligo pull-down from NIH 3T3 cell lysates. Each 300 µl lysate preparation 
added to magnetic bead complex consisted of approximately 120 µg total protein. 
Lane 1 enriched Gli2 eluent based on magnetic bead separation of biotinylated 
oligonucleotide Gli transcription factor binding sequences. Lane 2 is a control 
purification reaction using oligonucleotides with mutated Gli binding sequences. 
Eluents from oligo pull-down reactions were resolved on SDS-PAGE gels and silver-
stained to view total proteins, or electroblotted to nitrocellulose membrane for 
immunodetection using anti-Gli2 antibody. Sizes of HiMark protein standards are 
indicated on the left, and calculated size of observed bands on the blot are indicated 
on the right. Immunoblot detected bands were used to identify sections to remove in 
silver stained gels, prepared in parallel. Immunoblot protein bands were identified 
between 180 and 190 kDa. There was inconsistent detection of bands in the regions of 
78 kDa and yet proteins of other sizes were detected after enrichment but not 
detected in control purifications. Based on these results gel sections were removed for 
protein mass spectrometry protein identification. (B) Protein molecular weight marker 






5-02 Endogenous Gli2 detection in NIH 3T3 cell lysate using fluorescent 
detection immunoblotting 
In an attempt to improve upon previous ECL detection results, immunoblots were 
prepared using fluorescent immunodetection techniques. The aim was to better 
confirm identification of endogenous Gli2 and enable improved targeting of gel 
sections for MALDI-TOF analysis. 
Total cell lysate from NIH 3T3 cells was prepared, without Gli2 enrichment, for SDS 
PAGE and electroblotting to PVDF membrane. In each experiment, changes in Shh 
signalling pathway activity were compared by preparing lysate from unstimulated and 
stimulated cells. Shh pathway stimulation was achieved by Smoothened-agonist 
purmorphamine. The pathway activation, using the same purmorphamine media 
preparation, was validated by Shh-LIGHT2 cell based assay (Figure 5-02 G). 
Loading control, 220 kDa fatty acid synthase (FAS) was detected using Santa Cruz 
mouse anti-FAS primary antibody and fluorescent secondary anti-mouse (Licor 
800CW). A single band was identified and estimated to run at 216 kDa (Figure 5-02 A – 
C; green band). Gli2 was identified by fluorescent secondary antibody anti-rabbit (Licor 
680RD) that in turn identified rabbit anti-Gli2 primary antibody obtained from Dr 
Baolin Wang (Figure 5.02 A-C; red band). Two commercially available primary 
antibodies tested, failed to detect Gli2 (Figure 5-02 B and C). 
Gli2 immunodetection on PVDF membrane was improved by a number of optimisation 
steps. This included doubling the amount of protein loaded per lane, a 5 fold reduction 
of primary antibody concentration used and 2 fold reduction of secondary antibody 
concentration used. Also the Licor anti-rabbit secondary antibody for Gli2 was changed 
from Licor 680RD to Licor 800CW as it provided more sensitivity with less background 
(Figure 5-02 D). 
The two bands identified by Gli2 antibody were calculated to be 200 kDa and 78 kDa, 
based on Invitrogen Novex sharp protein marker standard curve estimates (Figure 5-02 
E). NuPAGE® 7% tris acetate gel has an ideal separation of between 35 kDa and 180 
kDa, so observing Gli2 at 200 kDa, instead of 185 kDa may simply reflect the sub-




processed Gli2 was still found at the expected 78 kDa, as it is within the gel’s optimal 
separation range. 
In Shh pathway stimulated and unstimulated cells both full length and cleaved Gli2 
bands were detected (Figure 5-02 D). Compared to unstimulated cells, the 78 kDa Gli2 
band intensity relative to full length 185 kDa Gli2 was 39% less in Shh pathway 
stimulated cells (Figure 5-02 F). The purmorphamine preparation used to stimulate NIH 
3T3 was successfully tested using the Shh LIGHT2 assay (Figure 5-02 G).  
ECL immunoblot detection of processed Gli2 using this antibody has been reported to 
require a protein purification step due to its low abundance (Pan et al., 2006). 
Processing of the 78 kDa repressor isoform is reported to reduce relative to Gli2 (Pan 
et al., 2006). In these experiments, 78 kDa Gli2 was detected without Gli2 enrichment. 
It continued to be detected after Shh pathway activation, although band intensity was 
reduced relative to full length Gli2. A possibility is that even at reduced abundance the 
78 kDa Gli2 protein was detectable using immunofluorescence detection as opposed 
to ECL reagent detection. These preliminary results therefore may reflect an improved 
sensitivity of immunofluorescent detection compared to reported results using ECL 
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Figure 5-02 Endogenous Gli2 detection in NIH 3T3 cell lysate using 
fluorescent detection immunoblotting 
(A, B and C) Representative images of NIH 3T3 total cell lysate SDS PAGE, electro-
blotted to PVDF membrane for immuno-detection of endogenous Gli2 protein. NIH 
3T3 cells total cell lysate loaded in each well contained 5 μg total protein. Lane 1 
unstimulated NIH 3T3 lysate whereas lane 2 contained lysate from Shh pathway 
stimulated cells.. Shh pathway stimulation was achieved by overnight incubation in 5 
μm purmorphamine in 0.5% DMSO in serum free media and unstimulated control in 
0.5% DMSO in serum free media. The purmorphamine used was directly tested in 
parallel with Shh-LIGHT2 cell based assay to ensure that it was able to induce pathway 
stimulated. Lane 3 contained unstimulated Shh-LIGHT2 cell lysate. Bands were 
identified by primary antibody provided Dr Baolin Wang and Licor anti-rabbit 680RD 
fluorescent secondary antibody.(A) Two clearly identifiable bands at 200 kDa and 78 
kDa based on Invitrogen Novex Sharp protein standard curve estimates. The single 
band identified in green and estimated at 216 kDa was Fatty Acid Synthase (FAS) Santa 
Cruz mouse anti FAS primary antibody and Licor anti-mouse 800CW secondary 
antibody. Changes in Gli2 expression was compared between unstimulated and Shh 
pathway stimulated (lane 1 and lane 2 respectively). Gli2 was also probed and 
detected in total lysate from the Shh-LIGHT2 cells (lane 3). (B and C) Two commercially 
available secondary antibodies from Abcam Laboratories (Ab26056 and Ab7195) failed 
to detect Gli2, although loading control FAS was detected. (D) Continued use of 
primary antibody provided by Dr Baolin Wang with improved results due to 
optimisation. This was achieved by a number of changes, including increasing total 
protein loaded to 18 μg per lane and switching the fluorescent secondary antibody for 
Gli2 primary from Licor 680RD (red) to Licor 800CW (green). (E) The two bands 
identified by Gli2 antibody were calculated to be 200 kDa and 78 kDa, based on 
Invitrogen Novex sharp protein marker standard curve estimates. (F) Changes in Gli2 
expression was compared in optimised immunoblot (D) between unstimulated and Shh 
pathway stimulated cells, lanes labelled “Shh-“ and “Shh +” respectively. In 
unstimulated and Shh pathway stimulated cells both full length and cleaved Gli2 bands 
were detected. Relative to full length 185 kDa, the Gli2 78 kDa Gli2 band intensity was 
39% less in Shh pathway stimulated cells, compared to unstimulated. (G) Pathway 
activation was validated by Shh-LIGHT2 cell based assay (p<0.01, n=4). The same 
purmorphamine media preparation applied to the NIH 3T3 cells was used on Shh 





5-03 Gli2 protein abundance is increased by expression plasmid construct 
transfection  
The aim was to increase the amount of Gli2 in cells by transfection of expression 
plasmid constructs. In the current model of Shh signal transduction, primary cilia are 
recognised as post translational processing centres for Gli2 and Gli3 (Price and 
Kalderon, 1999, Jia et al., 2002, Price and Kalderon, 2002, Jia et al., 2005, Pan et al., 
2009). 
The aim was to transfect NIH 3T3 cells with a plasmid to express GFP-tagged Gli2 
protein in order to examine, in our hands, over-expressed GFP-Gli2 protein 
localisation. The construct used was purchased from Addgene pCEFLmGFP-Gli2 (Kim et 
al., 2009a). The increase in Gli2 expression measured by RT qPCR detected a 184 fold 
increase in Gli2 in transfected cells compared to endogenous Gli2 expression in control 
transfected cells (Figure 5-03 A). To determine co-localisation with primary cilia, cells 
were stained with mouse anti-acetylated tubulin primary antibody, as tubulin 
acetylation is a post translational modification found predominately in primary cilia 
(Wloga and Gaertig, 2010). Results show co-localisation of GFP-Gli2 and primary cilia 
(Figure 5-03 B-G). 
To increase Gli2 protein for mass spectrometry analysis NIH3T3 cells were replaced 
with HEK293Tcells. Easy to transfect, HEK293T are a ciliating human cell line with a 
high rate of growth and protein synthesis. Preliminary FACS analysis of GFP 
transfection in HEK293T cells revealed a 98% transfection rate (Figure 5-04 A). The Gli2 
plasmid construct transfected for this purpose was HA-tagged mouse Gli2 plasmid 
construct, pCEFL3XHAmGli2 (Kim et al., 2009a). Plasmid construct pCEFL3XHAmGli2 is 
predominately the same as pCEFLmGFP-Gli2, instead replacing the GFP insert with a 
triplicate HA tag sequence (Kim et al., 2009a). Subsequent expression of HA-Gli2 in 
HEK293T can then be enriched by either oligo pull-down or HA tag 
immunoprecipitation. RT-qPCR analysis of pCEFL3XHAmGli2 transfected HEK293T cells 
detected a 6000 fold increase in Gli2 expression compared to cells transfected with 









































Figure 5-03 Gli2 protein abundance is increased by expression plasmid 
construct transfection 
(A) RT qPCR results of NIH 3T3 cells transfected with pCEFLmGFP-Gli2 (Kim et al., 
2009a). Normalised expression changes were calculated using the 2-ΔΔCT method 
relative to the expression of reference genes Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and Beta-2-microglobulin (B2M). A 184 fold increase in 
expression was detected in cells expressing GFP-Gli2 compared to endogenous Gli2 
expression. (B-D) Viewed by confocal microscopy, a representative example of GFP-
Gli2 co-localisation with primary cilia in NIH 3T3 cells transfected with pCEFLmGFP-
Gli2., (B) Cells were stained for acetylated tubulin (red), as tubulin acetylation is a post 
translational modification found predominately in primary cilia. (C) GFP-Gli2 
localisation is shown in green. (D) Merged channels show GFP-Gli2 and primary cilia 
localisation.(E) Analysis of the observed co-localisation by quantitative comparison of 
the channels fluorescent intensities. (F) The 7 µm cross sectional line (in red) across 
the primary cilium depicts the area measured for fluorescent intensity analysis across 
the cilium shown in (E). (G) A representative confocal microscopy control image 
analysis of untransfected NIH 3T3 cells that are also stained for acetylated tubulin and 
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Figure 5-04 Gli2 protein abundance is increased by expression plasmid 
construct transfection 
(A) FACS population histogram for detected eGFP transfected cells HEK293T. Selected 
cells are counted based on level of GFP expression and the region P3 denotes levels 
that adequately detect GFP to confirm transfection. Results show a 98% transfection 
rate in HEK293T cells after overnight incubation.  
(B) RT qPCR results of Hek293T cells transfected with pCEFL3XHAmGli2 (Kim et al., 
2009a). Normalised expression changes were calculated using the 2-ΔΔCT method 
relative to the expression of reference gene β-Actin. A 6000 fold increase in expression 





5-04 HA-Gli2 transfected and extracted from HEK293T cells is identified by 
MALDI-TOF mass spectrometry 
The aim was to extract overexpressed HA-Gli2 from HEK293T cells for MALDI-TOF 
analysis. HA-Gli2 was enriched using binding oligonucleotide sequences for Gli 
transcription factors to perform oligo-binding pull-downs (Section 5-01). Control 
enrichments were also performed, using mutated binding site sequence 
oligonucleotides or magnetic beads alone, to detect unspecific binding (Section 5-01). 
The aim of continuing with the oligo pull-down method of enrichment was, firstly, to 
compare the results with earlier attempts at endogenous Gli2 enrichment. This 
method also provides a test to ensure transcription factor promoter binding is not 
impaired by the HA tag on HA-Gli2. 
All results were normalised relative to 55 kDa β-tubulin abundance, a common protein 
used as a loading control but also referred to here as a marker to represent total 
protein after enrichment. The results show an increase in HA-Gli2 band intensity 
relative to controls (Figure 5-05 A). This increase shows that HA-Gli2 transcription 
factor binding is not blocked by the addition of an HA tag. After normalisation to β-
tubulin intensity, the band intensity of binding site oligo-enriched Gli2 was 
approximately 2.5 fold greater than in mutated oligo or bead-only controls (Figure 5-05 
B). Enriched HA-Gli2 was observed in silver stained SDS PAGE gels as a broad shaded 
band (Figure 5-05 A). Interestingly this was not observed in the controls for HA-Gli2 
enrichments and suggests higher fold enrichment than the 2.5 fold increase calculated 
from the immunoblot band intensity comparisons. However this may simply be due to 
the sensitivity thresholds of both methods. Enrichment increases protein 
concentration above the minimum sensitivity for silver staining (0.1 ng of BSA/mm2) 
allowing it to be visualised when otherwise it would not. Yet the high sensitivity of 
fluorescent immunodetection was able to detect Gli2 amongst any remaining total 
protein lysate in control enrichments. The silver stained gels also highlight the 
persistent amount of total protein in the purification eluents despite the numerous 
wash steps. It shows that to a large extent, the 2.5 fold increase would be improved if 




The area of silver stained gel identified as Gli2 was excised and prepared for MALDI-
TOF mass spectrometry. Three Gli2 peptides were discovered that together amounted 
to 2% coverage of the protein (Figure 5-05 C). Measures to increase the amount of 
protein for analysis focused on reducing loss during mass spectrometry sample 
preparation. There is a high rate of peptide loss inherent in the multi-step sample 
methodology of in-gel tryptic digestion. This includes 20 hours in-gel digestion at 370C, 
followed by extensive sonification and centrifugal evaporation. MALDI-TOF 
preparation further reduces the sample by its requirement for crystal matrix complex 
formation. Once matrix is formed, the sample is then not analysed in its entirety but 
instead selectively sampled by laser point ionisation. 
In summary, although detection coverage was low, these results provided the first 
identification of Gli2, made possible by the steps taken to increase protein abundance 
and a means to identify it by fluorescent immunodetection. Further improvements in 
Gli2 purification were attempted by using the HA tag for enrichment, with highly 
optimised anti-HA immunoprecipitation techniques. This method should provide high 
yield and specificity benefits of high affinity antibody binding and does not require Gli2 
to retain its structure. It is a method that fulfils the aims of ensuring optimal amount of 
































































Description of HA-Gli2 Enrichment lanes 
Lane 2    Lane 3    Lane 4 













Figure 5-05 HA-Gli2 transfected and extracted from Hek293T is identified 
by MALDI-TOF mass spectrometry 
(A) 4-12% Tris Acetate SDS PAGE of HEK293T lysate from cells transfected with 
constructs pcDNA3-HA-p190RhoGEF in lane 1, pCEFL3XHAmGli2 in lanes 2-4 and un-
transfected in lane 5. Lanes 2-4 are loaded with eluents from Gli2 pull-down 
purification procedure. (Lane 2) Gli2 was selected by binding to oligonucleotide 
sequence that corresponds to Gli2 transcription factor binding regions. (Lane 3) 
Prepared lysate controls for nonspecific binding using a mutated Gli2 binding sequence 
oligonucleotide. (Lane 4) Control enrichment with only magnetic bead. Proteins were 
electroblotted to PVDF membrane and probed by rabbit anti-HA and mouse anti-Beta 
Tubulin primary antibodies. Secondary antibodies 800CW (shown in green) anti-mouse 
reveals Rgnef in lane 1 and Gli2 in lanes 2 to 4. Secondary 680RD (shown in red) 
reveals Beta-Tubulin in all lanes. Lane 5 provides a negative control for background 
nonspecific binding. Silver staining SDS PAGE also reveals this band of HA-Gli2 pull-
down detected in lane 2 and is absent from lanes 3 and 4 controls. The total protein 
lysates are over developed in Lanes 1 and 5 in order to allow time to develop the HA 
tag pull-downs in lanes 2-4. HA-Gli2 purification is observed by the increase in HA-Gli2 
band intensity relative to control bands and in light of the decrease in total protein, 
demonstrated by the loss of intensity of the 55 kDa Beta tubulin. (B) After beta tubulin 
intensity normalisation in each lane, the Gli2 band intensity from the lane 2 pull-down 
is 2.5 times higher than controls in lane 3 and 4. Fluorescent band intensity for 78 kDa 
Gli2 is only observed after Gli2 enrichment. (C) A representation of Gli2 protein 
sequence with MALDI-TOF identified trypsinised sequences in red. The total sequence 




5-05 HA-Gli2 and HA-Rgnef protein enrichment by HA tag 
immunoprecipitation 
The aim of these experiments was to improve on HA-Gli2 protein enrichment for Gli2 
mass spectrometry characterisation. The method of enrichment was 
immunoprecipitation (IP) using an anti-HA magnetic beads complex. Pre-optimised and 
tested, this immunoprecipitation binding complex provides the high yield and 
specificity benefits of high affinity antibody binding. Unlike enrichment by target 
oligonucleotide binding (section 5-01) it captures Gli2 irrespective of the state of its 
tertiary protein structure. Removal of captured Gli2 from the complex was tested by 
two elution buffers; a basic (pH 8) 50 mM NaOH buffer and an acidic (pH 2) 100 mM 
glycine buffer. 
A positive control measure was also prepared by overexpressing HA-Rgnef in HEK293T 
cells. Details of the transfected plasmid construct pcDNA3-HA-p190RhoGEF can be 
found in Section 3-01. In these experiments HA-Rgnef solely provides a similar sized 
(190 kDa) HA-tagged protein to use as a positive control. 
Immunodetection for HA-Gli2 reveals bands from both basic and acidic elution buffers 
(Figure 5-06 A). In terms of migration and shape, the protein bands from the basic 
buffer were comparable to those detected in the lysate before purification. The 
protein band from the acidic buffer elution appears to have migrated less, appears 
fainter and seems more coalesced. In comparison, Rgnef HA immunoprecipitation also 
produced a band using the basic buffer and no band at all with the acidic buffer (Figure 
5-06 A). This may not be the result of protein degradation as the low pH may have 
simply compromised SDS PAGE loading buffer. Nevertheless the basic buffer was 
clearly providing better results and chosen for protein elution prior to MS preparation 
and analysis. Yet one consideration to take forward is that the stringency of the basic 
buffer is reported to cause HA antibody leaching from the beads (Pierce™ Anti-HA 
Magnetic Beads protocol 88836). This would therefore be a contamination to factor in 
for subsequent mass spectrometer analysis.  
Detected HA-Gli2 bands in relation to HiMark protein standard curve were calculated 
to be 216 kDa and 101 kDa, far larger than 185 kDa and 78 kDa published for Gli2. The 




40 kDa increase in Rgnef detected was used to proportionally re-calibrate the standard 
curve. Upon recalculation, Gli2 was approximated to 175 kDa and 82 kDa, within range 
of expected molecular weights. The comparison to Rgnef provides evidence that Gli2 is 
detected despite the discrepancy measured by the protein standard. Further evidence 
is the reported high specificity of the antibody used for Gli2 when overexpressing in 
HEK293T (Pan et al., 2006), and the lack of detected protein in control un-transfected 
lysate lane (Figure 5-06 A (lane 5)). Furthermore, Gli2 detection using anti-Gli2 
antibody instead of anti-HA, also detected a larger 200 kDa band for Gli2 (Section 5-
02). 
Also observed in this and previous experiments is how Gli2 protein bands appear 
vertically broader than would be expected for a single protein (Figure 5-06 A). Rgnef-
HA provides an example of a clearly defined band, as usually expected in western 
detection of a single protein (Figure 5-06 B). Protein degradation is a possible reason 
for the broader Gli2 band; however this seems unlikely as degradation would also be 
expected to be seen with Rgnef-HA and involve a wider and less consistent spread of 
detected protein. The broad band may therefore represent a range of PTM, ranging 
from a higher to low number of modifications to Gli2. To explain; the increased 
molecular weight of the highly modified Gli2 proteins would migrate less than their 
low or unmodified versions, resulting in a thickened band. 
Paired SDS PAGE gel followed by protein silver staining also detected the over 
expression bands of both HA-Gli2 and HA-Rgnef amongst surrounding total protein 
bands. The respective bands for HA-Gli2 and HA-Rgnef are not seen in each other lanes 
amongst the numerous comparable total protein bands detected. It provides early 
indication of adequate protein available for mass spectrometry analysis amongst the 
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Figure 5-06 HA-Gli2 and HA-Rgnef protein enrichment by HA tag 
immunoprecipitation 
(A and B) Immunoblots showing anti-HA immunoprecipitation enrichment of (A) HA-
Gli2 and (B) HA-Rgnef. SDS PAGE and immunoblot were prepared to analyse lysate 
before (lane 1) and after (lane 2) enrichment by incubation with anti-HA antibody 
conjugated magnetic bead complex. Two elution methods were tested; (lane 3) an 
acidic pH 2 glycine buffer and (lane 4) a basic pH 8 NaOH buffer. Highlighted by arrows 
are respective bands for (A) HA-Gli2 and (B) HA-Rgnef, detected by mouse anti-HA 
primary antibody and secondary anti-mouse 800CW in green (Licor). Also detected was 
β-Tubulin by rabbit anti-β Tubulin primary antibody and secondary anti-rabbit 680RD 
in red (Licor). (Lane 3) Acidic glycine buffer did not elute protein bands comparable to 
HA-Gli2 detected in lysate and HA-Rgnef elution was undetected. (Lane 4) In contrast, 
50 mM NaOH elution buffer performed better for both Gli2 and Rgnef having 
maintained the migration, shape and intensity detected in total lysate prior to 
purification step. (Lane 5) Silver stained SDS PAGE gels corresponding to basic buffer 
elution of Gli2 HA and Rgnef HA also detected protein bands as highlighted by (*). As a 
result the eluent derived from NaOH buffer was subject to, tryptic digest and 
subsequent peptides resolved by nano-flow high performance liquid chromatography 
for MS analysis. 
(C and D) Measurement of band intensity in immunoblots for HA-Gli2 bands in (A) and 
HA-Rgnef in (B) respectively. Intensity was normalised against detected β Tubulin as it 
was still observed to persist after purification of HA-tagged proteins. Band intensities 
in protein lysate prior to (pre) and after (post) immunoprecipitation were compared, 
along with final eluent. Hence compared to lysate, the result highlights the enrichment 




5-06 HA-Gli2 transfected and extracted from HEK293T cells is identified by 
Amazon Ion-Trap mass spectrometry 
The aim was to improve upon the preliminary MALDI-TOF identification of Gli2 by 
reducing the high peptide loss required for sample preparation (Section 5-04). Hence a 
new mode and method was employed using Ultimate™ 3000 RSLCnano HPLC system 
(Thermo Scientific Dionex) coupled to an Amazon ion trap mass spectrometer (Bruker). 
This enabled a direct route to protein analysis as the procedure does not require SDS 
PAGE followed by in-gel tryptic digest. Rather, the entire sample eluent can be 
analysed, providing a more rapid and more comprehensive analysis. 
The results of six independent peptide preparations showed that each significantly 
identified Gli2 and together provided a reproducible 28% sequence coverage (Figure 5-
07). Mapped out along Gli2’s protein sequence, the identified peptides were not 
randomly distributed and instead were found in localised regions of the Gli2 sequence. 
Hence peptides identified 6 times would normally be flanked by those identified 4 or 5 
times. This was effectively a Gaussian distribution pattern, as the frequency would 
reduce further from central well-defined regions, until there were sections of 
unidentified protein (Figure 5-07). It is a pattern that could reflect the exposed regions 
in the tertiary structure of Gli2. These regions identified are therefore hypothesised to 
be areas not hidden by protein folding or were at least easily exposed by reducing 
agents used. These regions would therefore be more responsive to trypsin enzyme 
digestion. As Gli2 is a large 185 kDa protein, the results suggest that more extensive 
protein degradation is required to achieve higher protein coverage. 
Two peptides characterised; aa788-aa803 (n=4) and aa804-aa814 (n=1) were identified 
as modified by multiple phosphorylation sites (Figure 5-07). The areas covered by 
these peptides correspond to region aa784-aa855, reported to be PKA, CK1 and GSK3 
phosphorylated sites (Pan et al., 2006). This was also an area that Prosite (de Castro et 
al., 2006) predicted to have multiple phosphorylation sites (Figure 5-07). Adjacent to 
this region, 73 amino acids downstream towards the C termini, a region aa873-aa1007 
was also readily identified by six peptide sequences, however phosphorylation in this 




MS coverage of the zinc finger domain between aa493-aa578 identified two serine 
phosphorylation sites (aa560 and aa559) that also corresponded to the Prosite 
predicted cAMP phosphorylation sites (Figure 5-07). Also a total of five phosphorylated 
peptides were also identified near the N-terminus and eight C-terminus (Figure 5-07). 
These sites were however unpredicted by Prosite. These specific “zinc finger”, N-






GLI2 MOUSE thesis summary
1544 aa
aa788 - aa803 (n=4)
aa955 - aa969
aa143 - aa157 (n=6)
aa722 - aa737 (n=6)
aa908 - aa920 (n=5)
aa921 - aa953 (n=2)
aa973 - aa1007 (n=3)
aa1355 - aa1363 (n=6)
aa1364 - aa1383
aa32 - aa63 (n=2)
aa228 - aa243 (n=4)
aa873 - aa892
aa899 - aa907 (n=6)
aa493 - aa501 (n=4)
aa537 - aa547 (n=4)
aa554 - aa563 (n=6)
aa1058 - aa1069 (n=5)
aa506 - aa530 (n=5)








aa128 - aa142 (n=5)




aa 790 Serine (n=2)
aa 791 Threonine
aa 792 Serine
aa 793 Threonine (n=2)
aa 789 Serine
























In blue: MS detected fragments 




Figure 5-07 HA-Gli2 transfected and extracted from Hek293T is 
characterised by Amazon Ion-Trap mass spectrometry 
Results of LC-MS Dionex 3000 Nano HPLC in conjugation with Amazon Ion-trap MS 
Analysis of protein extract from HEK293T cells transfected with pCEFL3XHAmGli2 (Kim 
et al., 2009a). The results are a summary of Gli2 identified from six independent 
peptide preparations that together provide 28% sequence coverage. Two peptide 
sequences identified in a region reported to have Gli2 phosphorylation sites (Pan et al., 
2006). These were aa788-aa803 and aa804-aa814 and within this sequence a 
combination of eight Serine and Threonine peptides were detected as modified by 
phosphorylation. Adjacent to this region, 73 amino acids downstream towards the C 
terminus side between aa873 and aa1007 was also readily identified by six peptide 
sequences but without any detected phosphorylation. Phosphorylation was detected 
in the zinc finger domain of Gli2 as well at either end of Gli2 sequence at the N and C 
termini. These terminal end phosphorylation were not predicted by the ScanProsite 
(http://www.expasy.org/tools/scanprosite/), whereas predictions were made that 





5-6-01 Phosphorylation of Gli2  
In these experiments HA-Gli2 was extracted from HEK293T cells during Shh signalling 
pathway inactivation for direct MS analysis of PTM. Direct MS sequencing of Gli2 
provides an independent assessment of potential PTMs that can be compared and 
contrasted against current findings. Table 5-01 provides a list of each Gli2 PTM 
identified along with any previous findings or related Prosite predictions. A region of 
particular interest for Gli2 is between amino acids 784-855, identified as PKA, CK1 and 
GSK3 phosphorylation sites for transcription factor regulation (Pan et al., 2006). In Gli2, 
phosphorylation of this region relates to negative regulation of the Shh signalling 
pathway (Pan et al., 2006). In confirmation, the MS analysis of the aa788-803 peptide 
fragment identified within this region of Gli2 detected multiple phosphorylated 
residues. This includes all the predicted PKA, CK1 and GSK3 phosphorylated sites 
identified as either primary or secondary sites of phosphorylation (Pan et al., 2009). 
This region also occurs in Gli3 and is subject to the same PTM (Pan et al., 2009). There 
is therefore very strong sequence homology between these two regions in Gli2 and 
Gli3 (Figure 5-08 C). These results therefore provide the first mass spectrometer 
derived evidence to confirm the active phosphorylation of this region. 
Prior to MS analysis, my Prosite analysis of Gli2 also predicted two potential PKA 
phosphorylation sites corresponding to the second and fifth zinc fingers. The MS 
peptide coverage I achieved did not extend to the second zinc finger, but did discover 
two phosphorylated serine residues (Serine aa559 and aa560) in the fifth zinc finger, 
that corresponded to the Prosite prediction. There are no reports of phosphorylation 
within the Gli2 zinc finger domain. However phosphorylation of the second zinc finger 
of Gli1 has been reported by others to negatively regulate Gli1 in a process that does 
not involve proteolytic cleavage (Kaesler et al., 2000). Zinc finger domains are well 
conserved in all the Gli proteins, so that by association this identified region of PTM in 
Gli2 may also be a means of negative regulation (Figure 5-08 B). It also raises the 
question of whether Gli1 and Gli3 are also subject to the same PTM and regulation as 
they also share homology with Gli2 zinc finger regions (Figure 5-08 B). Interestingly, 
the zinc finger domains are also retained in Gli2 and Gli3 repressor forms. The possible 
regulation of this shared region could therefore potentially provide an overriding layer 




sequence homology also extends to Drosophila and human Gli2 protein orthologues 
(Figure 5-08 C). 
The regions of PTM that bestow positive regulation of Gli1 and Gli2 by ULK3 
phosphorylation are broadly defined as being at either ends of the proteins 
(Maloverjan et al., 2010b). However the specific regions were only deduced by 
investigating broad Gli1 segments between aa1-426 of the N-terminus and aa754-1126 
of the C-terminus (Maloverjan et al., 2010b). Together these regions contain 125 
potential serine and threonine phosphorylation sites (Maloverjan et al., 2010b). In my 
study, specific phosphorylated N and C terminal serine and threonine residues were 
identified in Gli2 that by alignment come within these broad regions of Ulk3 
phosphorylation in Gli1 outlined by (Maloverjan et al., 2010b). Specifically these are 
five residues near the N-terminus between aa131-aa139 and a further eight near the 
C-terminus spanning between aa1365-aa1544 (Figure 5-08 A, E and F). In alignment 
with Gli1 there is almost no specific residue homology, it is however fair to hypothesise 
that although specific residue may differ in this broad region the function may be the 
same. There is certainly better homology in these regions with Gli3, particular in the N-
terminal regions (Figure 5-08 A, E and F). These regions are also retained in cleaved 





Table 5-01 Related evidence for MS detected Gli2 phosphorylation 
residue position and 
type 
Evidence for each Gli2 phosphorylation site.  
Grey shading denotes novel MS PTM detected 
aa131 Serine  
aa132 Serine  
aa134 Threonine  
aa136 Serine  
aa139 Serine  
aa559 Serine  
aa560 Serine  
aa789 Serine Predicted as cAMP phosphorylation site by Prosite*  
Identified as PKA site (Pan et al., 2006)  
aa790 Serine  
aa791 Threonine Identified as GSK3 and CK1 site (Pan et al., 2006) 
aa792 Serine Identified as CK1 site (Pan et al., 2006) 
aa793 Threonine  
aa795 Serine Identified as GSK3 and CK1 site (Pan et al., 2006) 
aa796 Serine  
aa799 Threonine  
aa801 Serine Predicted as PKC site by Prosite* 
Identified as GSK3 site (Pan et al., 2006) 
aa804 Serine Identified as GSK3 site (Pan et al., 2006) 
aa805 Serine Predicted as cAMP site by Prosite* 
Identified as PKA site (Pan et al., 2006) 
aa808 Serine Identified as CK1 site BW (Pan et al., 2006) 
aa1365 Threonine  
aa1371 Threonine  
aa1372 Serine  
aa1388 Threonine  
aa1391 Serine  
aa1397 Serine  
aa1400 Threonine  
aa1544 Threonine  







   GLI1_MOUSE    (10) VNSYSEPCCLRPLHSQGVPS   (376) YTDPSSLRKHVKTVHGP 
   GLI2_MOUSE   (122) MEHYLRSVHSSPTLSMISAA   (555) YTDPSSLRKHVKTVHGP 
   GLI3_MOUSE   (201) MD-YIRSLHSSPSLSMISAA   (618) YTDPSSLRKHVKTVHGP 
   GLI2_HUMAN   (126) MEHYLRSVHSSPTLSMISAA   (575) YTDPSSLRKHVKTVHGP 
CI_DROSOPHILA   (132) SSFHDPYVNCASAFHLAGLG   (589) YTDPSSLRKHVKTVHGA 
 
 
   GLI1_MOUSE   (548) -SSS-MSSAYTVSRRSSLAS   (953) YGSGFAPASANHKSGSY 
   GLI2_MOUSE   (789) SSTSTMSSAYTVSRRSSGIS  (1357) QQQLYARTTGQAMVTSA 
   GLI3_MOUSE   (849) SNTSTISSAYLSSRRSSGIS  (1384) RGYQPCASYGGNRRQAM 
   GLI2_HUMAN   (808) SSTSTVSSAYTVSRRSSGIS  (1390) QQQLAYARATGHAMAAM 
CI_DROSOPHILA   (769) FGISELNQRITELKMEPGTD  (1214) HQRQTEKSNYNQIIDSS 
 
 
   GLI1_MOUSE   (981) VGVNRPSHRPAAPPR-----  (1102) GETQFLNSSA 
   GLI2_MOUSE  (1383) KGPAGTMVSLAPQPS-QDTG  (1535) EESKFLNMMT 
   GLI3_MOUSE  (1412) LSDMSQSSRVNSIKMEAQGQ  (1574) EESKFLAVMQ 
   GLI2_HUMAN  (1418) KGAMGNMGSVPPQPPPQDAG  (1577) EESKFLNMMT 
CI_DROSOPHILA  (1242) IYPRNETENIFKVHGDHDNE  (1388) EENRYLQMMQ 
 
Figure 5-08 Sequence alignment with Gli1 and Gli2 against MS detected 
GLI2 phosphorylation sites and with human and Drosophila Gli2 protein 
homologues. 
Vector NTI-AlignX derived alignments based regions of MS detected Gli2 serine and 
threonine amino acid sequences (bold and underlined). Alignments were made with 
the other two mouse Gli protein family members (Gli1 and Gli3) as well as human GLI2 
and Drosophila Ci protein orthologues. Colour coding summarises collective amino acid 
similarities: black on white - non-similar residues, black on cyan - the occurrence of 
greater than 50% of a single residue; red on yellow - completely conserved residue in 
all sequences aligned. (A) N-terminal region of proteins alignment where 6 serine Gli2 
protein residues were MS detected for phosphorylation. All these residues share 
homology with Gli3 and human Gli2 and some with Gli2, although no similarity is 
detected with drosphila Ci. (B) Two MS detected Gli2 serine residues within the zinc 
finger in a region with complete sequence homology with all sequences in alignment. 
(C) This region produced a high number of MS detected Gli2 phosphorylation sites and 
incorporates a region of Gli2 and Gli3 that has been identified as PKA, CK1 and GSK3 
phosphorylation sites for transcription factor regulation (Pan et al., 2006). (D-F) Three 
C-terminal regions showing MS detected phosphorylated residues in Gli2. Overall 
sequence homology is these regions are not high amongst all the sequences, although 
specific residue matches do occur. 
  
     












5-07 Discussion - Mass spectrometer characterisation of Gli2 
The main strengths of the 28% coverage of Gli2 sequence by Amazon ETD analysis was 
the reproducibility of the regions identified. A strategy to improve sequence coverage 
requires a review of all steps involved in the process. At 185 kDa, Gli2 is a large protein 
to optimally denature and fragment. This particularly highlights the importance of 
sample preparation and as such is the focus of the next section as it provides the 
highest potential to improve Gli2 characterisation. 
Following on from sample preparation is the process of nano-HPLC and the aim here is 
to provide the optimal resolution of peptide fragments for mass spectrometry analysis. 
The time and gradient increase of the non-polar solvent is required to be uniquely 
defined for every protein analysed. Furthermore the nano HPLC flow rate of 0.25 µl 
min-1 is highly susceptible to even precise changes in set-up. Factors to consider 
include the precise integrity of the 20 µm internal diameter of silica tubing, to ensure 
samples are not dispersed causing broad chromatogram peaks. Care also needs to be 
taken to ensure the continuous quality of reagents. Peptides can then enter the MS by 
optimising the very fine process of sample nano-spray ionisation. 
One of the main processes of this study was mass spectrometer fragmentation of 
peptides (MS/MS fragmentation) which was achieved consecutively by both collision-
induced dissociation (CID) and electron transfer dissociation (ETD). The aim was to use 
alternative methods for MS/MS fragmentation in order to increase the opportunity of 
sequence coverage and PTM identification. ETD provides alternative fragmentation 
patterns that can complement CID-derived data, improve coverage or even identify 
novel modifications (Sobott et al., 2009, Juang et al., 2013). Using CID and ETD 
together in analysis of Gli2 resulted mostly in identification of the same peptide 
fragments. However ETD would identify the peptide by a different set of MS/MS ion 
pattern identification and in effect this process mostly enabled ETD to confirm CID 
identifications. However, a notable exception was that only by ETD was it possible to 
identify serine phosphorylation (aa559 and aa560) within the Gli2 zinc finger domain. 
A likely explanation is that the more energetic CID fragmentation removed the specific 




amino acid to phosphate bond. A summary discussion of all the Gli2 phosphorylation 
sites identified is provided in section 5-7-02.   
5-7-01 Sample preparation methods for proteome analysis 
The successful characterisation of HA-Gli2 extracted from HEK293T cells required a 
substantial change in the methodology from initial attempts at characterising 
endogenous Gli2 in NIH 3T3 cells. This included switching amongst the two major 
strategies for protein extraction and peptide processing; in-gel and in-solution 
digestion. “In-gel” involves denaturing and separation of proteins by SDS PAGE 
followed by digestion of proteins whilst trapped in the gel (Cohen and Chait, 1997). 
SDS PAGE is an effective means to resolve, denature and solubilise proteins, yet SDS 
inhibits enzymatic digestion and proves to be a readily ionised problematic MS 
contaminant. In comparison, the use of in-solution digestion demonstrated the extent 
at which peptides can be delivered to the mass spectrometer with minimal handling 
and intervention. The success of this method also required an abundant amount of 
Gli2, which was achieved through using an easily transfectable HEK293T cell line to 
overexpress a tagged HA-Gli2 construct. 
An interesting observation made during sample preparation was the thickened HA-Gli2 
band revealed after immunoblotting and even when directly silver staining SDS-PAGE 
gels. The conclusion proposed was that the broad band represented layers of Gli2 
PTM, ranging from a high to low number of modifications to Gli2. If these findings are 
related to PTM then they may also provide a means to detect modifications by 
examining changes in band thickness. This can be achieved by systematically blocking 
types of PTM prior to western detection and looking for a reduction in band thickness. 
In doing so PTMs can be quickly and easily detected allowing input to more specific 
mass spectrometry parameters for improved PTM detection. In future analysis this 
would provide a simple means to test for a range of PTM to then provide preliminary 
evidence to focus mass spectrometry investigations on specific modifications. 
Once Gli2 modifications are revealed by MS, specific Gli2 sequences that encode these 
regions can be modified by insertional mutagenesis for further expression analysis. In 
this way, sites of PTM can be associated to functions such as primary cilia localisation 




Nevertheless such methods are still limited on validating pre-identified sites of protein 
modification. Results may also be deemed unrepresentative if based on levels of 
protein overexpression that exceed endogenous limits. There is therefore a need to 
evidence these findings based on endogenous protein detection and do so across 
alternative cell types. The challenge is to improve traditional “in-gel” and “in-solution” 
sample preparation techniques so as to improve the sensitivity required to analyse low 
levels of endogenous protein. A solution may be filter-aided sample preparation 
(FASP), a method that aims to combine the advantages of in-gel and in-solution 
digestion techniques (Wisniewski et al., 2009). The method proposes containing 
proteins in ultra-filtration devices that enable complete depletion of any impurities 
after treatment. This includes denaturation with SDS as it can be completely cleared by 
a urea buffer treatment, before enzymatic digestion by trypsin. Peptides retained by 
ultrafiltration can then be concentrated in µl volumes before automated MS insertion. 
The success of this method is in the ability to fully denature protein with reduced 
handling, without retaining impurities and faster peptide processing. This will also 
reduce the loss and damage of peptide that occurs from “in-gel” sample preparation, 
particularly important when attempting to analyse low amounts of endogenous 
protein. 
FASP may therefore improve upon the 28% coverage achieved by in-solution digest, 
particularly as the coverage pattern favoured specific regions. Sequenced regions are 
hypothesised to be detected due to their accessibility to tryptic digest. Improved 
protein denaturation by FASP can prepare Gli2 for better accessibility to protein digest 
whilst still retaining the direct peptide to MS benefits of the in-solution digest. 
Finally, uses of additional enzymes in combination with trypsin such as, LysC, 
chymotrypsin, AspN and elastase, have been reported to also improve MS protein 
coverage (Winter et al., 2009). This is particularly relevant to phosphorylation analysis 



















6-01 General Discussion 
The set of specific experimental aims in this thesis were set in the context of a broader 
investigation relating to the molecular mechanism of Shh signalling in NT 
development. The starting point for this thesis came from the observation that mice 
carrying a disruption of the Tulp3 gene exhibit neural tube defects, and also 
demonstrate over-activation of the Shh signalling pathway (Cameron et al., 2009, 
Norman et al., 2009, Patterson et al., 2009). Tulp3 was shown to act as a negative 
regulator of the Shh signalling pathway, acting between Shh/Smo and cilia/Gli2. 
Investigations to find interacting protein partners of Tulp3 identified Rgnef and Trim71. 
Therefore in this thesis, the overall aim was to pursue the hypothesis that Rgnef and 
Trim71 may themselves play a role in regulating the Shh signalling pathway and how 
their functions then subsequently relate to NT development. 
The study of Gli2 PTM in this thesis was undertaken with the aim of detailing how Shh 
signal transduction manifests itself on the structure of a member of the Gli family of 
transcription factors. Precise understanding of exactly how Gli proteins are modified is 
still lacking. Using the Shh-LIGHT2 assay only reports on Shh activation states but 
cannot reveal the complex molecular mechanisms of pathway regulation (Section 3-
10), particularly when much of what is understood about pathway states of activation 
involves modifications at a protein level (Section 1-4-02). In this thesis only Gli-
dependent pathways are being examined, yet there are proposed examples of non-
canonical Shh signalling where Gli proteins are not required (Renault et al., 2010, 
Polizio et al., 2011). This reiterates the need to encompass an even broader 
understanding of Shh pathway activation and the molecular mechanisms involved. 
Amongst the Gli2 coverage by MS analysis in this thesis there was a consistently 
detected region between amino acids 784-855 that is of particular interest for Gli2 
PTM analysis. This region contains known PKA, CK1 and GSK3 phosphorylation sites 
that regulate the process of Gli2 proteolytic cleavage to repressor form (Pan et al., 
2006, Pan et al., 2009). A homologous region also exists in Gli3 providing the same 
function as in Gli2 (Pan et al., 2006, Pan et al., 2009). It should therefore be possible to 
use the same MS preparation and analysis techniques employed for Gli2 to also 




characterisation to confirm these findings for this region, the results also provide a 
level of confidence for the novel sites of Gli2 PTM detected in this thesis.  
Novel sites include Gli2 PTM identified within the zinc finger domain, a homologous 
region found in all three Gli proteins and across species in human, mice and 
Drosophila. Further understanding the purpose of modifications within this highly 
conserved region will therefore have a high probability of translating to human GLI 
protein function in the Shh signal pathway. Further investigation into Gli protein zinc 
finger PTM would therefore be an area of great interest particularly as zinc finger 
region PKA phosphorylation has been reported to negatively regulate Gli1 (Kaesler et 
al., 2000). 
The novel PTMs identified in both the N and C terminals of Gli2 represent regions that 
are relatively less known in function and appear to show the least homology to other 
Gli proteins or species orthologues. There is some evidence in Gli1 that ULK3 
phosphorylation within these broad regions results in positive regulation of Shh signal 
pathway (Maloverjan et al., 2010b). However this finding would require further 
investigation in Gli2 and as such have a high potential of discovering novel regulatory 
steps in Shh signal transduction relating to PTM. 
6-1-01 Rgnef - positive regulator of Shh signalling in neural tube development. 
Identifying localised Rgnef expression in the neural tube of developing embryos was a 
key finding in relating Rgnef activity to neural tube development. Functional evidence 
was then provided by the Shh-LIGHT2 assay in demonstrating that a loss or gain of 
Rgnef expression directly relates to suppression or activation of Shh pathway activity, 
respectively, and therefore identifies Rgnef as a positive regulator of the Shh signalling 
pathway. This is clearly opposite to negative regulator Tulp3 (Cameron et al., 2009, 
Norman et al., 2009, Patterson et al., 2009). Hence this suggests there is an 
antagonistic relationship between Tulp3 and Rgnef, in relation to Shh signal 
transduction. The evidence taken together proposes a model in which in Tulp3 
deficient mice, Rgnef expression in the NT results in the observed activation of the Shh 
signalling pathway.  One limitation with this model is that Rgnef has a highly localised 
expression domain, confined to the cells of the most ventral region of the neural tube 




activation over the ventral two-thirds of the neural tube. This would suggest that 
activation of the Shh pathway in the absence of Tulp3 is not dependent on the 
expression of Rgnef and the importance of Rgnef may only be in the NT floorplate.  
Mice that have compromised Shh signalling pathway activation, such as Shh-/- and Smo-
/- , do not have NTD and in the case of Shh-/- (Chiang et al., 1996, Zhang et al., 2001). 
Therefore we would also not expect Rgnef mutants to show NTDs. Yet in contrast, 
increased activation of the Shh signalling pathway often does cause NTDs (Ybot-
Gonzalez et al., 2002, Ybot-Gonzalez et al., 2007, Greene and Copp, 2009, Murdoch 
and Copp, 2010). Therefore we would predict that over-expression of Rgnef might lead 
to NTDs. It would be interesting to investigate the effect of Rgnef over-expression in 
developing mice and whether that would lead to NTD. 
Shh pathway activity is critical for regulating dorso-ventral patterning of the neural 
tube (Jessell, 2000). We would predict that the Rgnef-/- mutant mice would show some 
disruption of DV patterning. This has not been investigated but would test the 
hypothesis that a lack of Rgnef would result in a more dorsalised DV pattern from 
suppressed Shh pathway activation. Given the highly localised expression pattern of 
Rgnef, we would expect probably only subtle changes in DV patterning. Attempts to 
obtain some Rgnef mutant embryos to test this idea were, unfortunately, unsuccessful. 
Conversely, we would expect the opposite effect following Rgnef over-expression, with 
more ventralised DV patterning, similar to (though probably more subtle than) that 
observed in Tulp3 deficient mice. Attempts to test the over-expression of Rgnef 
involved construction of the bicistronic plasmid pCAGGS Rgnef (Section 3-6-01), 
encoding both Rgnef and GFP, with the aim of transfecting this into chick embryos. The 
experiment would have allowed the effect of Rgnef expression on patterning to have 
been tested. Unfortunately, this experiment didn’t work. 
Investigations into the cellular mechanisms involved have shown that over-expression 
of Rgnef impairs primary cilia formation. Primary cilia are central to the current model 
of Tulp3 negative regulation in Shh signalling. Hence a lack of primary cilia would 
remove the very purpose for Tulp3 IFT-A complex formation, proposed as a model of 
G-coupled receptor ciliary trafficking to induce cAMP driven PKA activation 




purpose of Tulp3 binding to Rgnef could therefore be to permit Rgnef from impairing 
ciliogenesis, hence a separate cytoplasmic complex that sequesters Rgnef in the 
cytoplasm (Figure 6-01). In mode of action the model can be compared to the multiple 
functions of Sufu; able to bind and sequester Gli transcription factors and yet form a 
complex with kinase GSK3 to promote proteolytic cleavage of Gli3. Yet all these 
specific molecular interactions by Sufu are united in the coordinated purpose of Shh 
pathway suppression (Ding et al., 1999, Dunaeva et al., 2003, Jia et al., 2009, Kise et al., 
2009). 
An alternative model is to propose that Tulp3 and Rgnef binding relates to Tulp3’s role 
in primary cilia protein traffic regulation across the transition zone (Figure 6-02). 
Evidence shows that Tulp3 and IFT-A protein binding is modelled on providing a 
permissive role into the primary cilia for G-coupled receptor protein transport 
(Mukhopadhyay et al., 2013). Yet the specific purpose of this complex may provide a 
means of regulation for exiting the primary cilia, particularly as IFT-A protein are 
required for retrograde transport within the cilia.  Furthermore, previous to this thesis, 
the same yeast-2-hybrid screen that identified Rgnef and Trim71 also detected nuclear 
pore complex Nup155 as another potential Tulp3 binding partner. Although nuclear 
pore complex proteins regulate protein traffic through the nuclear membrane, they 
have recently been localised to the base of cilia transition zones and shown to regulate 
ciliary traffic (Takao et al., 2014). There is also preliminary evidence that Nup155 is 
amongst the specific nuclear proteins identified with this dual role (In conversation 
with Kirsten J Verhey). Hence as a direct binding partner, Rgnef connection with the 
primary cilia structure should be fully investigated in terms of ciliary transport 
regulation and not just in terms of ciliogenesis. Hence the high Rgnef expression that 
results in a lack of primary cilia is instead proposed as evidence that implicates Rgnef in 
primary cilia mechanism rather than suggest a mode of action. Testing this hypothesis 
requires investigating Rgnef expression changes at levels that bear more resemblance 
to its endogenous range. Such investigations require assessing the effects of lower 
expression increases than induced by pcDNA3-HA-p190RhoGEF or pCAGGS Rgnef. This 
can be achieved by sub cloning plasmid constructs with reduced or controlled 
expression capability and investigate the effect of inducing graduated expression 




promoters or the use of drug inducible constructs, such as tetracycline-controlled gene 
expression systems  (Gossen and Bujard, 1992, Freundlieb et al., 1997, Gossen, 2006). 
The approach will help ensure that levels of induced cellular Rgnef are at levels that 
better reflect endogenous Rgnef expression. 
Adapted plasmid expression constructs can also be used to address the question of 
whether Rgnef acts as a GEF protein in Shh signal pathway activation.  Rgnef binding to 
scaffolding protein JIP-1 has been shown to promote JNK activation without GEF 
related RhoA activation (Meyer et al., 1999). Single point mutations within Dbl-
homology and plekstrin-homology (DH/PH) domains of GEF proteins will inactivate 
RhoA binding and GTPase activity (Chen et al., 2011b). This can enable comparisons 
with GEF mutated Rgnef constructs to test if Shh pathway activation is induced 
without RhoA activation. Although a study of this scale should first follow further 
protein pull-down investigation conducted in this thesis; that of western analysis of 
active Rho after Rgnef overexpression. Future analysis would require optimising the 
experiment for specifying active RhoA pull-down and would be possible by using 








Figure 6-01 Model proposing effects of ciliogenesis on Shh pathway 
activation by increased Rgnef expression 
(A-B) A simplified representation of the Shh signalling pathway proposing the effect of 
Rgnef overexpression on Shh signalling in relation to ciliogenesis.  (A) In the absence of 
Shh ligand Ptch1 inhibits Smo, preventing its ciliary accumulation. Gpr161 is 
transported to the cilium in complex with Tulp3 and IFTA proteins. Cilium levels of 
cAMP are increased by Gs alpha protein coupled receptor activation of the cAMP-
dependant pathway. PKA phosphorylates Gli3 and leads to it being targeted for 
proteolytic cleavage to the repressor form which translocates to the nucleus to repress 
gene expression. In the cytoplasm Tulp3 binds and sequesters Rgnef from inducing a 
suppressive effect on ciliogenesis (B) Rgnef overexpression suppresses ciliogenesis and 
primary cilia mediated Gli3 processing to Gli3 repressor is arrested. Instead Gli2 to Gli 








Figure 6-02 Model proposing effect of ciliary IFT transport by increased 
Rgnef expression leading to Shh pathway activation 
(A-B) A simplified representation of the Shh signalling pathway proposing the effect of 
Rgnef overexpression on Shh signalling in relation to ciliary IFT transportation. (A) In 
the absence of Shh ligand Ptch1 inhibits Smo, preventing its ciliary accumulation. 
Gpr161 is transported to the cilium in complex with Tulp3 and IFTA proteins. Cilium 
levels of cAMP are increased by Gs alpha protein coupled receptor activation of the 
cAMP-dependant pathway. PKA phosphorylates Gli3 and leads to it being targeted for 
proteolytic cleavage to the repressor form which translocates to the nucleus to repress 
gene expression. (B) Increased Rgnef expression permits Gpr161 to be transported 
from the cilium by retrograde IFT transportation through IFTA protein complex bridged 
by Tulp3. Binding partner Rgnef permits access from the primary cilium. Loss of ciliary 
cAMP deregulates PKA phosphorylation of Gli3 processing to Gli3 repressor. As Gli3 
processing to Gli3 repressor is arrested, Gli2 to Gli activator prevails over Gli3 






6-1-02 Future plans for investigating Trim71 in Shh signalling and neural tube 
development. 
An investigation of an involvement of Trim71 in Shh signaling has yet to be addressed 
as results in this thesis were identified to be false positive. Yet there is a strong basis 
for continuing future investigation into Trim71 in light of evidence in our laboratory 
that Trim71 and Tulp3 interact (Patterson, 2011). Furthermore Trim71 deficient mice 
exhibit neural tube defects (Maller Schulman et al., 2008). The main limitation in this 
thesis was the lack or low level of Trim71 expression in Shh-LIGHT2 cells, the cell line 
used to investigate effects on the Shh pathway. Using Shh-LIGHT2 cells for future 
investigations are therefore only limited to studying the effects of overexpressing 
Trim71. A major concern for continuing the use of Shh-LIGHT2 cells, or indeed the NIH 
3T3 cells from which Shh-LIGHT2 cells are derived, is about the validity of any given 
study that is based on inducing Trim71 expression in a cell that does not normally 
express it. Hence, a comparison of both knock down and overexpression requires use 
of a cell line with defined Trim71 expression as it would indicate its use in signalling 
mechanisms, and therefore one could be confident that other factors required for its 
function are also expressed. Interestingly, two cell lines that have been identified with 
significantly high Trim71 expression are embryonic cell derived. These are P19, a 
mouse embryonic carcinoma cell line and J1-ES, a cell line derived from agouti 
embryonic stem cells (Chang et al., 2012). In order to investigate a possible 
involvement in Shh signaling, changes in Trim71 expression should be considered in 
these cells lines relative to Shh pathway activity. This activity can be still be potentially 
monitored by transient transfection of the Gli reporter construct Gli-BS luciferase, as it 
is the construct stably transfected in Shh-LIGHT2 cells (Sasaki et al., 1997). Shh 
pathway activity can be monitored by RT-qPCR expression analysis of Ptch1 and Gli1, 
hence genes that upregulate in response to pathway activation. 
6-02 Conclusion 
Investigations into potential Shh pathway protein effectors, like Rgnef and Trim71, 
should ultimately be understood in terms of regulation by Gli transcription factor PTM, 
hence commitment to expressing target genes. This advancement in level of detail will 
help define the regulation involved in a single pathway with such diverse roles. This 




determining differentiation fates for the wide range of neural cells. Future aims are 
therefore centred on the idea that understanding the complexity of Shh pathway 
regulation requires deciphering the purpose of Gli transcription factor PTM. Although 
only Gli2 has been characterised in this thesis, the techniques established can be 
applied to a full investigation of pathway activation transcription as a whole by also 
characterising Gli1 and Gli3 PTM. 
Future investigations should therefore aim to investigate all three Gli transcription 
factors for mouse and human and in particular compare against changes in PTM after 
activation of the Shh signalling pathway.  Hence the results are a start to a future 
framework for investigating the complex transcriptional regulation of Shh pathway 
signalling. The aim is to identify the overall molecular mechanism of Gli protein PTM 
related to upstream effectors. Understanding NT development in terms of a more 
detailed molecular mechanism for Shh signal transduction can better inform the 
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